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SUMMARY 
Hypertrophic cardiomyopathy is a primary cardiac disorder with a heteroge-
neous expression. Although relatively uncommon, the disease has been studied 
extensively as appears from the numerous studies that have explored specific 
facets of hypertrophic cardiomyopathy. This review will focus on the anatomic 
abnormalities, the prevalence, symptoms and clinical outcome, therapeutic inter-
ventions and genetic mutations responsible for the disease. 
INTRODUCTION 
Hypertrophic cardiomyopathy as a clinical entity was first described by Brock in 
1957 (I). The diagnosis is based on the echocardiographic demonstration of a 
nondilated hypertrophied left ventricle in the absence of other cardiac or sys-
temic disease that can produce left ventricular hypertrophy (2). During the last 
decades the understanding of this complex disease has grown substantially. 
However, several individual investigators have characterised hypertrophic cardi-
omyopathy on the basis of their experience in a particular cohort of patients. 
Consequently, controversy has arisen with regard to the pathology, natural his-
tory, management and aetiology of this heterogeneous disease. In this article, we 
summarise many of these issues and propose therapeutic strategies for these pa-
tients. 
GENERAL CONSIDERATIONS 
Pathology 
The characteristic pathologic features of hypertrophic cardiomyopathy are 
asymmetric hypertrophy, especially of the interventricular septum (3,4), myo-
cardial fiber hypertrophy and disorganisation of myocardial cells (5,6), abnor-
mal thickened intramyocardial coronary vessels ("small vessel disease") (7-9) 
and interstitial fibrosis (10). In the majority of patients (approximately 90%), 
hypertrophy mainly involves the interventricular septum and anterolateral wall 
(I I, I 2). The posterior segment of the left ventricular free wall is least atfected. 
In a minority of patients myocardial hypertrophy is confined to the apical part of 
the letl ventricle. However, in Japanese patients with hypertrophic cardiomy-
opathy the apical type represents up to 25 % of cases (13). Patients with apical 
hypertrophic cardiomyopathy seem to constitute a subset of patients with dis-
tinct manifestations: hypertrophy is limited to the left ventricular apex, the elec-
trocardiogram is characterised by the presence of deep negative T-waves and the 
clinical course is more benign (13-15). 
Myocardial hypertrophy is not the only hallmark of hypertrophic cardiomy-
opathy. Klues et al. have described anatomic alterations in the mitral apparatus 
which may be present in this disorder: an increase of the mitral valve area, in-
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crease in length of the anterior leaflet, abnormal laxity and anterior displacement 
of the valve (16-19). Moreover, papillary muscles can be pmi of the disease pro-
cess and may be displaced to anteriorly and inwards towards another (20), in 
some patients papillary muscles insert directly into the anterior mitral leaflet 
(21). 
Obstructive versus llon-obstrllcfive hypertrophic cardiomyopathy 
(Table I) 
Obstl1lctive hype.irophic cardiomyopathy can be divided in a subaortic and a 
midventricular obstructive type (figure I). Subaortic obstruction is present in ap-
proximately 25 % of patients with hypertrophic cardiomyopathy (4,22). The ob-
struction results from a combination of left ventricular outflow tract narrowing, 
due to basal septal hypertrophy and anterior displacement of the mitral valve, 
and systolic anterior motion of the mitral valve (23,24). Systolic anterior motion 
of the valve can be induced by several mechanisms: I) Venturi forces: as a re-
sult of the narrowing of the outflow tract flow velocity increases and a pressure 
decrease develops above the valve. This cause the valve to be drawn towards the 
septum (25). 2) Flow drag: due to anatomic alterations in the mitral valve appa-
ratus (increascd length, laxity and valve area) and anterior displacement of the 
papillmy muscles, the mitral valve protrudes in the outflow tract and is exposed 
to flow drag (26). As a result of the systolic anterior motion significant mitral 
insufficiency can develop (12) (figure II). 
In a minority of patients, midventricular obstruction can be observed at the 
level of the papillary muscles when outspoken midventricular and apical hyper-
trophy is present. On echocardiography an apical chamber is visualized in sys-
tole. In this chamber an elevated systolic pressure is registered. The systolic 
pressure above the midventricular obstruction is normal, in contrast with the 
subaortic obstructive type where the systolic pressure in the whole left ventricu-
Table I 
I Hypertrophic cardiomyopathy I 
I obstructive I I non-obstructive I 
I \ I \ 
Sub aortic Midventricular Normal Impaired systolic function 
obstructive type obslruclive type systolic function ("burned·oul phase") 
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Figure fa 
Figure /b 
Apical transthoracic three chamber cchocardiographic presentation of a patient with hyper-
trophic cardiomyopathy and subaortic obstruction (upper panel) and of a patient with 
midvcntricular obstruction (lower panel), In the patient with midventricular obstruction, a 
maximal systolic gradient of 25 mill Hg was measured by pulsed Doppler echocardiogmphy 
at the level of the obstruction. 
Abbrcvatiolls: Ao=Aorta, LA= left atrium, LV= left ventricle. 
*= level of tile subaortic obstruction. 
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Figure If 
Transthoracic long axis echo cardiogram of a patient with hypertrophic cardiomyopathy and 
subaortic obstruction. Doppler colour flow reveals turbulent now in the len vcntricular out-
flow tract (LVOT), due to LVOT obstruction and turbulent now in the len atriulll (LA) as a 
result of mitral insufl1ciency UvfJ). 
Abbrevations: IVS= interventricular septllm~ LV= left ventricle 
lar cavity is elevated (25). Mitral insufficiency is generally absent in the 
midventricular obstructive type. Fighali et al. (27) and Ishiwata et al. (28) have 
shown a relation between this type of obstructive hypertrophic cardiomyopathy 
and apical myocardial infarction. Doppler recordings demonstrate peculiar apex 
to base flow patterns. As a result of the midventricular obstruction systolic apex 
to base flow suddenly stops. In the beginning of diastole flow from apex to base 
is registered (paradoxical diastolic flow), the apex just fills in the last part of di-
astole (29,30). In patients with midventricular obstruction and the presence of 
paradoxical diastolic flow, the incidence of cardiac events (systemic emboli, 
apical ischemia) is increased (29,30). 
On both types of obstructive cardiomyopathy it has been shown that the ob-
struction is dynamic and its severity is dependent on left ventricular contractil-
ity, preload and afterload (12). In the subaortic type, the left ventricular outflow 
tract gradient will increase with positive inotropic stimulation (31), interventions 
which decrease left ventricular volume (administration of nitroglycerin, Val-
salva manoeuvre) (31,32) and manoeuvres which decrease systemic vascular re-
sistance (therapy with vasodilatating drugs) (31,32). Moreover, one should 
realise that the outflow tract gradient in the subaortic type of hypertrophic ob-
structive cardiomyopathy is unstable and may show a day-ta-day variation not 
explained by changes in heart rate, blood pressure or left ventricular end-dias-
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tolic dimension. Therefore, a single measurement of the pressure gradient is not 
adequate to define the severity of the dynamic outflow tract obstruction in hy-
pertrophic obstructive cardiomyopathy (33). 
Nonobstructive hypertrophic cardiomyopathy can be classified as a cardiomy-
opathy with normal systolic function or with impaired systolic function 
("burned-out" or "end-stage" phase). Approximately 10 to 15 % of patients with 
the classical characteristics of hype.irophic cardiomyopathy (non-dilated, hyper-
trophied left ventricle with or without obstruction) will develop symptoms of 
congestive heali failure due to transformation of the disease in a condition that 
resembles dilated cardiomyopathy (32,34). On echocardiographic examination, 
the left ventricular wall thickness is only mildly increased or normal, left ven-
tricular endsystolic- and enddiastolic dimensions are increased and ejection frac-
tion is reduced. The depression of the left ventricular systolic function might 
well be the result of myocardial ischaemia and infarction, since in many of these 
patients extensive myocardial fibrosis is present (35,36). 
Clinical presentation 
It is important to realise that the majority of patients in unselected populations 
have no or little symptoms (37,38). When present, the main complaints are 
exertional angina, dyspnea and syncope or near-syncope (32,39,40). There arc 
three different pathophysiologic processes known to contribute to symptoms: 
myocardial ischaemia, abnormal diastolic function and left ventricular outflow 
tract obstruction (4). Each of these can produce similar hemodynamic changes 
and symptoms. Myocardial ischaemia, through compromising left ventricular 
function andlor diastolic function, may result in a reduction in cardiac output, 
hypotension and elevation of the left ventricular end-diastolic pressure. Thcse 
alterations will lead to complaints of angina, dyspnea and near-syncope. Abnor-
mal diastolic function, by elevating left ventricular enddiastolic pressure and re-
ducing left ventricular filling and left ventricular outflow tract obstruction 
tluough elevating systolic and diastolic left ventricular filling pressures leading 
to ischaemia, can produce identical complaints (4). 
The contribution of each these mechanisms in the creation of the clinica I pic-
ture differs from patient to patient. In order to reach benificial therapeutical re-
sults the most contributing pathophysiologic mechanisms must be clarified iu 
each patient as much as possible. 
PREVALENCE 
Hypertrophic cardiomyopathy is the most common cause of sudden cardiac 
death in young people, including competitive athletes. Since the majority of 
these young individuals is free of symptoms their death is dramatic and unex-
pected. These tragic events have raised questions concerning the prevalence of 
the disease and the methods by which it is detected. 
Hypertrophic Cardiomyopathy: Update and Ncw Perspectives 7 
Screening for hypertrophic cardiomyopathy can be performed by echocardiog-
raphy or genetic testing. The electrocardiogram is not appropriate as screening 
method for hypertrophic cardiomyopathy since many patients have a normal 
ECG(41). 
Several echocardiographic studies have estimated the prevalence of hyper-
trophic cardiomyopathy in the general population. The frequency with which 
hypertrophic cardiomyopathy occurs in the general population is quite uniform 
according to these studies. Maron et a!. (42) performed echocardiography in 
4111 men and women 23 to 35 years of age as part of the Coronal), Artery Risk 
Development in (Young) Adults (CARDIA) study, an epidemiological study of 
coronary risk factors. Hypertrophic cardiomyopathy was present in 7 subjects 
(0.17%). Only one subject had ever experienced cardiac symptoms, the electro-
cardiogram lVas abnormal in 5 of the 7 subjects. Hada et a!. (43) surveyed 12000 
adult Japanese workers initially with ECGs and subsequently with 
echocardiograms (in a subset of only about 12%): the prevalence for hyper-
trophic cardiomyopathy was 0.2%. In an other study by Savage et a!. (44) over 
3000 subjects (the offspring of the original Framingham cohort) were evaluated 
with M-mode echocardiography: 0.3% had evidence of hypertrophic cardiomy-
opathy. In an outpatient population referred for echocardiograpy because of sus-
picion of cardiovascular disease, Maron et a!. reported a 0.5% prevalence of hy-
pelirophic cardiomyopathy (45). Echocardiography may however underestimate 
the true prevalence of hypertrophic cardiomyopathy (46) The echocardio-
graphic definition for hypertrophic cardiomyopathy is a nondilated hypertro-
phied left ventricle in the absence of another cardiac or systemic disease which 
may cause increased left ventricular mass (42). This definition, however, ex-
cludes patients who have inherited the disease gene for hypertrophic cardiomy-
opathy but have not developed left ventricular hypertrophy and excludes pa-
tients who do have hypelirophic cardiomyopathy but have another coexsisting 
disease that may contribute to left ventricular hypertrophy such as hypertension 
or valvular heali disease (46). Theoretically, it would be most appropriate to use 
the various genetic abnormalities as a basis for the analysis of prevalence, the 
description of the phenotypic expression and description of the clinical course of 
hypelirophic cardiomyopathy. Nevertheless, genetic testing is complex, expen-
sive and probably more inaccurate to determine the prevalence of hypertrophic 
cardiomyopathy taken into account that a total of more than 70 gene mutations 
can create the phenotypical expression of hypertrophic cardiomyopathy and 
many additional genetic abnormalities remain to be documented (47,48). 
In conclusion, echocardiography remains the most sensitive and specific tool 
to determine the prevalence of hypertrophic cardiomyopathy: it is non-invasive, 
relative cheap and the number of patients that is misdiagnosed is probably rela-
tive small (47,48). 
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PROGNOSIS 
The natural history of hypertrophic cardiomyopathy is difficult to assess. Obser-
vational studies from tertiary referral centres have estimated the annual cardiac 
death to be 2-4% in adults (49-55) and as high as 6% in children (52,56,57). 
However the clinical outcome, derived from investigations performed at these 
centra, is profoundly influenced by referral bias (58). Hypetirophic cardiomy-
opathy is an uncommon, heterogeneous disease. Many patients remain free of 
symptoms during their lives, symptomatic patients may stay in a stable clinical 
Itlble II 
Prognosis of patients with hypertrophic cardiomyopathy. The upper panel represents pa-
tients from referral centra with the worst prognosis, the lower panel deals with studies in 
unselected populations of patients at the mild end of the disease spectrum. 
---
Patients (N) Mean FlU (Vrs) Annual mortality (%1 
Swan et al 85 4.0 3.5 
Sr Heart J 1971 
Hardarson at al 11. 4.6 3.5 
Lancet 1973 
Shah at al ,.0 5.2 3.4 
Cire Res 1974 
McKenna at al 254 6.0 5.9 (pis < 15 yrs) 
Am J Cardiol 1981 2.6 (piS> 15 yrs) 
Maron at al 9. 3.0 2.3 
Am J Cardiol1981 
Romeo al al 125 7.6 3.4 
Eur Heart J 1990 
Seller at al 13. 8.' 2.4 (surgery) 
J Am Coli Cardiol1991 3.6 (pharmacologic) 
Palienls (N) Mean FlU (yrs) Annual mortality (%) 
Shapiro et al 3. 3.1 0.0 
Sr Heart J 1983 
Spirito et al 25 4.4 0.0 
N Engl J Mad 1989 
Kofflard et al 113 7.3 1.0 
Am J Cardiol1993 
Cannan et al 37 7.7 0.7 
Circulation 1995 
Cecchi at al 202 10.0 0.6 
JACC 1995 
Hypertrophic Cardiomyopathy: Updatc and New Perspectives 9 
-----------------------
condition during many years and others have severe symptoms of heart failure 
or die suddenly. Patients who are referred to tertiary centres represent, for the 
most part, the segment of patients with severe symptoms, the ones who are can-
didates for surgical intervention or those who are at risk of sudden death. These 
patients with hypertrophic cardiomyopathy personify a selected minority and 
their clinical course seems to represent the worst end of the disease spectrum 
(58,59). Indeed, in unselected studies patients with hypertrophic cardiomyopa-
thy have a more favourable prognosis and the annual mortality is I percent or 
less (37,38,59-61). Table II depicts studies concerning the prognosis of patients 
with hypertrophic cardiomyopathy. 
Risk:factol'sfol' suddell death 
The risk for the individual patient with hype.trophic cardiomyopathy for prema-
ture cardiac death is not easy to determine. However, there is agreement among 
investigators that there is a small subgroup of patients who are particularly at 
high risk for sudden death (62). Especially, patients who have survived cardiac 
arrest (63,64), young patients with a family history of multiple sudden deaths 
(52,65) and those with a "malignant" cardiac gene mutation seem to be at sub-
stantial risk for premature death (66-68), although the last two findings may re-
flect the expression of the same phenomenon. Several clinical characteristics 
have been described that are related with an adverse prognosis, they include: the 
onset of symptoms in childhood (52), syncopal attacks (69,70), the presence of 
non-sustained ventricular tachycardia on ambulatory Holter monitoring (53,71), 
atrial fibrillation (38), substantial left ventricular hypertrophy (72), a marked 
outflow tract gradient (73) and exercised induced hypotension (74). However 
other studies could not confirm the relationship between these characteristics 
and untimely death (48,52,54,56,75-77). Identification of the individual patient 
at increased risk for sudden death cannot be made on the basis of presence of 
one of these variables due to the low positive predictive accuracy. However, 
their negative predictive value is rather high (62). Therefore it seems justified to 
reassure patients with hypertrophic cardiomyopathy with respect to their prog-
nosis if they have: (a) little or no symptoms, (b) no family history of premature 
death (c) sinusrithm on the electrocardiogram, (d) no ventricular tachycardia on 
24-hour Holter monitoring and (e) lack a left ventricular outflow tract gradient 
(62). Our experience is that most patients with the disease are at low risk and 
require no other treatment than careful echocardiographic and clinical follow-up 
(37). 
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THERAPY Crable III) 
Nonobstructive Cardiomyopathy 
Phal'lllac%gica/iherapy 
Since there are few controlled trials that have systematically compared the vari-
ous forms of pharmacological therapy, treatment for hypertrophic cardiomyopa-
thy is for the most part empirical and based on the experience of investigators 
familiar with this disease (4,62). Since the effectiveness of prophylactic treat-
ment is unknown, patients who are asymptomatic and are not at high risk for 
sudden death probably need no treatment (62). Those who have complaints of 
angina and/or exertional dyspnea can be treated with beta-blockers or 
calciumantagonists. Beta-blockers reduce myocardial oxygen demand and relief 
symptoms of angina through lowering heart rate, left ventricular contractility 
and myocardial wall stress during systole (78). Due to the decrease in heart rate 
and reduction of myocardial ischaemia beta-blockers may improve left ventricu-
lar diastolic filling and consequently diminish symptoms of dyspnoe and near 
syncope during exeltion (79,80). 
Verapamil is the most prescribed calciumantagonist in hypertrophic cardi-
Table III 
Diagram presenting the management of patients with hypertrophic cardiomyopathy in our 
clinic. 
Abbrevatiol1s: HTX= heart transplantation, ICD= implantable cardiac dctlbriIIator, [vi\,= mi-
tral valve, NYHA= New York Heart Association, SO"" sudden death, VT= ventricular tachy-
cardia 
Obstructive Non obstructive 
Normal systolic Impalted systolic 
funcUon luncUon 
~ ~ 
Asymptomatic .... No therapy Asymptomatic -.. No therapy Ace-inhibitor 
~ ~ Olurelics, Digitalis ~ 
Mild symptoms .... P·blocker or Mifd symptoms ---. p.blocker or Treatment---+- HTX 
(NYHA class II) verapamil (NYHA class II) verapamil failure 
~ ~ 
Severe symplons .... CombInation of Severe symplons ........ Combination 
(NYHA class III or IV) l3·bfocker and tNYHA class III or iV) ofp.blocker 
~ verapamlf ~ and verapamil 
Treatment failure Treatment failure 
~ "-. ---------... ~ 
" Surgical therapy 000 pacing Survivors SO 0i1lialem Nifedipine 
I ~ Sustained VT +1. p.blocker +/. p.blocker ~ 
Myectomy Myectomy + Amfodarone 
MYelongaUon ICD 
"-~---
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omyopathy, like beta-adrenergic blocking drugs verapamil reduces myocardial 
oxygen consumption by its negative inotropic and chronotopic effect. Moreover, 
verapamil decreases afterload through systemic peripheral vasodilatation. The 
benificial effect of verapamil on left ventricular mling and diastolic function, 
through lowering ofthc hemi rate, reduction of myocardial ischaemia and short-
ening of the left venticular isovolumic relaxation period, also contributes to alle-
viate symptoms (81,82). There is no benificial effect of either beta-blockers 01' 
verapamil on the prevention of sudden death (4,73). Two other caJciuman-
tagonists, diltiazem and nifedipine, are less prescribed. Diltiazem produces a 
small reduction in heart rate and has a benificial effect on diastolic function: 
there is a reduction of the isovolumic relaxation time and early-diastolic filling 
velocities at rest and during exercise are increased (83,84). In a double-blind 
crossover study comparing diltiazem (180 mg daily) and verapamil (240 mgl 
daily), improvements in exercise duration and maximal oxygen consumption 
were more outspoken with verapamil therapy (85) There are only few studies 
that have studied the effect of nifedipine therapy in patients with hypertrophic 
cardiomyopathy. Nifedipine is a more potent vasodilatator than verapamil, how-
ever most of its action is improvement of diastolic function: reduction of the re-
laxation time and increasing left ventricular compliance (86). Nevertheless, 
Yamakado et al. could not confirm the beneficial results ofnifedipine on the di-
astolic function (87). 
In nonobstructive hypertrophic cardiomyopathy and impaired systolic func-
tion ("burned-out phase"), the thempeutic approach is similar to that applied for 
heart failure, including therapy with angiotensin-converting-enzyme inhibitors, 
diuretics and digitalis (4,62). 
Pacemaker therapy 
Cannon et al. studied the role of dual chamber pacing in nonobstructive hyper-
trophic cardiomyopathy. These investigators examined 12 symptomatic patients 
with nonobstructive hypertrophic cardiomyopathy treated with dual-chamber 
pacing (88). Although permanent dual-chamber pacing resulted in improvement 
in symptoms and exercise tolerance, there was absence of objective evidence of 
hemodynamic 01' myocardial perfusion improvement during exercise, and a 
common need to reinitiate medical therapy over time because of persistent or 
worsening symptoms. Cannon et al. concluded that dual-chamber pacing cannot 
be recommended for routine use in patients with nonobstructive hypertrophic 
cardiomyopathy with symptoms refractory to medical management. 
Obstrllctive Hypertrophic Cardiomyopathy 
Pharmacological therapy 
With some exceptions medical therapy for obstructive hypertrophic cardio-
mopathy is equal to that for nonobstructive cardiomyopathy. Betablocking 
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agents are the most prescribed, because of their negative inotropic and c1J1'ono-
tropic properties. Moreover, the agents can reduce the exercise generated in-
crease in obstruction (89,90). The influence of beta adrenergic blockade on the 
basal outflow tract gradient is less significant (4,31). Verapamil can be used if 
therapy with betablockers is not succesfull: through its negative inotropic and 
chronotropic effects and benificial influence on diastolic function, the drug may 
lower the outflow tract obstruction and improve cardiac symptoms (91-93). 
However, in some patients the outflow tract gradient may increase through the 
vasodilatating properties of the drug and this may lead to serious complications 
as cardiogenic shock (94). Because of the outspoken reduction in systemic vas-
cular resistance, therapy with nifedipine can not be recommended in patients 
with obstructive hype.irophic cardiomyopathy. Disopyramide has negative ino-
tropic effects and especially this quality has been the reason to use this drug in 
the treatment of obstructive hypertrophic cardiomyopathy (95). It has been 
shown that dysopyramide reduces left ventricular outflow tract obstruction 
(96,97). In addition, dysopyramide can improve diastolic function (98). Therapy 
with disopyramide has resulted in improvement of symptoms and may be initi-
ated if therapy with beta adrenergic blocking agents or verapamil fails (96,97). 
However, due to its anticholinergic activity and side-effects, patients may dis-
continue therapy. 
Recently, Sherrid et al. (99) have studied the mechanism by which negative 
inotropic drugs cause elimination of the left ventricular outflow tract obstruc-
tion. These investigators concluded that negative inotropic drugs eliminate mi-
tral-septal contact and obstruction by decreasing left ventricular ejection accel-
eration. By slowing acceleration, these drugs reduce the hydrodynamic force on 
the protruding mitral leaflet and delay mitral-septal contact. This, in turn, results 
in a lower final pressure gradient. 
Pacemaker therapy 
Haemodynamic studies have revealed that DDD pacing in patients with hyper-
trophic obstructive cardiomyopathy may lower the left ventricular outflow tract 
gradient. The mechanisms by which cardiac pacing results in haemodynamic 
and clinical improvement are not completely understood. First, apical stimula-
tion of the right ventricular apex results in early activation of the left ventricular 
apical region. This leads to ejection of most of the left ventricular stroke volume 
before septal activation occurs. Second, due to the slower - non His-Purkinje 
system - spread of depolarisation, contractility and flow velocities are reduced 
and as a result the outflow tract gradient may be diminished. Third, since flow 
velocities are reduced and the contraction of the septum occurs late, systolic an-
terior motion of the mitral valve appears later and the duration of the septal-mi-
tral valve contact will be shortened. 
The timing of the A V interval is crucial in pacing for hypertrophic obstructive 
cardiomyopathy. The A V interval must be short enough to ensure ventricular 
Hypel1rophie Cardiomyopathy: Update and New Perspectives 
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capture in every instance. On the other hand, the A V interval must be long 
enough to maintain atrial contribution to diastolic filling. 
The first reports with respect to pacemaker therapy in obstructive hyper-
trophic cardiomyopathy were very promissing. Fananapazir et al. (100) studied 
44 patients (mean age 49 ± 14 years) with left ventricular outflow tract obstruc-
tion (mean gradient 87 ± 43 mm Hg) who had symptoms of angina, dyspnea or 
syncope despite therapy with p-adrenergic blockers or verapamil. Patients were 
in New York Heart Association functional class III or IV. After DOD pace-
maker implantation the left ventricular outflow gradient was reduced to 38 ± 38 
mm Hg (p<O.OOOI) and the functional class was improved (1.7 ± 0.7 versus 3.4 
± 0.5, p<O.OOOO I) In this study, follow-up evaluation was performed 1.5-3 
months after implantation. Fananapazir et al. (10 I) showed in another study that 
these favourablc results are maintained longterm: In 84 patients (mean age 49 ± 
16 years) with obstructive hypertrophic cardiomyopathy the New York Heart 
Association functional class had improved significantly (1.6 ± 0.6 versus 3.2 ± 
0.5, p<OOOO I) 2.3 ± 0.8 years after implantation of a DOD device. In a subgroup 
of 74 patients with significant outflow tract obstruction at rest, the left ventricu-
lar outflow tract gradient was reduced significantly at follow-up (27 ± 31 versus 
96 ± 41 mm Hg, p< 0.0000 I). Jeanrenaud et al. (102) reported equal long-last-
ing results in 8 patients with left ventricular outflow tract obstruction treated 
with DOD pacemaker therapy. 
However, other authors did not present equal beneficial results. Nishimura et 
al. (103) studied 19 patients with obstructive hypertrophic cardiomyopathy with 
a baseline gradient of 76 ± 61 mm Hg who were symptomatic despite therapy 
with P-blockers andlor calcium antagonists. Patients underwent double-blind 
randomization to either DOD pacing for 3 months followed by backup AAI pac-
ing for 3 months, or the same study arms in reverse order. In the DOD mode the 
left ventricular outflow tract gradient decreased significantly to 55 ± 38 mm Hg 
compared with the baseline gradient of 76 ± 61 nun Hg (p<0.05) and the gradi-
ent of 83 ± 59 mill Hg after AAI pacing (p<0.05). Symptomatic improvement 
was felt in 66 % of patients in the DOD-paced mode and in 42 % of patients in 
the backup AAI ann. Quality-of-life score and exercise duration were signifi-
cantly improved from the baseline state after the DOD pacing but were not sig-
nificantly different between the DOD and the AAI arm. These data show that 
dual chamber pacing results in modest reduction of the outflow tract gradient 
and that improvement in functional class can also occur from implantation of the 
pacemaker without its hemodynamic benefit (AAI mode), suggesting the role of 
a placebo effect. The same author warns for the deleterious effects of dual 
chamber pacing upon the diastolic function (104). Indeed, Nishimura et al. dem-
onstrated that DOD pacing in obstructive cardiomyopathy had an adverse effect 
on the diastolic function: there was a significant decrease in peak positive 
dP/dT, an increase in mean left atrial presssure and a prolongation oh, the time 
constant of relaxation. These results were confirmed by Betocchi et al. (105). 
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Most recently, Kappenberger et al. (106) published the results of a mul-
ticentre, prospective, European study (PiC-study) which investigated the effects 
of adding cardiac pacing to normal medical treatment in hypertrophic obstruc-
tive cardiomyopathy. In total, 82 symptomatic patients with obstructive hyper-
trophic cardiomyopathy were randomized to receive pacemaker therapy. Pro-
gramming the pacemaker in the DDD mode with optimal atrioventricular delay 
was considered to be pacemaker-activated; programming to AAI at 30 bpm was 
termed pacemaker non-activated. Programming in the active pacing arm during 
12 weeks was followed by pacing in the non-activated arm in 50% of patients, 
or the same study arms in reverse order in the other half. After the second 12-
week period the pacing mode preferred by the patient was programmed for 
long-term pacing. After 12 weeks of activated pacing the pressure gradient fell 
from 59 ± 36 mm Hg to 30 ± 25 nun Hg (p<O.OO I), New York Heart Associa-
tion functional class improved from 2.4 to 1.4 (p~O.OO I) and 79 patients pre-
fen'ed active pacing over inactivation of the pacemaker at the end of the cross-
over study. 
In conclusion, dual chamber pacing will result in most patients in a modest 
reduction in the outflow tract gradient and will provide symptomatic improve-
ment in selected patients. However, reduction of the left ventricular outflow 
tract obstruction with septal myectomy is much greater than with pacing, the di-
astolic function can deteriorate (especially important in patients with a combina-
tion of systolic and diastolic dysfunction) and the long-term outcome of dual-
chamber pacing is still unknown. In our opinion, the long-term outcome of dual-
chamber pacing has to be studied in multicentre, randomized trials before the ul-
timate role of pacing can be established. 
Surgel)' 
The largest experience in the invasive treatment of patients with obstructive hy-
pelirophic cardiomyopathy is surgical therapy. Surgery for hypertrophic cardi-
omyopathy is generally performed in patients who have a significant left ven-
tricular outflow tract gradient and severe symptoms despite maximal medical 
therapy (107-109). The classic approach is septal myectomy (the Morrow proce-
dure), in which a portion of the basal sephllll is resected tluough an aortotomy 
(110). This procedure usually results in adequate reduction in the obstruction to 
outflow (I 11-116). Moreover, septal myectomy will in most cases lead to a re-
duction in the left ventricular systolic pressure, a decrease ill the basal and peak 
myocardial o>;ygen consumption and a decrease in left ventricular end-diastolic 
pressure (117). The operation will result ill a widening of the left ventricular 
outflow tract, thereby increasing the distance between the sephllll and the mitral 
valve and as a result this procedure reduces the high outflolV tract velocity and 
Venturi forces that create systolic anterior motion of the mitral valve. Since mi-
tral regurgitation results from systolic anterior motion of the valve, this phenom-
enon is also relieved by septal myectomy. The net result of the procedure is that 
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quality of life of the patients is improved as manifested by a reduction in symp-
toms of exe.iional dyspnea, angina and syncope or near-syncope (107). How-
ever, septal myectomy probably does not change the natural history of the dis-
ease (4,37,111,113,116). Septal myectomy has been performed since 1958 (118) 
and during early experience operative mortality was as high as 5-8% (107,111). 
However, with increasing surgical experience operative morlality is less than 2 
percent at referral centers where the majority of the procedures are performed 
(113-116, (19). Operative mOliality is significantly higher when the myectomy 
procedure is combined with mitral valve replacement andlor coronmy bypass 
surgery (115,116,120). 
In selected patients septal myectomy is combined with mitral valve plication 
(121), extension of the anterior mitral leaflet by a pericardial patch (122) and 
mitral valve replacement (123). These additional procedures are performed if a 
suboptimal result is expected after septal myectomy alone, for instance in pa-
tients in which the basal septum is relatively thin and patients with intrinsic mi-
tral valve disease (especially those with enlarged mitral valves which may pre-
dispose to residual systolic anterior motion after septal myectomy resulting in 
persisting outflow tract obstruction). Extended myectomy with partial excision 
and mobilization of the papillary muscles may be performed if the papillary 
muscles are hypertrophied and malattached to the lateral wall (124). 
Mitral valve replacement is also performed without previous myectomy (125-
127). In general, mitral valve replacement will result in a more significant re-
duction of the left ventricular outflow tract gradient and left ventricular end-di-
astolic pressure. However, the long-term risks of t1u'omboembolism, prosthetic 
valve dysfunction and the need for anticoagulant therapy make valve replace-
ment an unattractive option for many patients with hype.irophic obstructive car-
diomyopathy. 
Non-surgical septal myocardial reduction 
This procedure was introduced by Sigwart and aims to reduce the septal mass by 
producing a septal infarction trough the injection of absolute alcohol in a septal 
branch of the anterior descending coronary artelY (128). Knight et al. treated 18 
patients with this technique and showed that it is a safe method of reducing left 
ventricular outflow tract obstruction (129). The new method has been tested and 
used by othe.·s with equal success (130-132). Further experience in prospective, 
randomized trials is needed to establish the role of this technique in treating pa-
tients with obstructive hypertrophic cardiomyopathy (133). 
GENETICS 
Hypelirophic cardiomyopathy can be caused by mutations in anyone of several 
genes that encode proteins of the cardiac sarcomere: beta-myosin heavy chain, 
cardiac troponin T, alpha-tropomyosin, cardiac myosin-binding protein C, ven-
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tricular myosin essential light chain, ventricular myosin regulatOl)' light chain 
and cardiac troponinl (134). Mutations in the beta-myosin chain gene constitute 
most of the cases of familial hypelirophic cardiomyopathy (67,135). The beta-
myosin heavy chain consists of 1936 amino acids and over 40 mutations in the 
genetic material encoding for these aminoacids have been described resulting in 
hypertrophic cardiomyopathy. For instance, in the most reported mutation 
Arg403Gln, the aminoacid arginine is replaced by glutamine at coding position 
403. Identification of the genetic defect has repercussions for clinical outcome. 
For example, the beta-myosin chain mutations Arg103Gln and Arg719Trp are as-
sociated with a high incidence of sudden death (136-139). Other mutations, like 
Va1606Met, Leu908Val and Glu'30Lys are associated with a benign prognosis 
(67,138). 
Generally, mutations in the gene encoding for cardiac troponin T will lead to 
left ventricular hypertropy that is substantially less than in patients with beta-
myosin chain gene defect related hypertrophic cardiomyopathy, yet the inci-
dence of sudden death is high in cardiac troponin T mutations and resembles the 
malignant beta-myosin mutations (66,140). Hypertrophic cardiomyopathy 
caused by alpha-tropomyosin mutations is usually associated with a benign 
prognosis (141). The estimated frequency with which a mutation on the corre-
sponding gene cause hypertrophic cardiomyopathy is depicted in Table IV 
(62,67,136,140). It is likely that that numerous other mutations in other genes 
await identification (48,133). 
Unfortunately, hypertrophic cardiomyopathy is a genetically heterogeneous 
disease and the same mutation will not always result in an identical phenotypical 
expression. For instance, the malignant beta-heavy chain Arg40JGln was not as-
sociated with poor outcome in a Korean family (139). Moreover, the degree of 
hypertrophy may vary in patients carrying the same mutation (68,142,143). 
These findings indicate that other factors, environmental as well as genetic, may 
It/ble IV 
Estimated percentages with which lIlutations on genes encoding for the 
proteins of the cardiac sarcomere cause hypertrophic cardiomyopathy_ 
P-Myosln heavy chain 
cardiac Troponin T 
a-tropomyosin 
myosin-binding protein C 
Myosin light chain 
Tropononin I 
other genes 
percentage 
,,35 % 
,,15 % 
<5% 
,,15 % 
< 1 % 
? 
? 
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modifY the phenotypic expression of the mutated gene. Lifestyle, riskfactors, ex-
ercise and modifier genes may play an impOliant role in the presence, pattei'll 
and extent of hypertrophy in this disease (68). For instance, angiotensin 1\ 
stimulates cardiac hypertrophy, and it is formed by angiotensin converting en-
zyme from angiotensin I. The ACE levels in the human heart are partly deter-
mined by the liD polymorphism: subjects with the DD genotype have higher 
ACE levels than subjects with II or ID genotypes. In patients with hype,irophic 
cardiomyopathy, the ACE genotype DD has been associated with more exten-
sive left ventricular hype'irophy (144,145). Angiotensin 1\ exerts most of its 
known cellular actions trough the angiotensin II type I receptor (A TI-R) (146). 
Recently, it has been shown that the ATI-R Ale polymorphism is associated 
with the extent of hypertrophy: left ventricular mass was significantly higher in 
patients with hypertrophic cardiomyopathy carrying the C allele (147). 
SPECIAL PROBLEMS 
The athlete's heart 
Hypertrophic cardiomyopathy is the most common cause of sudden death in 
young athletes « 35 years), occurring in up to 50% of cases (148-150). The ma-
Table V 
Criteria to distinguish the athlete's heart from hypertrophic cardiomyopathy. 
Abbrevations: ECG= electrocardiogram, HC1Vf= hypertrophic cardiomyopathy, LA= left 
atrium, L VED= left ventricular end-diastolic dimension, L VH= left ventricular hypertrophy, 
SAM= systolic anterior motion. 
Hypertrophic Cardiomyopathy Athlete's heart 
Unusual patterns of lVH yes no 
Septal thickness >15 mm yes no 
lVED <45 mm yes no 
LVEO> 55 mm no yes 
LA enlargement yes no 
Female gender and abnormal 
septal thickness (>12 mm) yes no 
Decrease of septal thickness 
with deconditioning no yes 
Abnormal ala ratio yes no 
SAM of the mitral valve yes no 
Family history of HCM yes no 
Prominent q·waves on the ECG yes no 
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jority of these deaths occm dming severe exel1ion (150). Athletic training leads 
to alterations in cardiac anatomy and these changes may resemble the anatomic 
feahlres of hypertrophic cardiomyopathy. Athletic training leads to an increase 
in the left ventricular wall thickness, especially the septal wall, end-diastolic left 
ventricular dimension and left ventricular mass (151-153). However, it is impor-
tant to distinguish the athlete's heart from hypertrophic cardiomyopathy, be-
cause identification of this disorder makes the athlete a patient with cardiovas-
cular disease with increased risk for prematme death and consequenses for 
health insmance. Besides, it disqualifies the athlete from competition and with-
holds the athlete from the health benefits of exercise. Echocardiography is an 
important tool to differentiate between the athlete's heart and hypertrophic car-
diomyopathy. Table V showes the criteria to distinguish the athlete's heart tj'Oln 
a patient with hypel1rophic cardiomyopathy. Most important, in the majority of 
competitive athletes left ventricular wall thickness does not exceed 12 mm. In a 
study by Pellicia et al. (152), the lell ventricular wall thickness was~ 13 mm in 
only 2% of947 elite Italian athletes. Moreover, unusual patterns of hypertrophy 
involving other segments than the ventricular septum or heterogeneous distribu-
tion of myocardial hypel1rophy favoms hypertrophic cardiomyopathy. Second, 
the leti ventricular end-diastolic cavity dimension is enlarged ( > 55 mill) in 
more than one third of highly trained male athletes (152,154). In patients with 
hypertrophic cardiomyopathy the end-diastolic dimension is usually < 45 nun 
(4), unless the disorder has evolved to the end-stage phase where the end-dias-
tolic dimension is increased and systolic nmction is diminished. Third, vigorous 
training in female athletes will not result in left ventricular thickness exceeding 
normal limits (152,155). Fomth, the ventricular wall thickness will show a sub-
stantial decrease with deconditioning . Maron et al. (156) showed that within 3 
months of deconditioning left ventricular thickness was reduced to norma I val-
ues in six highly trained athletes who had competed in rowing or canoeing at the 
1988 Seoul Olympic Games. Fifth, the trans mitral E/A ratio measmed by pulsed 
Doppler echocardiography is normal in athletes (157-159) and may be altered in 
hypertrophic cardiomyopathy. Classically, the "E", due to rapid filling, is de-
creased and the "A", due to atrial contraction is increased in hypertrophic cardi-
omyopathy (160,161). 
Atrial fibrillation 
The onset of atrial fibrillation has an important impact on the clinical status of 
the patient with hypertrophic cardiomyopathy: most of the patients have worsen-
ing of symptoms, especially the patients with impaired diastolic function 
(4,12,76,162,163). From previous studies, atrial fibrillation is present in 10-
15% of patients with hypertrophic cardiomyopathy (4,71,164). 
The incidence of atrial fibrillation is highest in patients with obstructive hy-
pertrophic cadiomyopathy due to concomitant mitral regmgitation and increased 
left atrial size (12,162,165). However, systolic and diastolic dysfunction in pa-
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tients may also lead to enlargement of the left atrium and the onset of atrial fi-
brillation (166). Atrial fibrillation is associated with an increased risk of sys-
temic tromboembolism (167,168) and prompt treatment with anticoagulant 
therapy is essential. There are controversial data concerning the presence of 
atrial fibrillation and the risk for cardiac death. Some authors have related atrial 
fibrillation with a poor prognosis (38,162,164), while others could not confirm 
this relation (37,76). The treatment of atrial fibrillation is aimed at restoration of 
sinus rhythm. Amiodarone is probably the most effective pharmacological agent 
to restore and maintain sinus rhytlull (76,117,170). However, since patients are 
frequently young and side effects are not unusual with amiodarone therapy, 
sotalol may be attempted first to re-establish sinus rhytlull (73). In patients with 
obstructive hypertrophic cardiomyopathy and atrial fibrillation, myectomy will 
lead to abolishment of mitral insufficiency and reduction of left atrial size and 
thereby restoration of sinus rhythm (172). If pharmacological conversion to si-
nus rhythm is not succcsfull, electrical cardioversion has to be attempted. In 
chronic atrial fibrillation therapy with beta adrenergic blocking agents or 
verapamil is usually effective to control heart rate and alleviate symptoms 
(4,12,76). 
Ventricular arrhythmias 
It should be emphasized that there is no generally accepted strategy for the man-
agement of ventricular tachycardia in patients with hypertrophic cardiomyopa-
thy. The prevalence of nonsustained ventricular tachycardia on Holter monitor-
ing is between 20 and 50 % in these patients (37,38,53,63,71,75,164,173). Most 
reports indicate that nonsustained ventricular tachycardia on Holter monitoring 
has a benign prognosis in asymptomatic patients (63,75,173) and that these pa-
tients should probably not be treated with antiarrhytlunic therapy (4,62,75). A 
more aggressive approach is warranted if ventricular tachycardia is sustained, 
associated with symptoms or when patients have survived cardiac arrest 
(4,62,73,173). Previous studies have shown that beta-blockers, verapamil and 
class I antiarrhytlnllic drugs do not diminish ventricular arrhythmias nor prevent 
sudden death (4,12,71,174,175). In contrast, amiodarone abolishes ventricular 
tachycardia during Holter monitoring in most patients with hypertrophic cardi-
omyopathy (174,176) and may prevent sudden death (176). However, other in-
vestigators could not confirm the finding that amiodarone prevents sudden death 
(12,173,177). Patients who slilvived cardiac arrest and who have a left ventricu-
lar outflow tract gradient may be successfully treated with myectomy (4,178). 
An implantable cardioverter-defibrillator may be implanted in patients with high 
risk for Iife-tlu'eatening tachyarrhythmias; for instance in survivors of cardiac ar-
rest and patients with genetic risk of sudden death. The role of programmed 
electrical stimulation is questionable. Most reports do not identify patients at 
high risk for sudden death if sustained ventricular tachycardia is induced by pro-
grammed electrical stimulation (4,62,173,179,180). 
20 Ch"pter I 
CONCLUSION 
Hypertrophic cardiomyopathy is a complex cardiac disorder with heterogeneity 
in pathophysiologic expression, clinical presentation, prognosis, management 
and genetic mutations that cause the disease. The knowledge about the various 
aspects of this disease is expanding continuously. However, the place of the 
newer treatment modalities (pacemaker therapy, septal myocardial ablation) has 
not been determined yet. The exact molecular pathogenesis of hypeJit'ophic car-
diomyopathy remains to be established and several factors that influence the 
phenotypic expression of the mutated gene are yet to be discovered. Elucidation 
of the molecular basis and the role of environmental factors will probably result 
in better understanding of the pathogenesis of this disease (143). 
It is hoped that the application of molecular genetics will help to stratify and 
develop more definitive therapy, for instance inhibiting the transcription of the 
defective gene. 
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ABSTRACT 
Overall annual cardiac mortality in hypertrophic cardiomyopathy (HC) has been 
reported to be between 2 and 4%, although these numbers are primarily from 
retrospective studies of patients referred to large research institutions. A clinic 
population of 113 patients with HC was prospectively studied to assess cardiac 
mortality in the overall group and in selected subgroups conunonly thought to 
be at high risk for sudden death. The mean age at diagnosis was 37 ± 16 years. 
DlII'ing follow-up, there were II cardiac and 2 noncardiac deaths. The al111l1al 
cardiac mortality was 1% (95% confidence interval 0.2-1.8%). Because of the 
small number of deaths, relative risk for cardiac death was not significantly dif-
ferent in the presence of young age ("; 30 years), family history of HC and sud-
den death, history of syncope or previous cardiac arrest, or both, ventricular ta-
chycardia on 24-hour Holter monitoring, or septal myotomy/myectomy for re-
fractory symptoms and outflow tract obstruction. It is concluded that HC has a 
relatively benign prognosis (I % annual cardiac mortality) that is 2 to 4 times 
less than that previously reported. 
INTRODUCTION 
Hypertrophic cardiomyopathy (HC) is notorious for an increased risk of un-
timely death (1-3), but its actual prognosis is poorly defined. Previous studies 
repOlied overall annual mortality rates between 2 and 4% (4-10). These rates for 
the most pali are based on hospitalized patients referred to large research institu-
tions and probably tell a bleaker story than actually exists for the general popu-
lation of patients with HC, as suggested by a recent study by Spirito et al. (II). 
These investigators followed a small number of outpatients with HC and 
found no case of sudden death or clinical deterioration over 3 to 6 years. Recent 
progress in electrophysiology (12,13) and genetics (14,15) has enabled investi-
gators to identify selected patients with particularly high risk for sudden death. 
Before such highly technical and invasive tests are used in all patients with HC, 
a more acclll'ate assessment of the overall prognosis in this disease is needed. 
Since 1970, we have followed a large number of patients at Olll' HC clinic, rep-
resenting the complete spectrum of the disease in regard to clinical presentations 
and treatment modalities. In Olll' experience with these patients, we have found a 
remarkably low incidence of cardiac death. 
METHODS 
Patiellt selectioll 
Patients in the HC clinic at the Thoraxcenter of Academic Hospital "Dijkzigt" 
generally are in I of the following 4 groups: (I) those diagnosed in our hospital 
or outpatients clinics, (2) those transferred from outlying hospitals for advanced 
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care, (3) outpatients referred from the community for advice and follow-up, and 
(4) self-referred family members of patients. 
Patients with identifiable causes of left ventricular hypertrophy, such as val-
vular aortic stenosis and uncontrolled systemic hypeltension, are not followed in 
the HC clinic and are not included in this study. 
Between 1970 and 1990, 113 patients were examined initially and at yearly 
intervals. Before 1979, the diagnosis of HC was based on clinical parameters 
alone; after 1979, it as based on the echocardiographic finding of a nondilated, 
hypertrophied left ventricle (any wall thickness> 15 mm) in the absence of 
known causes of left ventricular hypertrophy (16). For children, ventricular hy-
pertrophy was diagnosed in relation to published standards for height and 
weight (17). 
At the time of the initial visit, clinical characteristics including age at diagno-
sis of HC, family histOlY of HC or sudden death in a first-degree relative, or 
both, history of syncope or sudden death, symptoms and New York Hemt Asso-
ciation functional class were recorded. Physical examination and baseline labo-
ratory studies were performed, including M-mode and 2 dimensional echocar-
diography (as well as Doppler echocardiography after 1985), and 24-hour ambu-
latory electrocardiographic monitoring when possible. Invasive hemodynamic 
and angiographic studies were performed only in patients with symptoms refrac-
tory to medical therapy who were potential surgical candidates. Surgery was 
recommended if a peak left ventl'ieular outflow tract gradient >5011lmHg at rest 
01' with provocation was found. 
FollOW-III' 
Patients were assessed on a yearly basis or more frequently, as indicated. All pa-
tients were followed exclusively by I physician (FltC). 
Follow-up information on patients who moved out of Rotterdam was obtained 
from their private cardiologists. In cases of death, cause was determined by 
death certificate or autopsy when available, or by questioning of relatives or 
physicians involved in the patient's care. Cardiac death was defined as death 
from myocardial infarction, congestive heart failure or arrhythmia, or sudden 
death. Sudden death was assumed to be cardiac, and was defined as a witnessed 
death within I hour after the onset of symptoms or an unwitnessed death in a 
subject known to be alive and fi.mctioning normally 24 hours before (18). Epi-
sodes of successfi.llly resuscitated cardiac arrest during follow-up were classified 
as cardiac death for the purposes of analysis. 
Statistics 
Survival estimates and 95% confidence intervals were calculated according to 
the Kaplan-Meier method. The yearly mortality rate was calculated on the basis 
of all available follow-up time. To assess risk factors for cardiac death, 
univariate analysis was performed using the Cox regression model. For each in-
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dicator, the relative risk and 95% confidence interval are reported. 
RESULTS 
Baseline characteristics 
Clinical characteristics of the 113 study patients (60 male and 53 female) at the 
time of the initial visit are presented in Table I. The mean age at presentation to 
our institution was 38 ± 15 years (range 12 to 76). Forty-three patients were 
aged :<:30 years, and 6 patients were >65 years at the time of diagnosis. Fifty-
four patients reported history ofHC in:::1 first degree relative, of whom 40 pa-
tients also reported a family history of sudden death at a young age «40 years). 
Seven patients reported multiple sudden deaths in the family. No patient had 
family history of sudden death in the absence of HC. Twenty-four patients had 
syncope at presentation. One patient had a witnessed cardiac arrest and was suc-
cessfully resuscitated. Reported symptoms included dyspnea in 49 patients, 
exertional angina in 37, and palpitations in 34. Fifty-seven patients were asymp-
tomatic or had trivial symptoms (New York Heart Association functional class 
1),40 were mildly symptomatic (class II), and 16 were moderately symptomatic 
(class Ill). No patient had New York Heart Association class [v. 
Baseline medications included ~ blockers in 49 patients, calcium antagonists 
in 17, both ~ blockers and calcium antagonists in 6, and antiarrh)1hmics in4. 
The diagnosis of HC was confirmed by 2-dimensional echocardiography in 
all patients (19). Mean left ventricular wall thickness was 22 ± 4 mm (range 15 
to 40). Systolic anterior motion of the mitral valve was present in 64 patients. 
Left ventricular outflow tract obstruction >50 mm Hg at rest or with provoca-
tion was present in 38 patients, as determined by Doppler echocardiography or 
cardiac catheterization, or both. Of 98 patients who had at least one 24-hour 
Holter monitor, 37 had d episode of ventricular tachycardia (:::3 consecutive 
ventricular beats) recorded; none of these had sustained (>30 seconds) ventricu-
lar tachycardia. Holter recordings were generally obtained without discontinua-
tion of medications. 
FollOW-lip data 
No patient was lost to follow-up, and information was obtained in all surviving 
patients within 6 months of January 1990. Mean follow-up was 7 ± 6 years 
(range I to 19). 
During the follow-up period, 32 patients underwent myotomy/myectomy. 
One patient underwent concomitant mitral valve replacement for significant mi-
tral valve regurgitation, and 3 underwent concomitant coronary artery bypass 
grafting for significant coronary artery disease. No patient had intraoperative 
placement of a permanent pacemaker or automatic implantable cardioverter-
defibrillator device; however, 4 patients needed permanent pacemakers after 
surget),. There was I peri operative death, a patient with a preoperative gradient 
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Baseline characteristics of patients with hypcI1rophic cardiomyopathy. 
Patients 
Male/female 
Mean age (years) 
First visit 
Diagnosis 
Family history 
He 
HC and SO 
History 
Syncope 
Cardiac arrest 
Symptoms 
Dyspnea 
Angina 
Palpitations 
NVHA functional class 
" 
'" IV 
Therapy 
J3 blockers 
Calcium antagonists 
P blockers and calcium antagonists 
Antlarrhythmlcs 
LVOT gradient 
(at rest and/or provocation) 
>50mmHg 
NUmber (%) 
113 
60/53 
36±15 (range 12·76) 
37±16 (range 5·71) 
+ 54 (48%) 
o 35 (31%) 
24 (21%) 
+ 40 (35%) 
o 52 (46%) 
- 21 (19%) 
24 (21%) 
1 (1%) 
49 (43%) 
37 (33%) 
34 (30%) 
57 (50%) 
40 (36%) 
16 (14%) 
0(0%) 
49 (43%) 
17 (15%) 
6 (5%) 
4 (3%) 
+ 38 (34%) 
o 68 (60%) 
7 (6%) 
HC = hypertrophic cardiomyopathy; LVOT = leU ventricular outflow tract; NVHA = New York 
Heart Association; SO = sudden death; + = present; 0 = absent; - = unknown or not avail-
able. 
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Figure I 
Cardiac survival of 113 patients with hypertrophic cardiomyopathy. Numbers above horizon-
tal axis refer to numbers of patients at each follow-up period. VCI1icai bars indicate 95% con-
t1dcncc intervals. 
of 145 nun Hg and class II symptoms, who died of intractable congestive heart 
failure 21 days after surgery. Three surgical patients died suddenly in late fol-
low-up at a mean of 5 years after surgery. 
During the follow-up period, 12 patients died and I was successfully resusci-
tated from cardiac arrest, which in this study is considered a cardiac death. Two 
patients died of noncardiac causes: I at age 53 years from carcinoma of the 
lung, and I at age 76 from a cerebro vascular accident. In the latter patient, a 
cardiac source of cerebral embolus was considered unlikely. The remaining II 
deaths were cardiac, of which 9 were sudden by defined criteria, including the 3 
surgical patients and the I cardiac arrest slllvivor. One patient, the peri operative 
patient previously described, died from congestive heart failure. The remaining 
death was in an 80-year-old man who died at home of an undetermined but pre-
sumably cardiac cause. One patient who died had proven coronary altery dis-
ease. 
The mean age at cardiac death was 47 ± 18 years (range 26 to 80). The annual 
cardiac mortality in this population was 1% (95% confidence intelval 0.2 to 
1.8%). Figure I shows the Kaplan-Meier survival curve for patients free from 
cardiac death. 
For the purposes of analysis, patients were divided according to known or 
suspected risk factors for sudden death, including young age, family histmy of 
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both He and sudden death, history of syncope or sudden death, or both, and 
presence of ventricular tachycardia on 24-holll' Holter monitoring (8,13,20-23). 
No statistically significant difference in risk of cardiac death was found in any 
subgroup (,rable II). 
DISCUSSION 
This study is the first to report a benign prognosis for a large, relatively 
nonselected population of patients with He. In this population of 113 patients, 
only II died from cardiac causes during an average follow-up of 7 years, yield-
ing an annual cardiac mortality rate of only I %. Previous prognosis studies re-
ported overall annual cardiac mortality rates of 2 to 4% (4-7,9, I 0), with annual 
Table II 
Cardiac death in selected subgroups of patients with hypertrophic cardiomyopath)~ 
Cardiac Follow-up 
Subgroup Number Deaths (years) RR(el) 
Total 113 11 7±5 
(range 1-19) 
Age ~ 30 years 
+ 43 5 8±5 1.36 (0.44·4.18) 
0 70 6 7±6 
FH of HC and SD 
+ 40 3 7±6 0.65 (0.17-2.44) 
0 52 6 7±5 
21 2 9±5 
Syncope and/or cardiac arrest 
+ 31' 4 9±6 1.51 (0.48·4.81) 
0 82 7 7±5 
VT on Holter 
+ 37 2 8±5 0.55 (0.12-2.58) 
0 61 6 8±6 
15 3 4±3 
Surgery 
+ 32 4 8±6 1.45 (0.45·4.61) 
0 81 7 7±5 
. includes 7 patients with syncope during follow-up. 
CI ::: 95% confidence interval; FH ::: family history; RR ::: relative risk compared with patients 
in whom clinical feature is absent; VT ::: ventricular tachycardia; other abbreviations as in 
table I. 
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mortality rates up to 8.6% in selected high-risk subgroups (Table Ill) (7,8,13). 
In contrast to those previous studies, the present study is both prospective and 
all-inclusive; the analysis does not exclude patients who are asymptomatic. do 
not have outflow tract gradients or have had cardiac surgery. 
All patients in this study were treated by the same physician to the following 
flexible guidelines: initial trial of P blockers for relief of symptoms, if present; 
switch to calcium antagonists if symptoms persist; and surgical therapy for those 
with medically refractory symptoms in whom a significant outflow gradient is 
shown at cardiac catheterization. Antiarrhythmic therapy was used velY infre-
quently. We believe this therapeutic algorithm, although not unique to our insti-
tution, may have conferred a survival benefit in these patients. 
Of 32 patients who underwent myotomy/myectomy during follow-up, there 
was only I perioperative death. Equally good surgical results were obtained by 
Seiler et al (10) who recently reported only I perioperative death in 79 surgical 
patients. This is in sharp contrast to previous surgical series that reported opera-
tive mortality rates as high as 31% (4-7) and to current estimated rates of 5 to 
8% (I). The present data show a relatively good prognosis for patients surviving 
surgery, as do previous studies (6,7,10), although absolute protection against 
late sudden death does not occur. 
Other investigators have reported favourable prognoses in specific subgroups 
of patients with He, including the elderly (24), the nonobstructed (25), and 
those with apical hypertrophy (26). Only recently was the overall experience in 
a general He clinic repDl1ed: Spirito et al (II) found no cases of cardiac death 
or deterioration in 25 outpatients, although the follow-up period was brief (mean 
4.4 years) and the patient cohort small. 
As Spirito et al (II) point out, and we believe correctly, selection bias has 
likely led to misrepresentation of the true prognosis in He. They note that most 
patients in previous studies were hospitalized at I or 2 national referral centers. 
By inference, those patients are sicker and therefore have fatal complications 
more often than do those such as ours. However, it is difficult to prove the effect 
of selection bias, because a correlation between presenting clinical features and 
risk of subsequent death has not been shown in He (4,6,20,23), with the pos-
sible exception of prior cardiac event (7,13), and class IV dyspnea (5). Although 
those 2 clinical features are rare in the present study, they are uncommon in 
other studies as well (Table Ill). 
Because of the low incidence of cardiac death in tlllS population, we were un-
able to delineate statistically significant risk factors for this outcome. The clini-
cal features commonly believed to confer an increased risk of sudden death in-
clude young age, strong family histDlY of sudden death, previous histDlY of syn-
cope or cardiac arrest, and ventricular tachycardia on 24-hoUl' Holter mDllltor, 
especially when associated with symptoms (6-8,13,20-23). Recent genetic and 
electro physiologic studies identified new risk factors for sudden death, includ-
ing particular chromosomal abnormalities (14,15) and the presence of inducible 
Table III 
Comparison of clinical features of patients in different prognosis studies. 
Mean LVOT 
Follow-up Age NYHAclsss Gradient 
Number (years) (years) III ar IV present Syncope FH 01 SO 
Swan at al (4) 85 4.0 11 75 
Hardarson et at (5) 119 4.6 17 30 
Shah et al (6) 19o 5.2 69 93 51 
McKenna et al (7) 254 6.0 34 22 139 49 57 
Maron et al (8) 99 3.0 38 18 54 
Spirito ot aJ (11) 25 4.4 44 5 0 
Romeo at al (9) 125 7.6 34 78 44 43 15 
Seiler et al (10) 139 8.9 37 
Present study 113 7.3 37 16 38 31 40 
Number of patients with a "signifleantn gradient (definition varIes among investigators) 
t EstImated from data 
* Patients aged < 15 years 
§ Patients aged = 15 years 
Q Surgical patients 
11 Medical patients 
Abbreviations as in Table I and II. 
Annual 
Surgery Mortality (%) 
22 3st 
22 3St 
58 3.4 
33 5,9:1:f2.6§ 
15 2.3 
0 0.0 
0 3.4 
79 2A~/3.S1I 
32 1~ 
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sustained ventricular tachycardia (13). However, the present results suggest that 
applying genetic analysis and electrophysiologic testing to the general popula-
tion of patients with HC is unjustified. With an annual cardiac mortality of 1% 
in HC, such expensive and invasive studies should be reserved only for the few 
patients known by history to be at exceptionally high risk of sudden death. 
These findings also have important implications for the counseling of patients 
with He. Although it is still necessary to inform affected patients and their rela-
tives of the potential for sudden untimely death, physicians no longer need to 
paint an unduly bleak picture. The actual risk of dying in this disease is 2 to 4 
times less than that previously reported. With fllJiher advances in the detection 
and treatment of patients at high risk for sudden death, true prognosis in HC can 
only be expected to improve. 
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ABSTRACT 
Hypertrophic cardiomyopathy is a heterogeneous disease with a wide spectrum 
of clinical and haemodynamic manifestations. Pregnancy is generally consid-
ered a safe undeltaking in patients with hypertrophic cardiomyopathy. nevelthe-
less cardiac symptoms can develop or deteriorate during pregnancy. Studies that 
have investigated the clinical outcome of parturients with hypertrophic cardi-
omyopathy are for the most part retrospective. I'Ience, we prospectively fol-
lowed 9 patients with hypertrophic cardiomyopathy during pregnancy and deliv-
ery between 1988 and 1998. Our population represented the clinical heterogene-
ity of thc disease: Before pregnancy, syncopal attacks had been experienced by 
4 patients, dyspnea or angina was present in 4 patients, septal myectomy be-
cause of left ventricular outflow obstruction had been carried out in 5 patients, 
on 24 hour Holter monitoring one or more episodes of ventricular tachycardia 
were documented in 6 patients. Nine women had 20 pregnancies. Cardiac symp-
toms worsened in 2 patients during pregnancy, in whom one patient was treated 
with diuretics for relief of signs of healt failme. Five pregnancies ended in a 
spontaneous abortion. From 15 births, thitteen children were bom by vaginal de-
livelY and two by cesarean section because of fetal distress. In the perinatal pe-
riod, no child nor mother died. We conclude that pregnancy is well tolerated in 
patients with hypertrophic cardiomyopathy and that cardiological follow-up is 
necessaty during pregnancy for the surveillance of the patients' clinical condi-
tion. 
INTRODUCTION 
Hypertrophic cardiomyopathy is a heterogeneous disease characterized by a di-
versity in anatomical, haemodynamic and clinical presentation (1-4). The clini-
cal picture may differ from patient to patient: although the majority in 
unselected populations is asymptomatic, some patients have symptoms of an-
gina, healt failure or syncope (5,6). Pregnancy and delivery is usually well toler-
ated in patients with hypertrophic cardiomyopathy (7,8). However, symptoms 
can worsen and venous pulmonary congestion may develop during pregnancy 
and delivelY (7,9). Therefore, advise conceming pregnancy and delivelY should 
be individualized in these patients. We report the outcome of nine pregnant 
women with hypertrophic cardiomyopathy and present general advice for man-
agement of pregnancy and delivery. 
METHODS 
Between 1988 and 1998, nine patients from the "Thoraxcenter hypertrophic car-
diomyopathy clinic" were prospectively followed dming pregnancy and deliv-
ery. The diagnosis of hypertrophic cardiomyopathy was based on the echocar-
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diographic finding of a nondilatated hypertrophied left ventricle in the absence 
of known causes of left ventricular hypertrophy (10). At the time of the initial 
visit, clinical characteristics including age at diagnosis, family history of hyper-
trophic cardiomyopathy or presence of sudden cardiac death in a first degree 
relative, or both, history of syncope or sudden death, symptoms, New York 
Heart Association functional class and pharmacological therapy were recorded. 
Physical examination and baseline laboratory studies were performed, including 
twelve lead electrocardiography and echocardiography (M-mode as well as 
Doppler echo cardiography). All patients had undergone 24 hoUl' I-loiter monitor-
ing before pregnancy. Clinical characteristics, physical and echocardiographic 
examination were reevaluated before pregnancy, at midterm pregnancy and after 
delivery. The gynecologist was responsible for the welfare of the partUl'ients 
dUl'ing pregnancy and delivery. When indicated, (worsening of cardiac com-
plaints or signs of heaJt faiIUl'e), cardiac evaluation was performed more fre-
quently. 
RESULTS 
Baseline characteristics 
The clinical characteristics of 9 study patients are listed in Table I. One patient 
(patient no 2) had given bhth to 2 children before the diagnosis of hypertrophic 
cardiomyopathy was made. Since we included only patients who could be fol-
lowed prospectively, we eliminated these pregnancies from OUl' study. Nine pa-
tients were included with 20 pregnancies. The mean age at first presentation to 
our institution was 22 ± 6 years. Seven patients reported a family histOlY of hy-
pertrophic cardiomyopathy, of whom 6 patients also reported sudden death in a 
first-degree relative at a young age « 40 years). FoUl' women had experienced 
one or more syncopal attacks before pregnancy. Five women were asymptom-
atic prior to pregnancy, the symptoms recorded in the remaining patients in-
cluded dyspnea in 4 patients and exertional angina in 3 patients. All symptom-
atic patients were in TImctional class II according to the New York Healt Asso-
ciation. Five women had undergone septal myectomy because of the presence of 
a left ventricular outflow tract of more than 50 nnll Hg and complaints of angina 
or dyspnea despite therapy with betablockers andlor verapamil. In 4 patients this 
procedUl'e took place before the first pregnancy. The left ventricular outflow 
tract gradients, as presented in Table I, were evaluated one to six months before 
the first pregnancy in 8 patients and before the third pregnancy in patient no 2. 
All patients were in sinusrythm dUl'ing the study. On 24 hour Holter monitoring, 
five patients had one or more episodes of nonsustained ventricular tachycardia 
and in one patient an episode of sustained ventricular tachycardia was recorded 
without symptoms. 
Table I 
"-
Clinical characteristics of pregnant patients with hypertrophic cardiomyopathy_ co 
PI, Year Family NYHA Medication LVOT gradient VTon Year of Pregnancies 
no of birth history SD class pre during (mm Hg) Holter operation 
1962 + 15 + 1984 1988,1990 
2 1966 0 II 25 0 1977",1978",1991 
3 1967 0 V I(' 5 + 1994,1995 
4 1958 + II 4 + 1985 1994 
5 1967 + 0 10 + 1991 1988(A),1989 
1989(A), 1993, 1995 
6 1957 + 5 + 1992(A),1993,1995 
7 1966 + II Dis Dis- 50 + 1986 1988(A), 1991,1994 
8 1964 0 II V V,B 36 0 1997 
9 1962 + 12 0 1995 1996(A),1998 
Abbrevations: 
A= spontaneous abortus, B= beta blocker, D= diuretic, Dis: disopyramide, LVOT = left ventricular outflow tract, NYHA= New York Heart 
I 9 Association, pre= medical therapy before pregnancy, SD= sudden death, V= verapamil, VT = ventricular tachycardia, + = present, 0 = ~ 
'" absent, - = no therapy"= not included in the prospective study •• ;r= therapy was stopped during the first trimester of pregnancy. C; ~ 
w 
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Follow-up during pregnancy 
During pregnancy, four patients were treated with drugs, of whom 2 patients 
used verapamil (Table I). Patient no 3 discontinued verapamil at the first trimes-
ter of both pregnancies and restarted the drug after delivery. Patient no 8 contin-
ued verapamil troughout pregnancy. The outflow tract gradient had increased 
from 36 mm Hg before pregnancy to 90 mm Hg, at midterm evaluation. At 2 I 
weeks gestation she was hospitalized under suspicion of an acute appendicitis. 
Lapal'ascopy, however, did not confirm the diagnosis. Verapamil was discontin-
ued at discharge, because of the increase in obstruction and was replaced by 
metoproloi. On echocardiographic examination, four weeks later, the left ven-
tricular outflow tract gradient had decreased to 30 mm Hg. Pregnancy and deliv-
ery were uncomplicated afterwards. In patient no 7 disopyramide was stopped 
during the first trimester of both pregnancies and restmied after delivery. Two 
patients (no 2 and no 5) had worsening of symptoms during pregnancy. Patient 
no 2 was seen in our outpatient clinic at 38 weeks of her fourth pregnancy for 
progression of angina and dyspnea on exeliion. At physical examination, there 
were no overt signs of heart failure and she fulfilled her term without phannaco-
logical therapy. After delivery, cardiac complaints diminished and were compa-
rable with the prepregnancy period . Diuretic therapy was indicated in one pa-
tient (no 5) at the end of the fourth pregnancy for relief of symptoms of heart 
failure. 
Delivel}' 
Nine women had 20 pregnancies, five of whom ended in spontaneous abortion. 
The first pregnancy of patient no 5 ended in the delivery of a stillborn child at 
27 weeks. This patient was hospitalized because of excessive vaginal bleeding 
due to rupture of the placenta in the presence of placenta previa. Systolic blood 
pressure at admission was 75 mm Hg and was stabilized at 100 mm Hg after 
several blood transfusions. After delivery, the patients' recovery was uncompli-
cated. Autopsy of the female fetus of 640 grams did not reveal any cardiac ab-
normality. The characteristics of the 15 live-born infants are listed in Table II. 
There was no maternal nor neonatal death. Thirteen children were born by vagi-
nal delivelY, in one child vacuum extraction was needed because of fetal dis-
tress. Two intrauterine growth retarted children were born by cesarean section at 
39 weeks because of fetal distress. These two neonates were monitored in the 
pediatric clinic. DlII'ing their hospitalization no abnormalities were found and 
they were dismissed, 3 and 4 weeks after delivelY respectively. The other new-
borns were discharged the same or the other day after routine examination and 
observation. Birthweight averaged 2868 ± 716 gram (range 1280 - 4160 gram) 
and apgar scores were 8.6 ± 1.3 and 9.5 ± 0.9 after 5 and 10 minutes respec-
tively. Endocarditis prophylaxis was administered in 9 of sixteen deliveries. 
Table II ~ 0 
Characteristics of the neonates of patients with hypertrophic cardiomyopathy. 
Pt. Year of birth Birthweight Apgar score Mode of SSE 
no Gender (gram) 5 min-10 min delivery 
19S8/F 3300 10 -10 vaginal + 
1990/M 4160 10 -10 vaginal + 
2 1991/F 1280 8- 8 sectlo 0 
3 1994/M 2030 9- 9 vaginal 0 
1995/M 2430 9 -10 vaginal 0 
4 1994/M 3355 9 -10 vaginal 0 
5 1989/M 3340 8- 9 vaginal 0 
1993/M 3200 10 -10 vaginal + 
1995/F 3205 9 -10 vaginal + 
6 1993/F 2920 8 -10 vaginal(vacuum) + 
1995/F 2920 8 -10 vaginal + 
7 1991/F 3055 6- 9 vaginal + 
1994/F 2990 10 -10 vaginal 0 
8 1997/M 3030 9 -10 vaginal + 
9 1998/F 1800 6 - 7 sectlo + 
Abbrevations: 19 min= minutes, sectlo: sectlo caesarea, SSE= endocarditis profylaxis, += present, 0= absent. 
i .§ 
~ 
Co-> 
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Follow-lip atier delil'elJ' 
Uptill now, cardiac abnormalities are not found on echocardiographic examina-
tion in these children after maximal follow-up of nine years (range 0.1 - 9 
years). During follow-up two women (no 4 and 7) had cardiac events. Both pa-
tients were admitted to local hospitals after resuscitation because of ventricular 
fibrillation,S and 8 months after the latest pregnancy respectively. Patient no 7 
stayed comatose. Patient no 4 recovered without neurological injUlY, she was 
treated by implantation of an cardioverter defibrillator because of periods of sus-
tained ventricular tachycardia despite antiarrhythmic drug therapy. In the other 7 
patients clinical status was not different as compared to the prepregnancy pe-
riod. 
DISCUSSION 
In this paper we repOlt the outcome of 20 pregnancies in 9 patients with hyper-
trophic cardiomyopathy. Our cohort represented the heterogeneity in clinical 
presentation of tlus disease: while 5 patients were asymptomatic, 4 patients had 
complaints of angina or dyspnoe, 6 patients had ventricular tachycardia on 24 
hour Holter monitoring and septal myectomy because of left ventricular outflow 
tract obstruction was performcd in five patients. From 20 pregnancies, 15 chil-
dren were born alive, 13 by vaginal delivery and two by caesarean section. Five 
pregnancies ended in spontaneous abortion. Our results are in agreement with 
previous reports and confirm that pregnancy is generally well tolerated in pa-
tients with hypertrophic cardiomyopathy. 
Haelllod),nalllic changes dllring pregnancy and ils il1/llience on h)perlrophic 
c a rdi OIn)'op a I h), 
During pregnancy, important changes in the haemodynamic state take place. 
There is a reduction in the peripheral resistance beginning from the 12th week 
of gestation (II), nevertheless bloodpressure is unchanged in most patients since 
cardiac output is increased by 30-50% (12). In the last trimester, compression of 
the inferior caval vein by the expanding uterus can result in a decrease of 
venous return (13,14). During delivery, pain and stress causes sympathetic 
stimulation which leads to an increase in heartrate and contractility and further-
more the Valsalva manoeuvre may reduce venous return (13,14). 
The increase in contractility and decrease in pre- and afterload can augment 
the obstruction in patients with hypeltrophic obstructive cardiomyopathy, which 
in turn may lead to deterioration of the clinical condition (9,13,14). In patients 
with hypertrophic cardiomyopathy and diastolic dysfunction, the increase in in-
travascular volume and rise in heartrate is detrimental and may cause worsening 
ofsymptollls and pulmonary venous congestion (15). 
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Drug therapy during pregnancy 
Beta adrenergic blocking agents are traditionally prescribed in symptomatic pa-
tients with hypertrophic cardiomyopathy. Beta-blockers reduce myocardial oxy-
gen demand and relief symptoms of angina and dyspnea through lowering heart 
rate, reducing left ventricular contractility and reducing the exercise generated 
increase in obstruction (3,16,17). The use of these drugs in pregnancy is rela-
tively safe. There are no reports indicating that therapy with beta-blockers re-
suIts in fetal malformation (18). Intra-uterine growth retardation, neonatal 
bradycardia and neonatal hypoglycaemia are reported in a small number of pa-
tients (7,8,19,20). Verapamil is also widely used in the management of patients 
with hypertrophic cardiomyopathy, like beta-adrenergic blocking drugs, 
verapamil reduces myocardial oxygen consumption by its negative inotropic 
and chronotropic effect. Moreover, the drug may have a benificial influence on 
diastolic function (21,22). In patients with hypertrophic obstructive cardiomy-
opathy verapamil may increase the left ventricular outflow tract gradient 
through the vasodilatating properties of the drug (23). No teratogenic effects 
have been described in patients treated with verapamil for acute management of 
maternal supraventricular arrhythmias (24). The effects of chronic administra-
tion ofverapamil on the course of pregnancy is still unclear. 
Recommendations during labour and delivelJ' 
The use of beta mimetic tocolytic drugs is contraindicated in patients with hyper-
trophic obstructive cardiomyopathy, because the left ventricular outflow tract 
gradient increases and symptoms may worsen (8). Analgesia during labour is 
useful to diminish sympathetic stimulation (13,14). Epidural analgesia is not 
contraindicated, however adequate volume-expansion and careful bloodpressure 
monitoring is necessary, to avoid hypotension specially in patients with hyper-
trophic cardiomyopathy and outflow tract obstruction (25,26). Haemodynamic 
monitoring by pulmonary artery catheterization should be considered in patients 
who are severely symptomatic or have signs of heart failure to guide drug 
therapy (9). According to the statement of the American Heart Association pa-
tients with hypertrophic cardiomyopathy are at moderate risk for acquiring en-
docarditis (27). In our institution, endocarditis protylaxis is recommended in pa-
tients with distinct systolic anterior motion of the mitral valve and obstruction, 
and in patients with considerable mitral insufficiency. Oxytocin has been ad-
ministered safely in patients who require augmentation of uterine contraction af-
ter delivery (8,26). In general, vaginal delivery is considered safe and caesarean 
section is reserved for obstetretic indications. 
Gel1erall'ecOJllJJlendalio1ls 
Hypertrophic cardiomyopathy occurs both as a familial disorder, with an auto-
somal dominant pattern of inheritance, as well as in sporadic forms. The risk of 
inheritance in familial forms is 50%. However, it is important to note that pa-
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tients with identical gene mutations display variable clinical manifestations or 
even fail to express the disease (28,30). In the prepregnancy consultation it is 
important to explain the potential risk of pregnancy with respect to maternal and 
fetal well-being. Cardiological controls are necessary during pregnancy for the 
surveillance of the patients' clinical condition, to start or change therapy if 
symptoms worsen or to hospitalize the patient if there are overt signs of heart 
failure. Postpartum blood loss should be replaced by intravenous fluids, spe-
cially in patients with hypertrophic obstructive cardiomyopathy, because of the 
potential aggravation of the pressure gradient across the left ventricular outflow 
tract. After birth, echocardiographic evaluation should be performed every 2 to 
5 years in children (or sooner when cardiac symptoms develop) lasting until 
adulthood to recognize signs of hypertrophic cardiomyopathy. 
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ABSTRACT 
This study analyzes the alterations in size and geometry of the left ventricular 
(LV) outflow tract that occur in hypertrophic cardiomyopathy (HC) using tran-
sthoracic 3-dimensional echocardiography. Transthoracic 3-dimensional 
echocardiography was performed in 17 patients with He (4 after myectomy) 
and in 10 normal subjects. Images were acquired with the rotational approach, 
with electrocardiographic and respiratory gating. From the 3-dimensional 
datasets, short-axis parallel slicing of the LV outflow tract at Imm distance was 
performed at the onset of systole. For each slice, cross-sectional area and maxi-
mal and minimal diameter were calculated. Reconstruction of the LV outflow 
tract could be displayed in 3 dimensions in all patients, allowing orientation and 
clear definition of the irregular geometry. In patients with He, the minimal LV 
outflow tract cross-sectional area was smaller than in normal subjects (2.3 ± 1.0 
cm' vs 5.0 ± 0.9 cm', 1'<0.0001). The ratio between maximal and minimal 
cross-sectional areas was higher in patients with He than in normal subjects (2.6 
± 0.9 vs 1.4 ± 0.2, 1'<0.000 I). The ratio between maximal and minimal diameter 
of the smallest cross-section of the L VOT was also significantly higher in pa-
tients with He than in nonnal subjects (1.6 ± 0.3 vs 1.2 ± 0.1, 1'<0.001) and a 
value of 1.36 separated nonnal subjects limn He patients without previous my-
ectomy. In conclusion, precordial 3-dimensional echocardiography allows de-
tailed qualitative and quantitative infol1l1ation on the LV outflow tract. Patients 
with HC are characterized by a highly eccentric and asymmetric shape of the 
LV outfio,v tract, and by a smaller minimal cross-sectional area than seen in 
normal subjects. 
INTRODUCTION 
Postmortem studies and intraoperative findings indicate that 2-dimensional 
echocardiography may fail to give the full picture of the left ventricular (LV) 
outflow tract in patients with hypertrophic cardiomyopathy (HC) (1-6). Three-
dimensional echocardiography is a new imaging modality which provides 
unique infonnation on the spatial geometry of a given structure (7). Based on 
our experience in an un selected population (8,9), we believe that the alterations 
in size and geometry of the LV outflow tract in patients with He could be more 
accurately analyzed with precordial 3-dimensional echocardiography. With 
these concepts in mind, we designed this study to gain further insight into the 
complex geometry of the LV outflow tract in patients with HC. With this aim, 
analysis of the LV outflow tract was performed using 3-dimensional datasets 
obtained after acquisition of precordial echocardiographic images. 
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METHODS 
Study patients 
We prospectively selected 17 patients (13 men and 4 women; mean ± SD age 39 
± 15 years, range 19 to 65) with HC referred to the outpatient clinic of our insti-
tution for routine transthoracic echocardiographic follow-up. High-quality im-
ages were a prerequisite for inclusion in this study. The diagnosis of HC was 
based on M-mode and 2-dimensional echocardiographic demonstration of a 
nondilated hypeltrophic left ventricle in the absence of other cardiac or systenlic 
disease that could produce LV hypeltrophy (10). According to a previously es-
tablished classification (II), the patterns of distribution ofleft ventricular hyper-
trophy were: type I, I patient; type II, 3 patients; type ill, 12 patients; and type 
IV, I patient. Systolic anterior motion of the mitral valve was present in 12 pa-
tients and its severity was evaluated semiquantitatively from 0 = absence to 3+ = 
contact with the interventricular septum during systole (5). At the time of the 
echocardiographic study, a pressure difference was calculated 11-0111 Doppler LV 
outflow tract velocity recordings, and obstl1lction (gradient> 30 nllll Hg under 
basal conditions) was detected in 4 patients. A septal myectomy had becn per-
formed in 4 patients. Ten asymptomatic subjects without evidence of LV hyper-
trophy were also studied for comparison. These controls were 20 to 49 years 
(mean 28 ± 8) and 8 were men. 
Examination procedure 
Two-dimensional echocardiographic studies were performed with a commer-
cially available system (Vingmed CFM 750 [HOlton, Norway] or Toshiba 
Sonolayer SSH-140A [Tokyo, Japan]) equipped with a 3.5 MHz transducer, 
while the patient was lying in the 45° left recumbent position. After the follow-
up 2-dimensional echocardiographic study, the probe was positioned either at 
the left parasternal or apical window for acquisition of the tomograpllic images 
of the LV outflow tract for 3-dimensional reconstruction. Patient movement dur-
ing the image acquisition can be prevented by thoroughly explaining the proce-
dure before the study. The operator has to find the central axis of rotation so that 
the conical data sets encompass the LV outflow tract. During the acquisition, 
movements of the transducer holder must be avoided diligently. Minor images 
of the first and the fmal cut -plane indicate a correct 180" rotation. All subjects 
gave informed consent. 
Th"ee-dil'Ie"sioJ,al ecllOcardiography 
Image Acquisitioll. After the standard 2-dimensional examination, the video 
output of the echocardiographic systcm is interfaced to the acquisition system 
(Echo-scan, TomTec GmbH, Munich, Gennany) and the transducer is fixed into 
a cylindrical holder. A step-motor mounted on this holder can rotate the probe 
around its Iongihldinal axis via a wheel-work interface. The step-motor is con-
nected to the acquisition system which COllllllands the rotation of the probe at l' 
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intervals over a span of 180°. RespiratOly and electrocardiographic gating are 
perfonned after the operator has selected the end-expiratory phase by thoracic 
impedance measurement and an adequate R-R interval. Thus, only those beats 
falling in the predetermined R-R interval and at the end-expiratory phase are se-
lected by the steering logic of the system and acquired. Cycles that do not meet 
the preset ranges are rejected. Ninety sequential cross-sections are acquired, 
each during a complete heart cycle, encompassing a 3-dimensional conical vol-
ume. After distance calibration, images are stored in the computer memmy for 
subsequent analysis. 
Image Processillg. The raw data are resampled off-line according to their 
temporal and spatial location. The coordinates of each point are converted fi'om 
a polar to a rectangular system, and the space between contiguous points is elec-
tronically filled with a trilinear cylindric interpolation. Several algorithms are 
used to reduce noise and artifacts which can be created by patient and probe 
movements. 
Image Display Allalysis. [mages were analyzed as follows: 
I. After thourough examination of the 3-dimensional data sets with analysis 
of cardiac cross-sections in any desired plane ("anyplane echocardiography"), a 
cut-plane is selected where the LV outflow tract is visualized along its longitudi-
nal axis. 
2. The onset of ventricular systole is selected, as the first fi'ame during the 
cardiac cycle in which the mitral valve appears closed. 
3. Electronic parallel slicing ("paraplane echo cardiography") of the LV out-
flow tract perpendicular to the vertical axis is performed at I nlln intervals, from 
the hinge point of the anterior mitral leaflet to the point of coaptation of the mi-
tralleaflets, and the corresponding 2-dimensional images (both the stop frame at 
onset of systole and the dynamic sequence) are displayed. 
4. On the stop ibme image at the onset of systole, the endocardial contour of 
the cross-section is manually traced for automatic area measurement, and maxi-
mal and minimal diameters are also measured. 
5. Finally, reconstruction of the LV outflow tract at the onset of ventricular 
systole is displayed in wire frame mode and the representative image can be ro-
tated on the screen for versatile 3-dimensional evaluation (Figure I). 
From the analysis of the 3-dimensional datasets, the following measurements 
of the LV outflow tract at the onset of systole were considered: I) minimal 
cross-sectional area; 2) ratio between maximal and minimal cross-sectional area 
(max/min cross-sectional area), as an index of the "eccentricity" of the LV out-
flow tract (the higher the value, the greater the variations of the cross-sectional 
area throughout the length of the LV outflow tract); 3) ratio between maximal 
(Iatero-medial) and minimal (antero-posterior) diameter (maximin diameter) at 
the level of the cross-section with the minimal area, as an index of the "asym-
metty" of the LV outflow tract (a ratio of 1 indicates a circular shape, with the 
highest values corresponding to the more elliptical shape of the cross-sections). 
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Figure 1 
Analysis of left ventricular (LV) outflow tract in a patient with hypertrophic cardiomyopathy. 
From the 3-dimensional dataset, parallel slicing of the LV outflow tract perpendicular to the 
long-axis (paraplane echocardiography) is performed at I mm intervals, at the onset of ven-
tricular systole. In the left panel, 3 representative cut-planes are indicated. The corresponding 
cross-sectional 2-dimensional images with the manually traced endocardial contours are 
shown in the middle panels. The final wire frame mode display represented in the right 
panel can be rotated on the screen along the 3 main a.xes for versatile qualitative 3-dimen-
sional evaluation. 
AML = anterior mitral leaflet; A V = aortic valve; IVS = interventricular septum. 
Inter- and intraobserver reproducibility for the measurements of LV outflow 
tract with 3-dimensional echocardiography was assessed in all 27 patients. To 
assess interobserver variability, two observers (A.S. and Y.N.) independently 
measured the outflow tract area from the 3-dimensional datasets without prior 
knowledge of clinical data and without preselection of cut-planes. In addition, 
LV outflow tract cross-sectional area measurements were performed by I ob-
server (A.S.) on 2 occasions (3 months apart, without preselection of cut-planes 
from the 3-dimensional datasets) to assess intraobserver variability. 
Statistical analysis 
Values are given as mean ± SD. Student's unpaired t test was used to compare 
the differences between He and control subjects. Values ofp<O.05 were consid-
ered to be significant. Reproducibility of the LV outflow tract measurements 
was expressed in terms of mean differences and the 95% confidence intervals 
(12). 
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RESULTS 
Three-dimensional acquisition could be performed successfully in all patients. 
Echocardiographic acquisition of the image of the LV outflow tract for 3-dimen-
sional reconstmction was perfollned either from the parasternal (IF20) or apical 
(IF7) windows, according to the image quality. The examination including the 
calibration procedure, selection of the optimal axis of rotation, a number of test 
ntns, and the actual unage acquisition required approximately 10 minutes in ad-
dition to the time required for the standard 2-dimensional echocardiogram. 
Three-dimensional reconstruction of the unages was possible and of good qual-
ity in all patients. The time required for post-proeessulg the raw data, and recon-
struction and analysis of the images was approximately 20 minutes. Demo-
graphics, echocardiographic characteristics, and measurements of the LV out-
flow tract in each patient with He are reported Ul Table 1. 
Left velltricular OU(f/Oll' tract ill patiellts with hypertrophic cardiomyopathy 
verslIs normal subjects 
Cross-Sectiollal Area. The values of minimal cross-sectional area of the indi-
vidual subjects are plotted in Figure 2. The minitnal LV outflow tract cross-sec-
tional area calculated with 3-dimensional echocardiography was significantly 
smaller in patients with He than in the control group (2.3 ± 1.0 vs 5.0 ± 0.9 cm2, 
p<O.OOO1). Thit-teen of the 17 patients with He had a value smallel' than con-
trols, and 2 of the 4 He patients (nos. 6 and 17) with higher values were evalu-
ated after myectomy. After correction for body surface area the values were 1.3 
± 0.5 and 2.7 ± 0.6 cm2, respectively (p<0.0001). 
Shape. From the 3-dinlensional datasets, the reconstmcted LV outflow tract 
could be displayed as observed li-orn different viewpoints. This simplifies visu-
alization of the geometry and shape as well as the localization of the narrowing 
of the LV outflow tract in patients with He (Figure 3). A similar display in a 
norlllal patient is shown in Figure 4. Some examples of 3-dimensional recon-
stmction of the LV outflow tract in nOlll1al subjects and in patients with He are 
shmvn in Figure 5. 
MaxlMill Cross-Sectiollal Area (Eccelltricity IlIdex). The maximin cross-sec-
tional area of the LV outflow tract derived fi'om the 3-dimensional datasets are 
displayed in Figure 6. From this figure, it is apparent that patients with He had 
higher ratios (2.6 ± 0.9), with a broad range of values (from 1.5 to 4.2) indica-
tive of many ilTegular different shapes of the LV outflow tracts. In contrast, nor-
mal subjects had smaller ratios (104 ± 0.2), with a narrow range of values (from 
I.l to 1.6). In particular, each of the controls had a ratio of~1.6, whereas 15 of 
17 patients with He had a ratio of>1.6. The 2 patients with maximin cross-sec-
tional area of ~1.6 (patients 16 and 17) were evaluated after myectomy. Thus, 
an outflow tract area ratio of 1.6 appeared to separate patients with fi'om sub-
jects without He. 
Table J 
Demographics, patient characteristics, and measurements of the left ventricular outflow tract in patients with hypertrophic carliomyopathy, 
Pt. Age(yrs)/Sex type LVH Therapy Gradient SAM CSA(cm2) MaxiMin CSA Max/Min diameter 
#1 19M III V 58 3+ 2.9 2.0 1.9 
#2 21 M III < 10 2+ 2.4 2.5 1.7 
#3 22M < 10 1+ 3.0 1.8 1.4 
#4 24M IV < 10 2+ 2.9 2.4 1.6 
#5 25M III V < 10 2+ 2.7 2.4 1.6 
#6 31 F III S,V 50 3+ 1.3 4.2 2.0 
#7 38F II V <10 0 2.4 2.7 1.7 
#8 39 F III V <10 0 3.2 2.1 1.6 
#9 41 M III V 20 1+ 1.9 1.7 1.8 
#10 46F II A,V < 10 2+ 0.7 4.1 1.4 
#11 53M III < 10 1+ 1.5 3.8 1.9 
#12 63M II M 100 3+ 1.5 3.0 2.6 
#13 65M III V 35 3+ 2.0 3.0 1.6 
Mean±SD 37:t15 2.200.7 2.7±O.8 1.7S±O.3 
#14 31 M' III < 10 0 2.1 2.4 1.3 
#15 34M' III S < 10 1+ 0.9 3.9 1.2 
#16 44M' III S,V < 10 0 4.7 1.5 1.3 
#17 59M' III V <10 0 3.0 1.6 1.3 
Mean:tSD 42±12 2.701.6 2.3,,1.1 1.27±0.05 
Mean±SD 39±15 2.3±1.0 2.6:tO.9 1.6::1::0.3 
(overall) 
'Patients evaluated after myectomy 
A::; amiodarone; CSA = cross-sectional area; LVH::: left ventricular hypertrophy; M::; metropolol; Max./Min.::; maximal/minimal; S::; sotalol; 
SAM = systolic anterior movement; V :::: verapamil. 
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Figure 2 
Minimal cross-sectional area (CSA) of the left ventricular outflow tract in patients with hy-
pertrophic cardiomyopathy (HeM) and in normal subjects (0). 
+ = patients without obstruction; 0 = patients after myectomy; \j = patients with obstruction. 
MaxiMin Diameter (AsymmeIlJ' Jndex). The individual values of maximin di-
ameter of the LV outflow tract cross-section are displayed in Figure 7. This ratio 
was significantly higher in patients with He than in nonnal subjects (1.6 ± 0.3 
vs 1.2 ± 0.1, p=O.OOI). Of interest, patients evaluated after myectomy had the 
lowest values; conversely, the highest values were found in patients with He 
and LV outflow tract obstruction. An index of 1.36 appeared to separate normal 
subjects l1'mn patients with He who did not undergo operation. 
Repl'Odlicibii ity analysis oj three-dimensiollal ecl/Ocardiography: 
Jllterobserl'er Variability. The difference between the 2 observers for mea-
surements of the LV outflow tract was compared with the average of the 2 mea-
surements for each patient. The mean difference between the measurements of 
the 2 observers was 0.04 cm' (95% confidence interval - 0.08 to 0.12 cm') for 
cross-sectional area. 
Jlltraobserl'er Variability. The difference between the 2 measurements made 
by the same obselver was compared with the average of the 2 measurements for 
each patient. The mean difference between the 2 measurements was 0.13 cm' 
(95% confidence intelval - 0.0 I to 0.25 cm') for cross-sectional area. 
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Figure 3 
In this patients with hypertrophic cardiomyopathy, the wire frame display of the recon-
structed left ventricular (LV) outflow tract is represented as observed ITom different view-
points. The view at 0° corresponds to the cut-plane represented in the centra1llanel. The im-
ages obtained after incremental 60° clockwise rotation are displayed in the corresponding 
panels. There is an eccentric and aSYllll1lctl'ic shape of the LV outflow tract. From these im-
ages it is also apparent that the narrowing is localized at the middle-caudad part of the LV 
outnow tract and is mainly related to a reduction in the anteroposterior diameter. 
Figure 4 
Three-dimensional reconstruction of the left ventricular (LV) outflow tract in a normal sub-
ject, with the same display as in Figure 3. Note the uniformity (indicated by the minimal 
variations of the diameters throughout the lenght of the LV outflow tract) as well as the sym-
metry (indicated by the similar diameters of individual cross-sections fi'om different view-
points) of the LV outflow tract. 
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Figure 5 
Three-dimensional reconstruction of the left ventricular outflow tract with wire frame display 
in normal subjects (A to C) and in patients with hypertrophic cardiomyopathy (0 to F). The 
different irregular configuration of the left ventricular outflow tract in patients with hyper-
trophic cardiomyopathy can be evaluated. 
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Figure 6 
Ratio between maximal and minimal cross-sectional area (maximin CSA) of the left ventricu-
lar outflow tract in patients with hypertrophic cardiomyopathy (HCI'vI) and in normal sub-
jects. A high ratio indicates an eccentric shape of the left ventricular outflow tract. Symbols 
as in Figure 2. 
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DISCUSSION 
Hypeltrophic cardiomyopathy is a disease with a great individual variability and 
"no two hearts are alike" (13). The results of the present study indicate that 3-
dimcnsional echocardiography allows visualization of the varied complex geom-
etry of the LV outflow tract in patients with He. With quantitative analysis of 
the 3-dimensional datasets, we demonstrated that in patients with He the mini-
mal cross-sectional area is smaller than that in normal subjects. In addition, 
most patients with He have an in'egular shape of the LV outflow tract as dem-
onstrated by an eccentricity index of ~1.5. In normal subjects, this index is al-
ways 0;;1.6, indicating a uniform shape of the LV outflow tract, without signifi-
cant variation of the cross-sectional area throughout its length. We have also 
demonstrated that the cross-sectional shape of the LV outflow tract is more el-
liptical in patients with He than in normal subjects, as indicated by a higher ra-
tio of maximin diameter measured at the plane of the minimal cross-sectional 
area. TIllS finding is in agreement with the concept that in He the hypertrophic 
ventricular septum nanows the LV outflow tract mainly along its anteroposte-
rior diameter. Of interest, this asymmetry index was highest in patients with He 
and obstruction of the LV outflow tract at rest. In contrast, in He neither the 
minimal cross-sectional area nor the eccentricity index of the LV outflow tract 
separated this subgroup. This finding indicates that for similar cross-sectional 
area the asymmetry of the LV outflow tract plays an impoltant role in determin-
ing the presence of significant obstl1lction at rest. 
Patients who had undergone myectomy had a minimal cross-sectional area 
similar to other patients with He, including those with obstmction (Figure 2). 
However, fi'om Figure 7 it is clear that after myectomy the asymmetry index 
was lowest, indicating that the surgical remodelling of the LV outflow tract was 
adequate for the relief of the obstl1lction despite the finding that the cross-sec-
tional area remained small compared with that in normal controls, and remained 
in the same range as that of the other He patients without previous myectomy. 
Thus, in patients with He, precordial 3-dimensional echocardiography has the 
potential to playa major role in tailoring the standard surgical resection of the 
interventricular septum to the individual patient's anatomy, which is cmcial for 
safe and efficacious performance of myectomy, and also for evaluation of the 
results of surgery. 
Evaluation of left ventricular outflow tmetusing three-dimensional 
eehoeardiography 
Previous experience with 3-dimensional echocardiography for the evaluation of 
the LV outflow tract was based on morphologic analysis with volume-rendered 
display (14). In contrast, for quantitative analysis of the LV outflow tract per-
formed in the present study, we selected a multitude of cut-planes ("anyplane 
echocardiography") and performed a parallel scalming of the LV outflow tract at 
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Figure 7 
Ratio between maximal and minimal diameter (maximin diameter) measured at the cross-sec-
tion of the left ventricular outflow tract with the minimal area in patients with hypertrophic 
cardiomyopathy (HeM) and in normal subjects. A high ratio indicates an asymmetric shape 
of the left ventricular outflow tract. Symbols as in Figure 2. 
I Jilin intervals ("paraplane echocardiography"). This rate of sampling of the 
dataset is similar to the analysis done with magnetic resonance imaging or com-
puted tomography, and allows detailed spatial information (15). While some 
display modalities, such as volume rendering, are indicated more for representa-
tion of anatomical details (16-18), the wire fi'ame display format appears par-
ticularly suited to 3-dimensional reconstruction of the cardiac cavities, where ar-
eas, volumes, size and shape can be adequately evaluated. 
Lili/itatiol/s ojthree-dillJellsiolJaI ecllOcardiography 
In this study, patients were selected on the basis of high-quality images at 2-di-
mensional echocardiography, which yielded a success rate of 3-dimensional re-
construction of 100%. The same results cannot be expected fi'om an unselected 
population where poor quality precordial images may prevent adequate quality 
of the reconstruction. 
Echocardiographic images were acquired by an experienced technician and 
reconstl1lction was performed by a cardiologist after a learning period of> 50 
studies. This previous experience of 3-dimensional echocardiography prevented 
artifacts in the 3-dimensional datasets, limited the time required both for acqui-
sition and reconstruction, and resulted in a minimal variability for the measure-
ments. 
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ABSTRACT 
The design features of the cutting electrode and the electrical characteristics ofa 
monopolar electrosurgical device were specially adapted for performing a septal 
myectomy in patients with hypet1rophic obstructive cardiomyopathy. Both the 
cutting behavior and electrode design were found to facilitate myectomy. 
INTRODUCTION 
Septal myectomy is effective in relieving the symptoms of hypertrophic obstruc-
tive cardiomyopathy refractoty to medical treatment. Although many procedures 
have been advocated for the surgical treatment of hypet1rophic obstructive car-
diomyopathy, most surgeons approach the septum through an aortotomy, but 
some surgeons add a ventriculotomy to improve exposure (1-16). A conven-
tional myectomy can be technically demanding because of the midventricular 
location of the obstruction and the risk of disrupting septal integrity. The 
monopolar electrosurgical device called spark erosion was originally designed 
for intravascular applications (17). Impressed by its cutting characteristics, we 
constructed a modified device for use in septal myectomy. 
MATERIAL AND METHODS 
The cutting electrode is a quadrangular monopolar electrode composed of a 
metal foil (Fig I). The electrode is covered with an electrically insulating syn-
thetic resin, except for the cutting front side, which is 50 ~tm wide. The insula-
tion is able to withstand temperatures up to 400°C. The cutting electrode is con-
nected to a pencil with a malleable connection to allow the electrode to be ad-
justed with respect to the orientation of the handle. The width and depth of the 
myectomy depend on the dimensions of the electrode. Currently available (but 
not commercially) electrode sizes are lOx 6.5 mm, J J X 9 mm, and J 4 X 9 mm 
(width X depth) (Fig 2). After an initial resection, the width and depth of the my-
ectomy can be adjusted further. Because of the cutting characteristics, additional 
resections then can be done easily without fragmentation of the muscle tissue. 
The generator is battety operated, with an output impedance of 60 ohm deliv-
ering an alternating square-wave voltage at a frequency of 500 kHz, with an ef-
fective value of700 V (J 8). Direct current is blocked at both output terminals by 
capacitors to minimize stimulating side effects (19). Energy is applied during 
short pulses of 1.5 ms at a repetition rate of 12 Hz. These characteristics make 
possible a cutting speed t111'ough heart muscle of approximately 2 mm/s. Trans-
parent Perspex (methactylic acid) retractors were constructed in several sizes to 
optimize visibility and probe orientation during the procedure and to protect the 
aortic valve cusps, the mitral valve, and the anterior papillaty muscle (Fig 3). 
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Figure I 
The electrode, showing some of the special features. The cutting front side (solid arrowhead) 
can be distinguished easily from the insulated part of the electrode. The electrode support 
(open arrowhead) limits the depth of the myectomy. The malleable connection (open circle) is 
shown here in a heavily bent position, but can be positioned to any angle from +90 degrees to 
-90 degrees. 
Figure 2 
The myectomy procedure in a pig hear1. (A) The electrode has bcen advanced a few centime-
ters. (B) The electrode is withdrawn. The surh1ce of the trough is very smooth and no coagu-
lation effects can be observed on visual inspection. 
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Figure 3 
The set of transparent Pcrspex (mcthacrylic acid) retractors. 
Between February 1987 and March 1993, spark erosion septal myectomy was 
performed in 18 patients with hypertrophic obstructive cardiomyopathy. All 
these patients were symptomatic despite optimal medical treatment. The demo-
graphic data, preoperative and postoperative pressure gradients, and preopera-
tive and postoperative New York Heart Association functional class are summa-
rized in Table I. The peak systolic left ventricular outflow tract gradient was 
measured with continuous-wave Doppler echocardiography and expressed in 
millimeters of mercury. In 17 patients, the pattern of hypertrophy was graded as 
type III according to the classification scheme of Maron and colleagues (20). 
Patient 9 was classified as having type II hypertrophy. 
Patients were operated on with cardiopulmonary bypass and moderate hypo-
thermia. Cardiac arrest was induced by topical cooling and aortic root cardiople-
gia (St. Thomas' Hospital solution). The ventricular septum was approached via 
the ascending aorta through a hockey-stick incision. 
Septal exposure and visualization were improved by passing the appropriate-
sized transparent retractor through the aortic valve toward the left ventricular 
apex. Further improvement of exposure was obtained by exerting counter-
pressure on the external left ventricular wall. In 3 patients l there was an impor-
tant mitral insufficiency that was not caused by systolic anterior motion of the 
anterior mitral valve leaflet. 
Patient 3 had been treated for bacterial endocarditis 5 years preoperatively. 
A fier the myectomy, the valve was successfully repaired (closure of a tear in the 
anterior leaflet and commissuroplasty). Patient 9 had a destroyed anterior mitral 
valve leaflet as the result of recent bacterial endocarditis. At the time of opera-
tion, reconstruction of the valve seemed impossible and, in addition to the my-
ectomy, the valve was replaced with a mechanical prosthesis (St. Jude Medical, 
Table I 
Preoperativ~ and postoperative characteristics. 
Peak Gradientn 
(mm Hg) NYHAClass 
Patient 
No. Sex Age (y) Preop Postop Preop Postop 
1 F 51 36 8 III 
" 2 F 61 80 6 III 
" 3 F 19 62 ? III I 
4 M 38 36 10 III 
" 5 M 32 125 25 II 
6 F 30 10 5 III III 
7 M 58 81 5 III 
8 M 44 38 8 III 
9 M 40 36 8 IV 
10 F 36 100 50 
" 11 F 36 108 36 III 
12 F 61 100 8 III 
13 F 24 80 10 III 
14 M 29 74 8 III 
15 M 67 92 6 III 
16 M 55 200 4 III 
17 M 43 148 7 III 
18 M 31 140 16 III 
apeak systolic left ventricular outflow tract gradient measured by continuous~wave Doppler echocardiography. 
F = female; M = male; NYHA = New York Heart Association 
Additional procedures 
Mitral valve repair 
Mitral valve prosthesis 
Mitral valve prosthesis 
Mitral valve patch 
Mitral valve patch 
Mitral valve patch 
Mitral valve patch 
Mitral valve patch 
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St. Paul, MN). Patient II had severe mitral insufficiency stemming from a 
heavily calcified posterior mitral valve leaflet and annulus. After myectomy, the 
systolic anterior motion of the mitral valve decreased considerably but the mitral 
insufficiency persisted. An attempt to repair the valve failed, so this valve was 
also replaced with a mechanical valve (St. Jude Medical). 
More recently, a patch technique has been used in selected patients in addi-
tion to the myectomy. Figure 4 shows the epicardial echocardiograms from a pa-
tient obtained before and after spark erosion myectomy and mitral valve patch 
placement. 
The removed tissue was cut into 5-mm sections after formalin fixation, paraf-
fin embedding, and staining with hematoxylin-eosin and elastic van Gieson. All 
specimens were evaluated by one pathologist and one surgeon. The depth of 
thermal injury was measured by multiplying the number of injured cells by the 
diameter of the hypertrophied myocytes. 
RESULTS 
Our clinical experience, spanning February 1987 to March 1993, consists of 
septal myectomy performed in 18 patients. There were no peri operative deaths. 
Two patients received a permanent pacemaker: in I patient, because of a newly 
formed atrioventricular conduction block; in the other, because of conduction 
abnormalities preoperatively, which was followed by periods of abnormal atrio-
ventricular conduction postoperatively. Damage to the aortic or mitral valve was 
not encountered during or after the procedure, and no ventricular septal defects 
were created. 
Light microscopic evaluation of the surgical specimens from the 18 patients 
revealed an uniform pattern (Fig 5). The depth of complete cell destruction by 
thermal energy was two to three cell layers; complete destruction of four or 
more cell layers was never seen. Between this zone and the "normal" myocar-
dium was a zone of five to eight cell layers that showed hypereosinophilia, in-
creased vacuolization, and, in some cells, contraction bands. The cross-sectional 
diameter of myocytes in the setting of hypertrophic obstructive cardiomyopathy 
is between 25 and 35 [Ull (normal, IOta 15 [1m). The maximum depth of the 
thermal injury is thus between 175 and 385 [Ull if the damage to the 
hypereosinophilic zone is irreversible. Otherwise, the depth of the thermal in-
jury is between 50 and 105 [1m. 
Patient 5 died suddenly 8 months after the operation, and autopsy revealed a 
recent myocardial infarction. The surface of this patient's myectomy was cov-
ered with a thin and smooth connective tissue layer. His initial postoperative 
course had been uneventful. 
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Figure" 
Epicardial echocardiograms in the len ventricular long axis, before (A) and after (il) spark 
erosion myectomy and patch plasty of the mitral valve. Systolic frames with an open aortic 
valve. (A) The closed arrow points to the area of systolic anterior motion of the anterior mi-
tral valve lea net. (8) The open arrows point to the site of myectomy. Systolic anterior motion 
has completely disappeared. (Ao = aorta; LV = len ventricle; I JOCM = hypertrophic obstruc-
tive cardiomyopathy; !'viR = mitral valve regurgitation). 
Figure 5 
Representative photomicrograph of a resection specimen. The surface layer contains de-
stroyed cells; the hypereosinophilic zone and the "normal" myocytes ean be recognized eas-
ily. (Elastic \'an Gieson stain; xl SO). 
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COMMENT 
Treatment of hypertrophic obstructive cardiomyopathy with an electrosurgical 
device is not new. A wire-loop electrode, connected to a standard elcctrosurgical 
device, was used by Dobell and Scott in 1960 (4). Cooley and colleagues (9) 
also used a loop cautery device in I patient. To our knowledge, none of thesc 
devices stood the test of time and most surgeons use a surgical scalpel or a 
scalpellike device for myectomy or myotomy. However, the depth of the myec-
tomy is not precisely controlled with this instrument, and the fear of septal per-
foration may cause the depth of the septal resection to be inadequate. In per-
forming a resection with a scalpel, small myocardial fragments and a rough 
myocardial surface may be a source of concern. Therefore, a more controlled 
way of performing septal myectomy is desirable. 
In our opinion, the uncontrolled depth of thermal injury accomplished with 
traditional electrosurgical dcvices makes them unsuitable for use in septal myec-
tomy. The coagulating properties of electrosurgical devices depend on the so-
called crest factor (voltage peak divided by the voltage root mean squared). 
We developed a dedicated electrosurgical unit and electrodes for septal myec-
tomy possessing minimal coagulation effects. Compared with the properties of 
readily available electrosurgical units, our device has a much lower output im-
pedance in combination with a high effective voltage. This minimizes the warm-
up time needed to form a steam envelope around the electrode, which is re-
quired before sparking and cuttings can commence. 
With our device, the crest factor reaches its theoretical minimal value of I, 
rather than the usual 1.4 to 2 seen in conventional electrosurgical devices, byap-
plying an unmodulated square-wave alternating voltage. These specitications al-
low application of a brief cutting pulse, and this plus the low repetition rate 
maintain highly etfective cutting with a minimal accumulation of thermal en-
ergy. In addition, the electrical insulation of the electrodes improves the cutting 
behavior by minimizing the cutting area and preventing the bacl"vard arcing of 
sparks to areas already passed. Smoke and vapor production during cutting are 
negligible. The low cutting speed of 2 mmls allows the clectrode to be accu-
rately guided during the procedure. Compared with a wire-loop electrode, the 
quadrangular electrode is much stronger. 
The height of the electrode supports limits the depth of the myectomy to the 
electrode size selected, thereby reducing the risk of creating a ventricular septal 
defcct. The malleable connection of the electrode to the pcncil allows for the 
electrode to be precisely adjusted with respect tot the orientation of the handle. 
No patient in the present series died and no ventricular septal defect was caused 
by the procedure. In the study group, t patient (5.5%) suffered a new atrioven-
tricular conduction block. This does not seem excessivc in light of the experi-
ence described in the literature (21-23). Light microscopic reevaluation revealed 
there was no difference between this patient and the other patients with respect 
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to the depth ofthennal injury. Most likely this complication was relatcd to a sur-
gical tcchnical imperfection, rather than to the electrical device. 
In conclusion, both the design features and the cutting characteristics of the 
spark erosion device facilitate the performance of myectomy in patients with hy-
pertrophic obstructive cardiomyopathy. 
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ABSTRACT 
Objectives. The plll'pose of this study was to describe the clinical and func-
tional results of combined antcrior mitral leaflet extension and myectomy in pa-
tients with hypeltrophic obstructive cardiomyopathy. 
Background. Septal myectomy is the most commonly performed surgical pro-
cedure in patients with hypertrophic cardiomyopathy and left ventricular out-
flow tract obstruction. Because of the role of the mitral valve in creating the out-
flow tract gradient, mitral valve replacement or plication is performed in se-
lected cases in combination with myectomy, olien with better haemodynamic 
results than those of myectomy alone. Mitral valve leaflet extension, in which a 
glutaraldehyde-preserved autologous pericardial patch is used to enlarge the mi-
tral valvc along its horizontal axis, is a novel surgical approach in patients with 
hypertrophic obstructive cardiomyopathy. 
Methods. Eight patients with hypertrophic obstmctive cardiomyopathy were 
treated with mitral leaflet extension and myectomy. Pre- and postoperative data 
(Nell' York Heart Association functional class, number of drugs prescribed, 
width of the interventricular septum, severity of the mitral valve insufficiency, 
severity of the systolic anterior motion of the mitral valve and the outflow tract 
gradient) were compared with 12 patients undergoing myectomy alone. 
Resu!ts. Preoperative evaluation demonstrated that mitral insufficiency and 
systolic anterior motion of the mitral valve were more severe in the group un-
dergoing mitral valve extension (p<O.OO I and p<O.05 respectively). There were 
no deaths associated with slll'gery. Two patients, both treated by myectomy 
alone, died during the follow-up period. Postoperatively, patients treated with 
mitral valve extension had less mitral insufficiency (p<O.005), less residual sys-
tolic anterior motion (p<O.O I), greater improvement in New York Heart Asso-
ciation functional class (p~O.05) and greater reduction in the number of drugs 
(p<O.005) and in septal thickness (p<O.05). 
Conclusions. Mitral leaflet extension in combination with myectomy is a 
promising ncw surgical approach that may provide superior results to those of 
myectomy alone. FlII'ther studies are needed to determine the clinical value of 
this procedure. 
INTRODUCTION 
SlII'gery for hypertrophic cardiomyopathy is generally performed in patients 
who have a significant left ventricular outflow tract gradient and severe symp-
toms despite maximal medical therapy (1-4). The most commonly performed 
procedure is septal myectomy (the Morrow procedlll'e) (5), which usually results 
in an adequate reduction in the obstruction to outflow (6-9). Because of the con-
tribution of the mitral valve in generating the outflow tract gradient (10-13), mi-
tral valve replacement alone or in combination with myectomy is also per-
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formed, often with better hcmodynamic results than those of myectomy alonc 
(8,9,14, IS). However, the long-term risks of thromboembolism and hemorrhagc 
associated with prosthetic valves and the need for anticoagulant therapy make 
mitral valve replacement an unattractive option for many patients with hyper-
trophic cardiomyopathy, who are frequently young and physically active (1,16). 
Mitral leaflet plication in combination with myectomy has rccently been pro-
posed (17) as a successful alternative to mitral valve replaccment in hyper-
trophic cardiomyopathy. Another altcrnative procedure is anterior mitral leaflet 
extension, one of several valve repair techniques developed by Carpentier (18) 
and Chauvaud et a\.( 19), in which a glutaraldehydc-preserved autologous pcri-
cardial patch is used to cnlarge the mitral valve along its horizontal axis. The 
application of mitral leaflet extension in patients with obstructive hypertrophic 
cardiomyopathy has not been reported previously. In this report we present the 
immediate results and early follow-up data (up to 4 years) in 8 paticnts treated 
with combined anterior mitral leaflet extension and myectomy. Results are com-
pared with those of 12 patients undergoing myectomy alone. The possible 
mechanisms of action of mitral leaflet extension are also discussed. 
METHODS 
Indica/iOllS 
Indications fOI' surgery in our Hypertrophic Cardiomyopathy Clinic include a 
rest or provokable left ventricular outflow tract gradient 2'50 mmHg and persis-
tent symptoms despite an adequate trial of medical therapy, consisting of beta-
adrenergic blocking agents, calcium channel blocking agents, or both. Preopera-
tive cchocardiography and cardiac catheterization for invasive hemodynamic 
measurements and angiography are performed in all patients for whom surgery 
is proposed. Postoperative assessment includes repeat echocardiography I week 
and again several months after operation. Repeat cardiac catheterization is not 
routinely performed unless clinically indicated. 
The decision to perform anterior mitral leaflet extension in conjunction with 
myectomy is made at the time of operation if, in the surgeon's view, myectomy 
alone is likely to yield a suboptimal result. Conditions that favor inclusion of a 
valve procedure includc atrial fibrillation, limited septal hypertrophy, marked 
systolic anterior motion of the mitral valve and significant mitral regurgitation 
(1,4,5). 
Patients 
Between 1986 and 1988, the myectomy procedure was performed by two sur-
geons (L.A.H. and an older colleague who taught L.A.H. the myectomy proce-
dure). From 1988 on, all operations, including all mitral valve procedures, were 
carried out by a single surgeon (L.A.H.). A total of20 patients underwent septal 
myectomy; 8 of whom underwent concomitant anterior mitral leaflet extension. 
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The primary reason for performing mitral leaflet extension was mitral regurgita-
tion and systolic anterior motion of the mitral valve of particular severity; one 
patient had chronic atrial fibrillation associated with significant mitral regurgita-
tion. 
SlIl'gicailechlliqlle 
Open chest epicardial echocardiography is used extensively during the proce-
dure for ongoing assessment of septal thickness, systolic anterior motion of the 
mitral valve and detailed structure of the mitral leaflets. Continuous wave and 
Doppler color echocardiography are used to quantifY the outflow tract gradient 
and mitral regurgitation and their responses to physiologic manipulation such as 
volume infusion and administration of inotropic agents. The images are regis-
tered on video-tape for otT-line analysis. Patients are operated on with standard 
techniques of cardiopulmonary bypass with moderate hypothermia and crystal-
loid cardioplegic arrest (St. Thomas's solution). An autologous pericardial patch 
is harvested, trimmed of fat and extraneous tissue, immersed for 10 min in 
0.62% glutaraldehyde and then placed in a normal saline bath. The aorta is 
opened by an oblique incision and septal myectomy is performed to the left of 
an imaginary line through the nadir of the right aortic cusp, with a locally de-
signed electrocautery device, described in detail elsewhere (20). In brief, the 
cutting electrode of the device is a quadrangular monopolar electrode composed 
of a metal foil. The cutting electrode is connected to a pencil with a malic able 
connection to allow the electrode to be adjusted with respect to the orientation 
of the handle. The width and depth of the myectomy depend on the dimensions 
of the electrode. Currently, three different electrode sizes are available: lOx 6.5, 
II x 9, and 16 x 9 nUll (width x depth). The procedure is guided by intraopera-
tive echocardiography with the removal of additional septal myocardium if nec-
essary. 
Next, anterior mitral leaflet extension is performed according to the method 
described by Chauvaud et al.(19), with the following modifications: the pericar-
dial patch harvested at the beginning of the procedure is cut to an oval shape 
approximately 3 em wide and 2.5 cm long. The anterior mitral leatlet is incised 
longitudinally from its subaortic hinge point to the rough zone. The patch is 
sewn onto the ventricular surface of the leaflet at the site of the incision by using 
three running polypropylene monofilament sutures (Fig. I ). Immediate results 
are assessed by intraoperative echocardiography after weaning from cardiopul-
monary bypass, with particular attention to residual systolic anterior motion, mi-
tral regurgitation and the left ventricular outtlow tract gradient. Reinstitution of 
bypass for the purpose of modifying the surgical result was not required in this 
cohort of patients. 
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Figure I 
Schematic representation of mitral leaflet extension. The pericardia! patch is clearly seen in 
the middle of the drawing, within the anterior mitral lea net. The area of the myectomy is seen 
in the interventricular septum, demarcated by dots. The ostia of both the left (LCA) and right 
(RCA) coronary arteries are indicated for orientation purposes. 
Data collection and analysis 
All patients were assessed clinically preoperatively and postoperatively by the 
same physician (F.J.T.C.), who was also responsible for their medical manage-
ment. Transthoracic echocardiographic data were reviewed by two physicians 
who had access to data on the patients' histories and surgical procedures. Inter-
ventricular septal thickness was determined by two-dimensional echocar-
diography in the parasternal short axis view at the site of the myectomy. Mitral 
regurgitation was assessed by color Doppler echocardiography and graded on a 
scale of 0 to 4+. Systolic anterior motion of the mitral valve was assessed from 
the two-dimensional images and graded as 0 (absent), I + (mild: minimal mitral-
septal distance > I 0 mm during systole), 2+ (moderate: minimal mitral-septal 
distance 00;10 n1ln during systole) or 3+ (marked: brief or prolonged contact be-
tween mitral valve and septum) (21). Peak len ventricular outtlow tract gradient 
at rest or with provocation was estimated with Doppler echocardiography by us-
ing the modified Bernoulli equation, P ~ 4y2, where P is pressure gradient and 
Y is Doppler-determined blood velocity. When echocardiographic data were in-
adequate or unavailable, catheterization data were used. Intraoperative epicar-
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dial echocardiograms were performed in all patients before and aller cardiopul-
monary bypass. The recordings of those patients who underwent anterior mitral 
leaflet extension were available for futher analysis. 
The left ventricular outflow tract and mitral valve leaflet areas were calcu-
lated according to previously described methods (2 I ,22). In brief, the left ven-
tricular outflow tract area is calculated in the short axis view at the level of the 
mitral valve at the onset of systole. The first frame in the cardiac cycle (onset of 
ventricular systole) when the mitral valve appears closed is taken for analysis. 
On the stop li'ame the innermost margins of the outflow tract are traced on the 
screen and the demarcated area is calculated by utilizing an off-line computer 
and a dedicated software program (23). The mitral valve leaflet area is derived 
l1'OIn the mitral valve opening area (MVOA). The latter is measured by tracing 
the innermost margins of the mitral valve in the parasternal short-axis view at 
the point of maximal opening. The mitral valve leaflet area (MLA) is then calcu-
lated by using the formula MLA ~ 2. 19 + 3.06 x MVOA validated by Klues et 
aJ. (22). 
Statistics 
Data were expressed as mean value ± SO. The Wilcoxon test was used to com-
pare clinical characteristics before and after operation of the patients with com-
bined myectomy and anterior mitral valve extension and those with myectomy 
alone. The characteristics compared were age, New York Heart Association 
functional class, number of drugs prescribed, width of the interventricular sep-
tum, severity of systolic anterior motion, severity of mitral insufficiency and left 
ventricular outtlow tract gradient. 
RESULTS 
Patient characteristics and surgical Oil/come 
Preoperative and postoperative clinical and transthoracic echocardiographic 
characteristics of the 8 patients undergoing myectomy combined with anterior 
mitral valve extension and the 12 patients undergoing myectomy alone are pre-
sented in Tablc I. The postoperative clinical and echoeardiographic data refer to 
the latest patient follow-up. There were no deaths or serious complications asso-
eiated with the surgical procedures. Patients 4 and 6 in the group with myec-
tomy alone died during follow-up: Patient 4 died of congestive heart failure 6 
years alter operation and Patient 6 died suddenly 2 years alter the procedure. 
Statistical differences between the two groups are presented in Table 2. Pre-
operative mitral regurgitation and systolic anterior motion of the mitral valve 
were worse (p<O.OO I and p<0.05, respectively) in the patients who underwent 
combined myectomy and mitral valve extension than in patients who underwent 
myectomy alone. Nonetheless, postoperative residual mitral regurgitation and 
systolic anterior motion were significantly better (p<0.005 and p<O.O I, respec-
Table I 
Preoperative and postoperative clinical and transthoracic echocardiographic data of patients with hypertrophic obstructive cardiomyopathy treated with ei-
ther combined myectomy and mitral valve extension or myectomy alone. 
Patient 
MMIMLE 
#1 
#2 
#3 
#4 
#5 
#6 
#7 
#8 
MM alone 
#1 
#2 
#3 
#4 
#5 
#. 
.7 
#8 
#9 
#10 
#11 
#12 
Age/Sex OK-Date 
DM 
aF 
~M 
MM 
~M 
_F 
aM 
~F 
54M 
29 F 
52 F 
6" 
38 M 
32 M 
30 F 
38M 
~M 
36 F 
_F 
~F 
5/91 
9{91 
2/92 
1193 
3/93 
6/94 
6/94 
6/94 
3/86 
8/86 
2/87 
12/87 
7/88 
11/88 
5/89 
7/89 
3/90 
6/90 
4/91 
2/93 
Pm 
3 
3 
3 
2 
3 
2 
3 
2 
3 
3 
3 
3 
3 
2 
3 
2 
3 
2 
3 
3 
NYHA 
Post 
2 
2 
2 
2 
3 
2 
2 
Med. 
P,e Post 
A,C,D,W C,W 
B 
B,C 
B 
C 
C 
B 
C 
C 
C 
C,W 
B,C 
C 
C 
C 
C 
B 
C 
B 
B,C,W 
C 
C 
C,W 
A 
B,D,W 
A.D,I.W 
B 
a,C,D 
C 
B 
A 
B 
B,C,W 
p", 
27 
30 
35 
22 
22 
29 
22 
20 
28 
30 
27 
26 
30 
24 
a 
20 
33 
30 
20 
31 
IVS(mm) 
Post 
20 
20 
25 
15 
15 
20 
18 
15 
24 
26 
18 
21 
a 
18 
19 
20 
30 
22 
18 
27 
P,e 
3+ 
3+ 
3+' 
3+ 
2. 
2. 
2. 
3. 
2. 2. ,. 
,. 
,. 
2. 
,. 
o 
o 
o 
,. 
o 
MR 
Post 
,. 
,. 
o 
o 
,. 
o 
o 
,. 
,. 
3. 
,. 
o 
o 
,. 
o 
o 
o 
o 
2. 
,. 
P'e 
3. 
3. 
3. 
2. 
3. 
3. 
3. 
3. 
2. 
3. 
2. 
,. 
3+ 
3+ 
,. 
,. 
2. 
3. 
3. 
,. 
SAM 
Post 
o 
1. 
o 
o 
o 
o 
o 
1. 
2. 
3+ 
o 
o 
,. 
3. 
o 
,. 
,. 
o 
3. 
,. 
Peak LVQT-gradient(mmHg) 
P,e 
92 
58 
74 
100 
112 
121 
100 
100 
80· 
60 
100 
80· 
81 
160 
36 
81 
50 
100 
70 
147 
Post 
5 
25 
9 
9 
36 
16 
6 
36 
16 
50 
7 
5 
7 
41 
4 
5 
12 
3. 
64 
a 
'assessed by angiography. A = antiarrhythmic agents; B= beta-adrenergic blocking agents; C = calcium channel blocker: D = diuretic drug, F = female, I = angiotenSin-
converting enzyme inhibitor; [V$ = interventrieular septum; LVOT = left ventricular outflow tract; M = male; MM = myectomy; MMIMLE = myectomy and mitral valve 
extenSion; MR = mitral regurgitation, NYHA = New York Heart Association functional class; Post = postoperative; Pre = preoperative; Pt = patient; SAM = systolic 
anterior movement; W ~ warfarin; - = none. 
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Table 2 
Baseline and postoperative characteristics in patients treated by myectomy and mitral valve 
extension and in patients treated by myectomy alone. 
MM/MlE MM P value 
Baseline 
Age (yr) 42 ± 10 41 ± 10 0.94 
NYHA class 2.6 ± 0.5 2.6± 0.5 0.59 
Number of drugs 1.5±1.1 1.3±O.7 0.96 
IVS width (mm), (range) 26 ± 5, (20-35) 27 ± 4, (20-33) 0.56 
MR' (grade) 2+/3+ 012+ < 0.001 
SAM" (grade) 2+/3+ 1+/3+ < 0.05 
lVOT gradient (mm Hg) 95 ± 20 67± 36 0.33 
Postoperative 
NYHA class 1.7 ± 0.7 0.05 
Number of drugs 0.5 ± 0.6 1.8±1.2 < 0.005 
IVS width (mm), (range) 19 ± 4, (15-25) 22 ± 4, (16-30) < 0.05 
MR' (grade) 0/1+ 0/3+ < 0.005 
SAM" (grade) 0/1+ 0/3+ < 0.01 
lVOT gradient (mm Hg) 18 ± 13 23± 20 0.35 
. Range of mitral regurgitation observed In the two respective patient groups . 
.. Range of systolic anterior movement observed In the two respective patient groups. 
Data are presented as mean value ± SO, range or grade. IVS = width of the interventricular 
septum; other abbrevatlons as In Table 1. 
tively) in the group with the combined procedures. Moreover, this group had 
greater improvement in functional class (p~0.05) and a greater reduction in both 
the number of drugs prescribed (p<0.005) and the width of the interventricular 
septum (p<0.05). 
JHilra! valve measurements 
The mitral valve leaflet and left ventricular outflow tract areas of patients under-
going combined myectomy and mitral valve extension were calculated from in-
traoperative epicardial echocardiographic data according to previously descibed 
methods. The mean mitral valve leaflet area of 15.9 ± 2.0 cm' is considerably 
above mean values for the general population « 12 cm'). All patients belonged 
to a subset of patients with hypertrophic cardiomyopathy, as described by Klues 
et al. (24), with enlarged mitral leaflets, relatively large left ventricular outflow 
tract area ( 22.0 cm' [mean 2.9 ± 0.7 cm']) and a distinctive sharp-angled bend 
of the anterior mitral leaflet. 
By transthoracic echocardiography, the anterior mitral valve extension proce-
dure did not induce obvious changes in the length or thickness of the anterior 
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Figu/'e 2 
Two-dimensional, long-axis transthoracic echocardiograms from the same patient before and 
after combined anterior mitral leaflet extension and myectomy. Both are systolic frames trom 
the same point in the cardiac cycle. Left, Preoperative image, demonstrating marked systolic 
anterior movement of the distal anterior mitral leatlet (SAM, single arrow). Right, Postopera-
tive image, showing no significant systolic anterior movement of the valve. Note also the 
widened outflow tract aftcr myectomy and the probable position of the pericardial patch 
(double arrows). The mitral valve itselfis not demonstrably longer or thicker, although differ-
ences in technical quality prevent direct comparison. IVS = interventricular septum; LV =: left 
ventricle; L VOT = len ventricular outflow tract. 
mitral leaflets, although subjectively they appeared somewhat less flexible. Fig-
ure 2 shows a typical postoperative transthoracic echocardiogram without any 
residual systolic anterior motion of the mitral valve and a widened left ventricu-
lar outflow tract. 
DISCUSSION 
Anterior mitral leaflet extension is a novel surgical approach to the treatment of 
obstructive hypertrophic cardiomyopathy. The procedure entails grafting a patch 
of autologous pericardium onto the center pOliion of the anterior mitral leaflet, 
effectively increasing the size (mainly the width) of the leaflet. In the eight pa-
tients who underwent anterior mitral leaflet extension in combination with septal 
myectomy, the extension procedure lVas safe and effective in abolishing or 
greatly reducing systolic anterior movement of the mitral valve and mitral regur-
gitation and in lessening symptoms. Patients undergoing the combined proce-
dure had significantly greater improvement in functional class and required 
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fewer number of drugs postoperatively than did the 12 patients undergoing my-
ectomy alone. 
The reduction of septal thickness in both groups is not in contrast with the re-
sults of other institutions (25-27). Nevertheless, our approach may not be as 
agressive as the double myotomy-myectomy procedure reported by Morrow 
(28). However, overzealous septal myectomy must be avoided, because it may 
cause complete haert block, septal defect 01' increased mortality (29-3 I). The op-
timal myectomy procedure reduces septal thickness to a minimum without aug-
menting morbidity and mortality. Starting in 1972 we performed myectomy 
with or without mitral valve extension in 46 patients with only I in-hospital 
death. We cannot exclude that these good results were obtained because of a 
less agressive septal myectomy. 
Although the principal benefit of anterior mitral leaflet extension appears to 
be the abolition of systolic anterior movement and mitral regurgitation, the pre-
cise mechanism of this effect is not clear. In fact, the idea of enlarging the ante-
rior mitral leaflet is counterintuitive, given the awareness of the role that the mi-
tral valve plays in producing the systolic anterior movement. 
Mechanisms of oUIf/ow tract obstruction 
Outflow tract obstruction in patients with hypertrophic cardiomyopathy results 
from a combination of len ventricular outflow tract narrowing, due to basal sep-
tal hypertrophy, and systolic anterior motion of the mitral valve (I, I 1,32). Sev-
eral mechanisms for systolic anterior motion have been proposed: I) the Venturi 
mechanism, by which the hypertrophied septum and anterior displacement of 
the mitral valve create outflow tract narrowing, increased flow velocity, de-
creased pressure above the valve and, consequently, the development of systolic 
anterior motion, partly due to the abnormal laxity of the mitral valve (10, I 2-
14,22,24,32-35). 2) Anatomic alterations in the mitral valve apparatus. These 
may predispose to systolic anterior motion due to flow drag, the combination of 
increased mitral leaflet area, length and laxity and anterior displacement of the 
papill3ly muscles allowing the mitral leaflets to protrude into the left ventricular 
outflow tract and thus exposing them to flow drag. 3) Inward displacement of 
the papill3ly muscles toward one another. This displacement can produce rela-
tive chordal slack in the central leaflet pOitions; consequently, the systolic ante-
rior motion will be greatest in the center of the valve (36). 
Recently a combined pathologic and echocardiographic review by Klues et al. 
(24) confirmed that an enlarged mitral valve is present in a subset of patients 
with hypertrophic cardiomyopathy. These investigators classified patients with 
obstructive hypertrophic cardiomyopathy into two categories: I) patients with 
an enlarged mitral valve, relatively large left ventricular outflow tract area and 
distinctive sharp-angled bend of the anterior leaflet (typical systolic anterior mo-
tion) and 2) patients with a normal-sized mitral valve, small outflow tract area 
and "atypical" systolic anterior motion. All of our patients treated by the com-
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bined myectomy-mitral valve extension tcchnique belonged to the subset of pa-
tients with an enlarged mitral valve. This finding is impOliant because an en-
larged mitral valve may predispose- to residual systolic anterior motion of the 
valve after myectomy, resulting in a suboptimal outcome with persisting out-
flow tract obstruction. 
Possible mechallisms of actioll o{mitralleqf/et extellsioll 
How, then, does fliliher increasing the size of the anterior mitral leaflet with a 
pericardial patch abolish the systolic anterior motion? Both the Vcnturi mecha-
nism and the flow drag of the leaflets described earlier may be counteracted by 
anterior mitral leaflet extension. The distal end of the patch lies in the proximity 
of the bending point of the anterior leaflet. The patch may merely serve to 
stiffen the leaflet, making it less lax and less likely to buckle in the presence of 
Venturi forces or flow drag forces. Subjectively, the anterior mitral leaflets after 
combined myectomy and mitral valve extension did appear less "l1oppy" by 
two-dimensional echocardiography, without compromise in leaflet mobility or 
coaptation. 
The mitral valve extension technique increases the width (horizontal dimen-
sion), not the length (vertical dimension), of the anterior leaflet. Conceivably, 
increasing the width of the anterior mitral leal1et could erect the relative lax 
chordae attaching central pOliions of the mitralleal1et and thus prevent buckling 
of central parts of the valve. 
Currently we perform the mitral valve elongation procedure in patients under-
going surgelY who are likely to have suboptimal results from myectomy alone. 
These may include patients with particulaty severe systolic anterior motion of 
the mitral valve and mitral regurgitation, as well as patients with chronic atrial 
librillation or limited septal hypertrophy. In retrospect, all of our patients who 
underwent combined myectomy and anterior mitral valve elongation belonged 
to the subset of patients with an abnormally enlarged anterior mitral leaflet sur-
face area. Whether equal results can be achieved in patients with a normal-sized 
mitral valves is unknown. 
SUMMARY 
Adequate and predictable relief of outflow tract obstruction is the primary goal 
of surgery for hypertrophic cardiomyopathy. Multiple techniques, including 
simple septal myectomy, extended myectomy using intraoperative echocardiog-
raphy and multiple periods of cardiopulmonary bypass (31), mitral valve re-
placement (J ,8,9) and mitral leanet plication (17), are currently available to the 
cardiac surgeon. Anterior mitral valve extension is a promising new surgical ap-
proach to obstructive hypelirophic cardiomyopathy that may provide more satis-
factory results than thosc of myectomy alone. The mitral valve extension proce-
dure is known to be a safe and reliable therapy in other conditions such as rheu-
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matic valve disease and bacterial endocarditis with perforation (19). Further ex-
perience needs to be gained in obstructive hypertrophic cardiomyopathy before 
its widespread use can be recommended. 
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ABSTRACT 
Background. Ischemia occurs frequently in hypertrophic cardiomyopathy 
(HCM) without evidence of epicardial stcnosis. This study evaluates the hypoth-
esis that the occurrence of ischemia in HCM is related to remodelling of the 
coronal)' microcirculation. 
Methods and Results. End-diastolic septal wall thickness was significantly 
incrcased in patients with HCM (25.8 ± 2.9 mm) in comparison with cardiac 
transplant recipients (control subjects: 11.4 ± 3.0 mm; p< 0.05). Although the 
diameter of the left anterior descending coronaJY artelY (LAD) was similar in 
both groups (3.0 ± 0.8 versus 3.0 ± 0.5 nllll, p~ NS), the coronary resistance 
reserve (CRR= CRRbasa/CRRhypcremic)' corrected for extravascular compression 
(end-diastolic left ventricular pressure), was reduced to 1.5 ± 0.6 in HCM (p< 
0.05; control, 2.6 ± 0.8). Arteriolar lumen (AL) divided by wall area was lower 
in HCM (21 ± 5% versus 30 ± 4%; 1'< 0.05), and capillary density tended to 
decrease (tJ'om 1824 ± 424 to 1445 ± 513 n1l11', p~ 0.11) in HCM. CRR was 
linearly rclated to normalized AL according to the formula: CRR ~ 0.1 AL-
0.45 (l~0.57; p< 0.05). Further analysis revealed that CRR, AL, and capillary 
density were all linearly related to thc degree of hypertrophy. 
Conclusions. Decrements in CRR were related to changes of the coronary 
microcirculation. Both the decrease in CRR and these changes in the coronalY 
microcirculation were related to thc degree of hypertrophy. All these factors 
might contribute to the well-known occurrence of ischemia in this patient group. 
AL 
CFR 
CRR 
HCM 
HTx 
LAD 
SELECTED ABBREVIATIONS AND ACRONYMS 
normalized alteriolar lumen 
coronary flow reserve 
coronar), resistance reserve 
hypertrophic cardiomyopathy 
cardiac transplant 
left anterior descending coronary artery 
INTRODUCTION 
Anginal symptoms and signs of ischemia occur frequently in patients with HCM 
without detectable lesions of the major epicardial alteries (1-5), suggesting that 
the presence of ischemia is the result of abnormalities of the coronary microcir-
culation. Indeed, postmOitem analysis of HCM healts showed the existence of 
arterioles with abnormally thick walls (6,7). Furthermore, in experimentally in-
duced hypertrophy, it has been shown that the hypertrophic process is accompa-
nied not only by decrements in coronary flow reserve (CFR) but also by struc-
tural changes in the coronary microcirculation (coronary remodelling), including 
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a decreased capillary density (8-10). The resulting increased diffusion distances 
for oxygen and the disturbed perfusion of the capillary bed have been forwarded 
as an explanation for ischemia (8-10). 
Although the CFR is decreased in HCM, in accordance with the findings of 
experimentally induced hypertrophy (9, I 0), it is unknown at present whether the 
decreased CFR is related to the abnormal arterioles and whether a decrease in 
capillary density accompanies this decrease in AL. To that end, we measured 
CFR in combination with a quantitative analysis of AL, wall area and capillary 
density in myocardial tissue obtained during surgery (HCM) and obtained from 
endomyocardial biopsies (HTx). 
METHODS 
Sll~iects and i'rotocol 
Studies were performed in a group of patients with hypertrophic obstructive car-
diomyopathy (HCM; IF 10) who were referred for cardiac catheterization. The 
control group consisted of asymptomatic cardiac transplant recipients (HTx 
group; n~ 8) undergoing follow-up coronary angiography after transplantation. 
Informed consent was obtained from all patients. Patients in the HCM group 
were symptomatic, New York Heart Association (NYHA) class II or III, despite 
~-blockade therapy (n~ 5) or therapy with calcium antagonists (n~ 5). These pa-
tients were considered candidates for surgery (myotomy/myectomy). Medical 
therapy was continued in both groups. Right heart catheterization was per-
formed with a 7F balloon-tipped flow-directed thermodilution catheter. A 7F 
tempormy pacemaker was positioned into the right atrium. Left heart catheter-
ization was carried out, after which left ventricular angiography and coronary 
arteriography were performed with standard techniques. A 0.014-in Doppler 
guidewire with a floppy distal end (Cardiometrics,Inc) was introduced through a 
81' guiding catheter and positioned at the midsegment of the LAD to measure 
Doppler flow velocity at rest and after hyperemia. In both groups, hearts were 
paced at a constant heart rate of 100 bpm to avoid metabolic vasodilatation dur-
ing determination of the CFR. After optimization of the settings of the velocity 
signal and 3 to 5 minutes after intra coronary injection of a bolus of 2 to 3 mg 
isosorbide dinitrate, baseline recordings of flow velocity and perfusion pressure 
were collected and digitized at a sample rate of 125 Hz, for off-line analysis. 
Maximal hyperemia was induced by an intracoronary bolus injection of 18 ~lg 
adenosine (10). 
Doppler measlIrements 
The sample volume of the Doppler wire was positioned at a distance of 5.2 mill 
from the transducer and was ~2.25 mm wide. After power spectral analysis 
based on a fast Fomier transform algorithm, the maximal Doppler shift (kHz) 
was automatically tracked and converted to the instantaneous velocity values 
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(cm/s). CFR was defined as hyperemic devided by basal velocity (V'o,). Coro-
nat)' Resistance was defined as (P - P.,)IV where P is aOliic pressure and 
ao '"'-' cor, ao 
P oj is end-diastolic pressure. P oj was subtracted to account for increments in ex-
travascular compression. CRR was defined as the ratio of basal divided by over 
hyperemic resistance. 
Quantitative Allgiographic Measurements 
A validated on-line analysis system operating on digital images [ACA-DCI, 
Philips (II)] was used during the catheterization procedure. With this system, 
the end-diastolic diameter of the LAD was determined in the segment of the 
LAD in which the sample volume ofthc Doppler wire was located. 
EcllOcardiogl'aphic measurements 
Two-dimensional echocardiographic studies were performed (HP Sonos 1500) 
with the heart being visualized from standard cross-sectional planes while im-
ages were recorded on videotape (VHS) for off-line analysis. Septal wall thick-
ness was measured in diastole from both the parasternal short-axis and long-axis 
views. From the recordings on videotape, representative stop-frames from the 
various cross-sectional planes were acquired to determine septal wall thickness 
with the aid of a computer and a dedicated software program. To obtain an aver-
age for septal wall thickness the various cross-sectional planes were pooled. 
One patient from the control group was not analysed due to insufficient image 
quality. Thickness of the septal wall for the HCM and the control groups was 
defined as the degree of hypertrophy. 
Hist%gica/measurements 
The Illyocardial tissues from the HCM group (n= 9) and from the control group 
(n= 8) were obtained from surgical myectomy (left ventricular septal tissue; 
weight, 0.3 to I g) and Illyocardial biopsies (right ventricular septal tissue; 
weight, 0.5 to I mg), respectively. During catheterization, one HCM patient pre-
sented without a subvalvular pressure gradient and was not operated on. The tis-
sue was fixed with paraldehyde and immersed in 10% buffered formalin. van 
Gieson staining was used for identification and analysis of intramyocardial 
small arteries. Arterioles were identified on the basis of the appearance of a 
layer of media and diameter < 100 11m. Only arterioles with round cross sections 
and without side branches were analysed. Capillaries were identified with spe-
cific antibodies (CD34) against endothelium. Quantitative morphometric analy-
sis of the histological sections occurred with an in-house-developed software 
program applied to a morphometric system (Clemex Techn Inc) that calculated 
density of capillaries (capillaries per square millimeter), taking tissue shrinkage 
into account. Five cross sections per patient (= 1000 capillaries) were analysed. 
In addition, software was available that allowed us to trace the arteriolar lumen-
intima and adventitia-media borders, which defined the lumen and wall thick-
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ness regions. The areas of these regions were obtained from the number of pix-
els in the two regions. Normalized wall area is given by circular wall area/(lu-
men area +wall area). This value was calculated for 10 arterioles per patient. 
Data are presented as mean ± SO. Regression analysis, ANOV A and I tests 
were performed with standard statistical software (SPSS). A value of p< 0.05 
was considered significant. 
RESULTS 
The HTx recipients, who served as control subjects, had no cardiac complaints, 
and all of them had normal coronary arteriograms. The time interval of catheter-
ization after transplantation was 4 ± 2 years. Medication of HTx-patients at the 
time of catheterization was imunosuppresion (IF 8) Ca'+ antagonists (n~ 8); as-
pirin (n~ 5) and dipyridamole (n~ 4). No member of the control group had signs 
of rejection on the basis of the biopsies. Age distribution between the HCM 
(45.5 ± 14.6 years) and control (48.7 ± 6.0 years) groups were similar. HCM 
patients were symptomatic (NYHA class II or III), whereas all members of the 
control group were symptom free (NYHA class I). HCM patients had a 
subvalvular gradient of 88 ± 31 n1lu Hg and a lower aortic pressure (103 ± 14 
versus 120 ± 15 mm Hg, p< 0.05), a higher end-diastolic left ventricular pres-
sure (22 ± I versus 12 ± 6 mm Hg, p< 0.05), a lower cardiac index (2.7 ± 0.5 
versus 3.5 ± 0.7 Lim', p< 0.05) and a lowel' heart rate during baseline conditions 
(70 ± 13 versus 97 ± 13 bpm, p< 0.05) than the control group. 
End-diastolic septal wall thickness was significantly increased in patients 
with HCM (25.8 ± 2.9 nuu) compared with members of the control group (11.4 
± 3.0 mm; p< 0.05). All HCM patients had normal angiograms. The diameter of 
the LAD was similar in both groups (3.0 ± 0.8 versus 3.0 ± 0.5 nun). Coronaty 
velocity during baseline conditions was higher for HCM-patients (34 ± II ver-
sus 20 ± II cmls, p< 0.05), whereas velocities during hyperemia were similar 
(49 ± 20 versus 53 ± 22 cm/s). As a consequence the CFR was reduced from 2.6 
± 0.8 in the control group to 1.8 ± 0.9 in HCM group (p< 0.05). Coronat)' resis-
tance values, corrected for extravascular compression (see above), were lower 
(3.7 ± 2.1 versus 6.5 ± 2.2 mm Hg.s.cm· l, p< 0.05) during baseline conditions 
and were similar during hyperemia (2.6 ± 1.5 versus 2.6 ± 1.0, p~ NS) in HCM. 
Consequently, the CRR was lower (1.5 ± 0.6 versus 2.6 ± 0.8, p< 0.05) in HCM 
than in the control group. Arteriolar wall area was similar (5720 ± 2130 versus 
7107 ± 3544 fun'; p~ NS), but lumen area (1273 ± 688 versus 2260 ± 1165 
11m'; p< 0.05) and diameters were significantly lower (19.6 ± 4.5 versus 25.9 ± 
4.3 11m; p< 0.05) in HCM compared with control values. Consequently, AL was 
lower in the HCM (21 ± 5%) than in the control group (30 ± 4 %; p< 0.05), and 
capillary density tended to decrease from 1824 ± 424 to 1445 ± 513 per square 
millimeter in HCM (p~ 0.11). In addition, both the CFR and the CRR were lin-
early related to AL according to the formula CFR ~ 0.1 AL - 0.45 (I~ 0.57; p< 
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0.05) and CRR ~ 0.07 AL + 0.35 (F 0.50; p< 0.05; Fig I A). Further analysis 
revealed that the degree of AL (AL ~ -0.85 Hyp + 43.7; t= 0.71; p< 0.05; Fig 
I B), the CFR (CFR ~ -0.17 Hyp + 5.9; r~ 0.80; 1'< 0.05), the CRR (CRR ~ -1.2 
Hyp + 4.7; r~ 0.7; p< 0.05; Fig Ie) and the capillary density (CD ~ -51 Hyp + 
2750; t= 0.53; P< 0.05; Figure I D) were all inversely related to the degree of hy-
pertrophy (Hyp). In addition, a linear relationship between AL and capillary 
density was measured (AL ~ 42 CD + 577, t= 0.54; p< 0.05). 
DISCUSSION 
In symptomatic patients with HCM without evidence of a functional stenosis of 
the epicardial vessels, decrements in CFR were detected, confirming earlier 
studies (I -5). Similar decrements in CRR were measured, implying that these 
findings could not be explained by increments in extravascular compression 
(9, I 0). Abnormal arterioles with decreased lumen were detected in HCM pa-
tients, suggesting that a structural change in the coronaty arterial vascular tree 
might be related to this finding. Indeed, a positive relationship between both 
CFR and CRR and AL, corrected for tissue shrinkage by normalization to the 
wall area (7), was detected. Furthermore, an inverse relationship was noted be-
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tween AL and the degree of hypertrophy, confirming earlier postmorlem studies 
(7). Because of this relationship, an inverse relationship between CFR and the 
degree of hypertrophy could be measured. Again, a similar relationship was 
found between CRR and degree of hyperlrophy, implying that extravascular 
compressive forces were not essential for these findings. In large-animal models 
of pressure·overload induced left ventricular hyperlrophy, vascular medial hy-
pertrophy has been observed only when the coronary circulation was exposed to 
high perfusion pressures. The present arteriolar abnormaliJies were obtained at 
normal to low aortic pressures and might imply that hyperlrophy of the arteri-
oles, in parallel to the hypertrophy of the myocardium, is an independent pro-
cess (7). 
A decreased capillary density has been measured in several animal studies 
with experimentally induced secondary hypertrophy and recently in humans 
with secondary hypertrophy (12,13). Although differences between the groups 
in capillary density did not reach levels of statistical significance, there clearly 
was a an inverse relationship between capillmy density and degree of hypertro-
phy. Furthermore, the decrements in capillary density and decrements of AL are 
related in HCM. These findings may imply that the decreased AL induces peri-
ods of ischemia, which results in increased angiogenesis. This angiogenesis nor-
malizes the decrements itj capillary density. However, because we did not 
analyse HCM myocardial tissue without hypertrophy, we cannot exclude the 
possibility that the occurrence of changes in the coronmy microcirculation in 
HCM is a more independent phenomenon and not directly related to the degree 
of hypertrophy (6,7). 
In conclusion, septal hypertrophy is associated with decrements in CFR and 
CRR in HCM patients. Arterioles of HCM patients exhibited a smaller lumen at 
similar wall thickness, which correlated well with decrements in CFR and CRR. 
These findings suggest that abnormal arterioles might contribute to the perfusion 
abnormalities found in these patients, resulting in recurrent myocardial is-
chemia. 
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ABSTRACT 
Objectives. The purpose of this study was to investigate which haemo-
dynamic, echocardiographic and morphometric data are responsible for the re-
duction in coronary flow reserve in patients with hypertrophic obstructive cardi-
omyopathy. 
Background. Anginal symptoms and signs of ischaemia are frequently present 
in patients with hypertrophic cardiomyopathy despite the presence of normal 
coronary arteries. It has been postulated that periods of ischaemia are related to 
the reduction in coronary flow reserve in these patients. Although single 
haemodynamic, echocardiographic and morphometric variables have been re-
lated to the decrease in vasodilatory capacity, the relative contribution of each of 
these factors is not known. 
Methods. In 10 patients with hypertrophic obstructive cardiomyopathy, mean 
[±SD] age 44 ± 14 years and 8 cardiac transplant recipients, mean [±SD] age 51 
± 6 years (control group), coronary flow reserve was calculated at the proximal 
or mid-segment of the left descending coronary artelY. In all subjects we deter-
mined the New York Heart Association functional class, medical therapy, width 
of the interventricular septum and left ventricular posterior wall, indexed left 
ventricular mass, cardiac index, left ventricular end-diastolic pressure, left ven-
tricular outflow gradient, systolic and end-diastolic diameter of the left descend-
ing coronary altelY and first septal branch, lumen to wall ratio of the arterioles 
and capillary density in septal endocardial myocardium. We then evaluated the 
relationship between these variables and the coronary flow reserve by linear re-
gression analysis. 
Results. Coronary flow reserve was reduced in patients with hypertrophic ob-
structive cardiomyopathy compared to cardiac transplant recipients, 1.6 ± 0.7 vs. 
2.6 ± 0.8 respectively (p~0.009). An increase in the thickness of the left ven-
tricular septal myocardium (p~0.005), indexed left ventricular mass (p~0.005), 
left ventricular end-diastolic pressure (p~0.0002) and left ventricular outflow 
tract gradient (p~0.03) and a decrease in percentage lumen of the arterioles 
(p~0.04) were all related to the reduction in coronaty flow reserve. 
Conclusions. Several haemodynamic, echocardiographic and morphometric 
variables are responsible for the reduction in coronary flow reserve in patients 
with hypertrophic obstructive cardiomyopathy. The importance of each of these 
variables in reducing the vasodilatory reserve may differ from patient to patient. 
INTRODUCTION 
Chest pain is frequently present in patients with hypeltrophic cardiomyopathy, 
despite the presence of normal epicardial coronary arteries (I). Anginal symp-
toms can be triggered by exercise and atrial pacing, usually in combination with 
reversible perfusion defects detected by Thallium-20 I imaging and abnormali-
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ties in lactate melabolism (2-4). These objective signs of ischemia occur prefer-
entially in patients with a reduction in coronary vasodilatory capacity and it has 
been postulated thai a reduccd coronary flow reserve induces periods of is-
chemia in patients with hypertrophic cardiomyopathy (3,5). A number of inde-
pendent mechanisms are associated with this decrease in coronary flow reserve: 
I) elevation of left ventricular end diastolic pressure (6), 2) systolic compression 
of Ihe septal branches (7,8), 3) the existence and degree of the left ventricular 
outflow gradient (9), 4) "small vessel disease" of the intra myocardial arterioles 
(10, II) and 5) lack of compensatory gro\\1h of the comnar), micmcirculation 
(4). Although all mechanisms have a role in creating an imbalance between oxy-
gen supply and demand, their relative contribution to the decrease of coronal,), 
flow reserve has not yet been evaluated in hYPCl1rophic cardiomyopathy. The 
aim of the study was to investigate to which extent each of the separate vari-
ables mentioned above contribute to the reduction of comnary flow reserve in a 
group of patients with hypertmphic obstructive cardiomyopathy. To that end, 
haemodynamic and echocardiographic variables and histological data of the 
coronary microcirculation were obtained in patients with hypertrophic cardi-
omyopathy and compared with a control gmup consisting of asymptomatic car-
diac transplant recipients undergoing routine follow-up comnary angiography I 
to 5 ycars after transplantation. To evaluate changes in the coronary vascular 
bed we investigated septal myocardial tissue specimen of patients with hyper-
trophic cardiomyopathy, cardiac transplant recipients and a control group ofvic-
thns of cal' accidents without cardiovascular disease. In each subject we deter-
mined the degree of small vessel disease and capillm')' density. 
To our knowledge, this study is the first to describe the influence of a combi-
nation of heamodynamic, echocardiographic and morphometric data on the re-
duction of coronary flow reserve in patients with obstructive hypertrophic cardi-
omyopathy. 
METHODS 
Patient pop Illation 
To study haemodynamics and changes in the coronary vascular bed in hyper-
trophic cardiomyopathy, patients with obstructive hypertrophic cardiomyopathy 
(N~IO, mean age 44±14, range 20-63 years) were compared with a control 
group of asymptomatic cardiac transplant recipients (N~8, mean age 51±6, 
range 40-61 years) undergoing routine follow-up coronary angiography I to 5 
years after transplantation. Patients with hypertrophic cardiomyopathy were 
symptomatic, New York Heart Association Class II or lll, despite therapy with 
P-blockers andlor calciumantagonists and were candidates for surgical treatment 
(myectomy-myotomy according to Morrow) (12). The left ventricular outflow 
tract gradient was assessed by cardiac catheterisation and was> 30 mm Hg at 
rest in all patients with hypertrophic cardiomyopathy. Nine of 10 patients with 
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hypertrophic cardiomyopathy underwent septal myectomy-myotomy, the left 
ventricular outflow tract gradient in one patient was considered to low to expect 
considerable improvement of symptoms after surgery, The myocardium ob-
tained at surgery was used for morphometric analysis of the intramyocard ial ar-
terioles and capillaries. Cardiac transplant patients were studied I to 5 years af-
ter cardiac transplantation. These patients were asymptomatic. We obtained 
myocardial material by right ventrieular septal biopsy in these patients to deter-
mine the presence of rejection. Pa.i of this material was used for the morpho-
metric analysis of the coronary bed. These data were compared with myocardial 
tissue from left ventricular septal endocardium collected from victims of traffic 
accidents (N~ I 0, mean age 38± 19, range 8-58 years) without apparent cardio-
vascular disease. 
Cardiac Catheterization 
Cardiovascular therapy was continued during the study for both patients with 
hypertrophic cardiomyopathy and cardiac transplant recipients. After intrave-
nous administration of 10 000 IU heparin and 250 mg acetylsalicylic acid right 
heart catheterization was carried out with a 7F balloon-tipped flow-directed 
thermodilution catheter. Left heart catheterization was performed with a 8F 
double-sensor high fidelity pig tail catheter (Cordis 811-180, Roden, the Nether-
lands). At baseline the following parameters were evaluated: Mean central 
venous pressure, mean pulmonary wedge pressure, left ventricular systolic and 
end-diastolic pressure, peak left ventricular-aOliic gradicnt, cardiac output and 
cardiac index. In addition, left ventricular and coron3lY angiography was per-
formed according to standard techniques. The end-systolic and end-diastolic di-
ameters of the left descending coronary artery and the proximal part of the first 
septal branch were calculated by quantitative angiographic measurement at the 
site of the Doppler sample volume (CAAS-system) (13). 
CoronaJyf/ow velocity measurements and Gnalys;s 
After right and left cardiac catheterization, coronary flow velocity was measured 
in patients with hypertrophic cardiomyopathy and cardiac transplant recipients 
by use of a 0.014" Doppler guidewire with a floppy shapable distal end 
(Cardiometries,lnc.) (14), which was advanced through a 8F guiding catheter 
and positioned at the proximal 01' mid-segment of the left descending coronary 
artery. The sample volume from the Doppler wire is positioned at a distance of 
5.2 mm from the transducer and has an approximated width of2.25 nun due to a 
divergent ultrasound beam. After real-time processing of the quadrature audio 
signal, a fast-Fourier algorithm is used to increase the reliability of the analysis 
(15). The flow velocity measurements obtained with this system have been vali-
dated in vitro and in an animal model using simultaneous electromagnetic flow 
measurements for comparison (14). Before the assessment of the coronary flow 
reserve, the hearts were paced from the right atrium at 100 beats/minute and this 
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rate was kept constant during the remainder of the protocol. After optimization 
of the settings of the velocity signal and 3 to 5 minutes after intra coronary in-
jection of a bolus of 2 to 3 mg isosorbide dinitrate, baseline flow velocity was 
measured. Maximal flow velocity was acquired by measurement of the peak ef-
fect of an intra coronary bolus injection of 18 flg adenosine. The dose of ad-
enosine used has been shown to produce maximal vasodilation in humans (16). 
Coronary flow reserve was defined as the ratio between maximal flow velocity 
at the peak effect of the adenosine injection and that under baseline conditions. 
Qualltitative Allgiographic Measurement 
The guiding catheter, filmed devoid of contrast medium, was used as a scaling 
device. A previously validated on-line analysis system operating on digital im-
ages (ACA-DCI, Philips, Eindhoven, The Netherlands) was used during the 
catheterization procedure (17). With this system we calculated the end-diastolic 
and end-systolic diameter of the left anterior descending coronary aliery and the 
proximal part of the first septal branch. Care was taken to select the pOliion of 
the segments in the LAD where the Doppler catheter was located. The derived 
vessel diameters at the tip of the Doppler quidewire were used to calculate the 
vessel lumen area assuming a circular shape of the vessel. This vessel area was 
multiplied with the spatially averaged Doppler velocity (assuming a parabolic 
profile) to obtain coronary flow (ml/min). 
Ec//Ocardiography 
Two-dimensional echocardiographic studies were performed with commercially 
available equipment (Toshiba Sonolayer SSH-140A). The heart was visualised 
in a number of cross-sectional planes using standard transducer positions and 
images were recorded on videotape for off-line analysis. Septal and posterior 
left ventricular wall thickness was measured in diastole from both the paI·aster-
nal short axis and long axis views (18,19) In the short axis view, the magnitude 
ofleft ventricular hypertrophy was assessed at the levels of both the mitral valve 
and papillary muscles (19,20). For the ventricular septum, two segments were 
evaluated: the cephalad position, which extended from the cardiac base to the 
distal margins of the mitral leaflets, and the caudal position, which included the 
portion of the left ventricle imaged below the mitral leaflets (21). From the re-
cOl·dings on videotape representative stop-frames from the various cross-sec-
tional planes were acquired to determine septal and posterior left ventricular 
wall thickness with the aid of a computer and a dedicated software program 
(22). Mean septal thickness was calculated by averaging the data for the width 
of the septum, mean posterior wall thickness was calculated in the same way. 
Left ventricular mass was calculated according to the method developed by 
Devereux et al.(23): LVmass (g) ~ 0.8{1.04[(IVS + LVED + Lvpwi -
LVED3]} + 0.6 g, where IVS and LVPW are enddiastolic thickness of the inter-
ventricular septum and posterior wall respectively and LVED is the left ven-
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tricular enddiastolic diameter. left ventricular mass was indexed by body sur-
face area (g/m2). 
MOIphomelric analysis of arlerioles 
The myocardial specimen from patienls with hypertrophic cardiomyopathy 
(N~9), cardiac transplant recipients (N~8) and victims of cal' accidents (N~ I 0) 
were fixed by immersion in 4% phosphate-buffered formaldehyde. The group of 
victims of cal' accidents consisted of subjects without detectable signs of cardio-
vascular disease. Care was taken that only specimen from the endocardial sepia I 
site was utilised for analysis in all three groups. After fixation, the myocardial 
lissue was processed for paraffin sectioning and staining. For identification and 
analysis of intra myocardial small arteries an elastic von Giesson staining was 
used according to Tanaka et al.( I 0). In brief, each preparation was magnified 
with a light microscope (Zeiss, Germany) and digitized for further analysis with 
a quantitative morphometric system (!BAS system, Kontron, Germany). Only 
round appearing vessels without side branches were studied. For each arteriole, 
the wall (intima plus media) and total vessel area were traced and the areas 
were, via appropriate gain settings, converted to square micrometers. The ad-
ventitia was not included in Ihe measurements since Ihe distinction between ad-
ventitia and perivascular fibrosis was difficult. Percent lumen area was calcu-
lated from the ratio of lumen area (l), and Wall area (W) plus lumen area (l) 
as LI(W+L)xIOO%. The external diameter (D) of the intramyocal'dial coronary 
atierioles was calculated by Ihe formula: D~ 2x "!wall + lumen arealIT. In each 
subject at least 10 atierioles were identified and used for analysis. 
M0I1Jhollleiric analysis of capillaries 
In order to elucidate the capillary density in the above mentioned myocardial 
specimens, sections (411) from formalin fixed, paraffin embedded tissue were 
stained with antibodies directed against the CD-34 epitope ( Biogenex, San 
Ramon, MO) as described below. After deparaffinization and rehydration sec-
tions were rinsed with phosphate-buffered saline and incubated with normal 
goat serum (DAKO, Glostrup, Denmark), antibodies directed against the CD-34 
epitope, biolinylated secondary antibodies (Multilink, Biogenex, San Ramon, 
MO) and peroxidase labelled streptavidin (Biogenex), respectively. The subse-
quent immunoproduct was visualised with 3.3' diaminobenzidine . In negative 
controls the primary antibody was replaced by normal mouse serum (DAKO, 
Glostrup, Denmark). The CD-34 antibody demonstrated endothelial cells from 
capillaries in human myocardium most consistently, whereas CD-31 antibodies 
and the lectin Ulex Europeaus (in general more specific endothelial markers) 
left some capillairies uncoloured. In our experience, staining by Jones' silver 
methanamine, which was used by Rakusan et al. (30) to analyse capillary den-
sity in human myocardium, provided SUboptimal results: discrimination of indi-
vidual capillaries was more difficult and moreover, this staining method left 
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some capillaries uncoloured. Quantitative morphometric analysis of the sections 
with an area of 62.500 [tm' was performed with a specially developed software 
program applied to a morpometric system (Clemex Techn Inc., Quebec, 
Canada). We payed special altention that cross-sections were originating from 
the endo- or mid myocardium, only regions were selected where Ihe cardio-
myocytes were cut transversely and no or only minimal fibrosis was present. For 
each patient at least five different regions were selected. The number of cardiac 
myocyte, and therefore the capillary-myocyte ratio was not determined because 
of the inabilily 10 outline myocytes correclly. Figure I shows an example of 
capillary density in a patient with hypeltrophic cardiomyopathy and a victim of 
a car accident respectively. 
., 
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) 
F(gure 1 
The capillary density of a victim of a car accident is represented at the len pancl. At the right 
panel, the capillary density of a patient with hypertrophic cardiomyopathy is displaycd. Note 
the dccrcase in number ill capillary vcssels in hypertrophic cardiomyopathy (magnification 
40 x). 
bllerobserver variability 
The pcrcentage lumen of Ihe arterioles and the capillary density was indepen-
dently quantified by Iwo different observers. The variance of percentage lumen 
and capillary density was <3% and < 5% respectively. 
Statistica! analysis 
Data are presented as mean ± SO. To evaluate differences between groups un-
paired student I-test was ulilized. The relationship between coronary flow re-
serve and haemodynamic, echocardiograhic and morphometric variables was 
evaluated by linear regression analysis. A value of p< 0.05 was considered to bc 
significant. 
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RESULTS 
Patient characteristics 
Demographic information, haemodynamic and morphomelric data are presented 
in Table I. Patients with hypertrophic cardiomyopathy (N~IO) were all symp-
tomatic: nine from ten patients had complaints of angina andlor dyspnoe, synco-
pal attacks as sole expression of the disease was present in one patient. Cardiac 
transplant recipients (N~8) were free of symptoms. Beta-blockers andlor 
caiciumantagonists were prescribed in nine from ten patients with hypelirophic 
cardiomyopathy, one patient did not use medical therapy. Statistical differences 
in patient characteristics behveen the two groups are displayed in Table 2. Pa-
tients with hypertrophic cardiomyopathy had increased thickness of the inter-
ventricular septum (2.3±0.3 cm, range 2.0-3.0 cm) and posterior wall (\.3±0.3 
cm, range I. 1-1.8 cm), compared with thickness of septal- (J.I±O. I cm, range 
\.0-1.2 cm) and posterior myocardial wall (I.I±O.I cm, range 0.9-1.1 cm) of 
cardiac transplant recipients; p~ 0.000 I and p~ 0.005 respectively. At baseline, 
resting heali rate tor patients with hypelirophic cardiomyopathy averaged 70± I 3 
beats per minute, which was significantly lower than the resting heart rate for 
cardiac transplant recipients (97± I 3 beats per minute, p~ 0.005). The indexed 
len ventricular mass in patients with hypertrophic cardiomyopathy (I 87±4 I gl 
m') was increased compared to cardiac transplant recipients (89± I 5 g/m'), p~ 
0.0001 
Cardiac index was depressed in patients with hyperlrophic cardiomyopathy; 
this finding could mainly be attributed to the lower heart rate in patients with 
hypertrophic cardiomyopathy, since stroke volume was not statistically different 
in both groups. Len ventricular end-diastolic pressure was significantly higher 
in the patients with hypertrophic cardiomyopathy (21±8 nun I-Ig vs. 9±3 mm 
Hg, p~ 0.0007). 
Selective coronaty angiography did not show epicardial coronary artelY dis-
ease in the two groups. Systolic and enddiastolic lumen-diameters of the left an-
terior descending artelY and first septal branch were comparable in patients with 
hypertrophic cardiomyopathy and cardiac transplant recipients. Septal perforator 
artery compression, defined as a disappearance of part of the septal artelY during 
systole (8) was not observed in patients with hypertrophic cardiomyopathy nor 
in cardiac transplant recipients. 
MOIpJlOlI/etric and histological analysis 
The exte1'11al calibre of the intramyocardial arterioles in patients with hyper-
trophic cardiomyopathy (42.0±7.8 Ilm) and cardiac transplant recipients (46.1 
±12.7 Ilm) were not significantly different from the exte1'11al calibre of victims 
of car accidents (49.9± I 3.4 ~l1n), p~ O. I 4 and p~ 0.45 respectively (Table 2). In 
contrast, the percentage lumen was reduced in patients with hypertrophic cardi-
omyopathy (21.3±5.2%) compared to cardiac transplant recipients (30.4±3.3%) 
:;:: 
" 
" 
"" Table I 5 in' 
Baseline. echocardiographic. haemodynamic and morphometric data of patients with hypertrophic cardiomyopathy and cardiac transpant recipients. 3 ~ 
t:i 
" 
" AGE/SEX NYHA Therapy IVS LVPW LVmass/ Cardiae LVeOp LVOT- % lumen IMSA Capillaries CF" § 
(mm) (mm) BSA (glm~ Index (mm Hg) gradient (mm (n/mm") §: 
(llminimj H9) o'il HCM 
#1 4SF 
" 
20 11 168 2.8 12 32 3.10 if 
#2 S9M 
'" 
B 23 13 202 2.4 28 100 14.9 1379 1.33 ;0 
#3 3SF 
" 
V 30 18 276 3.1 23 124 18.9 849 1.12 " 0-
#4 27F 
'" 
B 25 12 205 2.9 26 100 16.0 864 1.20 12 #5 44F 
" 
V 20 11 122 3.2 14 100 22.1 1541 2.10 0' 
#6 20M 
" 
V 23 11 182 2.9 23 58 27.S 1768 1.22 = 
.7 41 F 
'" 
B,V 24 18 199 1.8 37 124 19.7 969 0.97 
= 
.8 63M 
'" 
B 17 13 147 2.3 16 74 18.4 1686 1,13 n 
.9 62 M 
'" 
V 22 12 184 3.4 20 88 30.7 1496 1.41 0 
<3 #10 43M 
'" 
B 22 12 186 2.0 13 e4 23.4 2451 1.68 
= ~ 
HTX '< 
." #1 49 M A,C,N,P 11 10 91 3.4 9 26.1 1308 3.38 0' 
#2 61 M C,D,N,P 12 10 88 3.2 6 26.6 1747 4.01 ~ 
#3 40M A,C,N,P 11 10 82 4.8 10 35.3 2079 2.00 ;0 
#4 57M C,D,N,P 11 11 119 4.1 11 31.2 2373 2.70 ~ 
.5 51 M e,D,N,p 11 10 84 3.4 5 31.2 1511 2.25 
" ~#6 SSM A,C,N,P 10 10 73 3.2 7 33.7 2050 3.13 
" .7 SaM A,C,D,V 10 9 71 2.6 11 28.0 2245 1.97 
.8 S2M A,C,N,P 11 10 100 3.9 13 31.5 1279 1.72 
Therapy! A..aspirin, B""P-blocker, C=eyclosporin, D=dlpyridamole. N=nifedipln. V=verapamU. CFR=coronary flow reserve, IMSA::::intramyocardial small arteries,IVS::::interventricular 
septum, LVEDP",left ventricular enddiastollc pressure, LVmass=left ventricular mass, LVOT-gradient",left ventricular outflow tract gradient, LVPW .. left ventricular posterior wail, 
NYHA",New York Heart Association functional class. 
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Table 2 
Comparison of patient characteristics between subjects with hypertrophic cardiomyopathy 
and cardiac transplant recipients. 
HCM(N=10) HTX(N=8) p-yalue 
Age (years) 44±15 51±6 0.13 
IVS(mm) 26±3 11±t 0,0001 
LVPW(rnm) 15±4 10±1 0.005 
LVmass/B$A (glm') 187±41 89±15 0.0001 
Cardiac Index (Umlnlm1) 2.7±0.5 3.StO.7 0.009 
LVEOP (mm Hg) 21±S 9±3 0.0007 
LADed (mm) a.29±O.96 3.12±0.48 0.48 
LADes (mm) 3.14±0.92 a.OSiO.51 0.63 
SAed {mm} 1.49±O.43 1.25±0.22 0.09 
SAes(mm) 1.34±O.41 1.15±0.20 0.24 
Exlernal Dlameler of IMSA 42.0±7.8 46.1±12.7 0.46 
Ulm) 
lIW+L(%) of IMSA 21.3±5.2 30.4±3.3 0.0007 
CaplJlary density (N/mm') 1445±514 1824±425 0.11 
Coronary flow reserve 1.6±O.7 2.7±O.S 0.009 
Dala are presented as mean values ± SO. L=lumen area, lADed:enddlastolic diameter of the left 
descending coronary artery, lADes:endsystoHe diameter of the left descending artery, SAed=enddias-
toile diameter of Ihe seplal artery, SAes=endsystolle diameter of the septal artery, W=wall area. Other 
abbreviations as In Table 1 
and the normal control group (30.9±5.7%), p= 0.0007 and p= 0.001 respec-
tively. 
The capillaty density was diminished in patients with hypelirophic cardiomy-
opathy (1445±514/mm') compared to cardiac transplant recipients (1824±425/ 
mm'), however this difference was not significant (p= 0.11). In victims of car 
accidents the number of capillaries (3883± 798/mm') was larger compared to pa-
tients with hypertrophic cardiomyopathy (p= 0.000 I) and cardiac transplant re-
cipients (p= 0.000 I). 
COJ'OJ1(JIJ
'
flOll'reSen'e 
The coronaty flow reserve in patients with hypertrophic cardiomyopathy was re-
duced compared to cardiac (ransplant recipients, 1.6±0.7 vs. 2.6±0.8, p= 0.009. 
Since this decrease in coronary flow reserve may be due to different mecha-
nisms we performed univariate regression analysis to determine which factors 
contributed to the variance in the vasodilatory reserve. We evaluated the follow-
ing parameters: left ven(ricular septal thickness, left ventricular posterior thick-
ness, indexed left ven(ricular mass, left ventricular end diastolic pressure, left 
ventricular outflow gradient, cardiac index, systolic and enddiastolic lumen of 
the left anterior descending coronary aliery and first septal branch, the percent-
age lumen of the intramyocardial small atieries and the capillary density. An in-
crease in the thickness of the left ventricular septal myocardium (p= 0.005), in-
dexed left ventricular mass (p= 0.005) (Figure 2), left ventricular enddiastolic 
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figure 2 
'Il1e relation between the coronal), now rescrve (CFR) and left ventricular mass corrected tor 
body surface area (LVmass/BSA, g/ni) in patients with hypertrophic cardiomyopathy (e) 
and cardiac transplant recipients (+). 
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Figure 3 
The relation between the coronary now rescrve (CFR) and lell ventricular enddiastolic prcsK 
sure (LVEDP, mmllg) in patients with hypertrophic cardiomyopathy (e) and cardiac trans-
plant recipients (+). 
pressure (p~ 0.0007) (Figure 3) and the left ventricular outflow gradient (p~ 
0.03) and a decrease in percentage lumen of the alterioles (p~ 0.04) were all re-
lated the reduction of coronary flow reserve. The reduction in capillary density 
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in patients with hypertrophic cardiomyopathy was not significantly related to the 
reduction in the vasodilatory reserve (p~ 0.10). Multivariate analysis was not 
performed because of the small patient numbers. 
DISCUSSION 
Previous studies have described the role of coronary flow reserve in hyper-
trophic cardiomyopathy and have related the reduction of the vasodilatory re-
serve in these patients with single echocardiographic, haemodynamic and mor-
phometric alterations. This is the first study to relate a combination of clinical ( 
increase in indexed left ventricular mass, increase in left ventricular enddiastolic 
pressure, the degree of the left ventricular outflow gradient) and pathologic fac-
tors (decrease of the percentage lumen of the arterioles) with the reduction in 
coronary flow reserve. 
MOIphometric allalysis o/myocardialtisslle: the role o(small vessel disease 
In patients with hypertrophic cardiomyopathy post-mortem histologic analysis 
of left ventricular myocardium has revealed the presence of abnormal 
intramyocardial arterioles with markedly thickened walls and narrowed lumens 
(24,25). The presence of abnormal intramyocardial small alleries has been con-
sidered as one of the possible mechanisms for reduction in coronary flow re-
serve in these patients (10,11). Indeed, in our study we could find a positive re-
lationship between the degree of alleriolar dysplasia and the decrement in the 
vasodilatory reserve. Since myocardial tissue was obtained from different sites 
(left ventricular septal endocardium for patients with hypertrophic cardiomyopa-
thy, right ventricular septal endocardium in cardiac transplant recipients), this 
could have affected the present results. Nevertheless, Tanaka et al. (10) demon-
strated that the percentage lumen of the intramyocardial arterioles was identical 
in the right, middle and left thirds of the ventricular septum in hearts with hyper-
trophic cardiomyopathy and normal hearts. To evaluate the role of small vessel 
disease in cardiac transplant recipients we compared the percentage lumen of 
intramyocardial arterioles in this group with that of normal hearts: no significant 
differences were found. 
AI01phomefric allalysis a/myocardial fiSSile: fhe role a/the capillm)' dellsity 
Although the small arteries and arterioles mainly control the blood flow of the 
coronary circulation, the capillary density and distribution are of crucial impor-
tance in the process of exchange between blood and tissue (26). In patients with 
hypertrophic cardiomyopathy ischaemia might be due to an increased oxygen 
diffusion distance caused by an inadequate growth of the capillaries. The exist-
ence of this phenomenon has been confirmed in studies with mature animals 
with pressure-overload hypertrophy (27,28). However, there are only few stud-
ies that have investigated the coronary vascular microcirculation in the normal 
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human population and in patients with pressure-overload hypertrophy. Rakusan 
et al. (29) showed that the left ventricular capilialY density is similar to other 
mammalian species, and that pressure-overload left ventricular hypertrophy in 
children demonstrates proportional eapillmy angiogenesis, whereas in adults, 
hypertrophy appears to be associated with failure of eompensatolY angiogenesis. 
To our knowledge, there are no studies concerning the role of capillmy angio-
genesis in hypertrophic obstructive cardiomyopathy. In our study, we showed 
that there was a clear reduction in capillary density in patients with hypertrophic 
cardiomyopathy compared with patients without cardiovascular disease and car-
diac transplant recipients, however the decrease in capillary density did not 
reach statistical significance in patients after heart transplantation (p~ 0.1 I). 
There was only a weak relation between the reduction in coronary flow reserve 
and the decrease in capillary density (p~ 0.10). However, the patient population 
could have been to small for differences to appear. In comparison with the study 
by Rakusan et al. (29), the capillmy density in normal subjects was higher in our 
study (3883 vs. 2249 per square nun). An explanation for this difference may be 
found in the staining-method we used for the detection of the capillaries. Indeed, 
we tried to colour capillmy vessels with the Jones' silver methanamine method 
used in study by Rakusan et ai, however in our experience this method pre-
sented suboptimal results. 
Lill/italions oflhe silldy 
First, in our study we used cardiac transplant recipients as a control group. To 
use cardiac transplant recipients as a "control" -group is debatable, nevertheless 
Vassali et al. showed that coronmy flow reserve is comparable with the normal 
population I to 6 years after transplantation (30). The group of cardiac trans-
plant recipients had no signs of acute allograft rejection or epicardial coronary 
artery disease, conditions which are known to diminish the coronary vaso-
dilatory reserve (31,32). Although coronary flow reserve is comparable with the 
normal population, patients after heart transplantation can not be considered 
"normal". From the parameters we studied which could influence coronary flow 
reserve, the reduction in capillmy density in cardiac transplant recipients was the 
most striking difference in comparison with the normal situation. Second, the 
sample size of the patient populations we studied was relatively small, as a con-
sequence: I) Only univariate analysis could be performed 2) Only very clear 
differences in patient characteristics will show significancy. A larger sample 
size might reveal other factors, like capillmy density, being responsible for a de-
crease in vasodilatOlY reserve in patients with hypelirophic obstructive cardi-
omyopathy. Moreover, in our study, the contribution of systolic compression of 
the septal alielY could not be studied since this phenomenon was not present in 
either patients with hypertrophic cardiomyopathy or cardiac transplant recipi-
ents. Third, the medical therapy was maintained throughout the study. This 
could have affected coronmy flow reserve. However, since all patients with hy-
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Figure 4 
IVlechanisms underlying the reduction in coronary now reserve in hypertrophic cardiomyopa-
thy. 
pertrophic cardiomyopathy had serious complaints of angina andlor dyspnea, it 
was not considered ethical to discontinue medical therapy. 
Conclusions 
Many patients with hypertrophic cardiomyopathy manifest evidence of myocar-
dial ischaemia. Myocardial ischaemia is often the result of a reduction in coro-
nmy flow reserve in these patients. Figure 4 gives an update from what we and 
others found concerning the role of clinical and pathological variables with rela-
tion to the coronary flow reserve in patients with hypertrophic cardiomyopathy. 
Some interrelations are yet unknown: especially this accounts for the relation 
between the left ventricular mass and variances in the microcirculation. More-
over, the importance of each of the variables in reducing coronary flow reserve 
Illay differ Ii'olll patient to patient. 
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ABSTRACT 
The development of left ventricular hypertrophy (L VH) in subjects with hyper-
trophic cardiomyopathy (HCM) is variable, suggesting a role for modifying fac-
tors such as angiotensin II. We investigated whether the angiotensin II type I 
(ATI-R) A/Cli66 polymorphism, the angiotensin-converting enzyme (ACE) in-
settion/deletion (liD) polymorphism and/or plasma renin activity influence LVH 
in HCM. 
Left ventricular mass index (L VMI) and interventricular septal thickness 
(lVS) were determined by two-dimensional echocardiography in 104 genetically 
independent subjects with HCM. Extent of hypertrophy was quantified by a 
point score (Wigle score). Plasma prorenin, renin and ACE were measured by 
immunoradiometric or fluorimetric assays, and ACE- and AT/-R genolyping 
were performed by polymerase chain reactions. 
The ACE D allele did not affect any of the measured parameters except 
plasma ACE (p< 0.02). LVMI was higher (p< 0.05) in patients carrying the 
ATI-R C allele (190 ± 8.3 gim') than in AA homozygotes (168 ± 7.2 g/m'), and 
similar patterns were observed for IVS (23.0 ± 0.7 vs. 21.6 ± 0.7 mm) and 
Wigle score (7.0 ± 0.3 vs. 6.3 ± 0.3). Plasma renin was higher (p< 0.05) in car-
riers of the C allele than in AA homozygotes. Multivariate regression analysis 
however revealed no independent role for renin in the prediction of L VMI. 
Plasma prorenin and ACE were not affected by the A T/-R A/Cll66 polymor-
phism, nor did the ACE- and A T1-R polymorphisms interact with regard to any 
of the measured parameters. 
We conclude that the A T1-R CII66 allele modulates the phenotypic expression 
of hypeltrophy in HCM, independently of plasma renin and the ACE lID poly-
morphism. 
ACE 
Ang 
ATI-R 
BSA 
HCM 
IVS 
LVH 
LVM 
LVMI 
MI 
PCR 
SAM 
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angiotensin-converting enzyme 
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INTRODUCTION 
Hypertrophic cardiomyopathy (HCM) is characterized by idiopathic myocardial 
hypertrophy. HCM occurs as a tlunilial disorder, with an autosomal dominant 
pattern of inheritance, as well as in sporadic clinical presentation. Currently, six 
genes (~-myosin heavy chain, cardiac troponin T, a-tropomyosin, cardiac myo-
sin binding protein-C, essential light chain-I, regulatory light chain) have been 
identified that may cause HCM (1-5). Patients with identical gene mutations dis-
play variable clinical manifestations or even fail to express the disease (6-8). 
Other factors, genetic as well as environmental, may therefore modify the phe-
notypic expression of the mutated gene. 
It is now generally believed that angiotensin (Ang) II, formed by ACE from 
Ang I, is not only a potent vasoconstrictor, but also an important modulator of 
cardiac hypertrophy (9, I 0). ACE inhibition induces regression of cardiac hyper-
trophy, independent of load, and prevents dilatation and remodeling of the ven-
tricle after myocardial infarction (MI) (11-14). Cardiac ACE levels are in-
creased following MI (11,15,16), as well as during pressure overload-induced 
left ventricular hypertrophy (17). The ACE levels in the human heali are in part 
determined by the so-called insertion/deletion (I/D) polymorphism, subjects 
with the DD genotype having higher tissue ACE levels than subjects with II or 
ID genotypes (18). According to some (19-21), but not all (22,23) studies the 
frequency of the D allele is higher in patients with HCM. Moreover, the extent 
of hypertrophy in subjects with HCM is influenced by the ACE I/D polymor-
phism (20,22,23), suggesting that Ang II may modifY the phenotypic expression 
of hypertrophy in HCM. The latter association may depend upon the underlying 
gene mutation, since it was found only in subjects with mutations in the Arg 403 
codon of the ~-myosin heavy chain gcne (23). 
Ang II exerts most of its known cellular actions through the angiotensin II 
type I receptor (ATI-R) (24). Recently, the C allele of a polymorphism located 
in the 3' untranslated region of thc AT I-R gene (corresponding to an adenine/ 
cytosine (A/C) substitution at the 1166 position) has been shown to increase 
synergistically the risk of MI in subjects carrying the ACE D allele (25). 
It was the aim of the present study to investigate whether the ATI-R C allele 
influences the extent of hypertrophy in HCM, for instance through an interac-
tion with the ACE D allele. Since cardiac angiotensin generation depends 
largely on kidney-derived (pro)renin takcn up from the circulation (26-28), we 
also studied the relationship between plasma (pro)renin, cardiac hypertrophy 
and the ATI-R C allele in subjects with HCM. 
METHODS 
Paliellis 
One-hundred and sixteen patients with HCM (age 21-81 years; median 47 years) 
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visiting the Hypertrophic Cardiomyopathy Clinic at the Thorax Center of the 
Academic Hospital "Dijkzigt" between December 1994 and Janu3lY 1997 for a 
routine follow-up were included in the study. HCM had been diagnosed on the 
basis of echocardiographic criteria showing a nondilated, hypertrophied left ven-
tricle (any wall thickness> 15 mm) in the absence of known causes of left ven-
tricular hypertrophy such as systemic hypertension or valvular disease (29). 
From each patient a peripheral venous blood sample was collected for measure-
ment of plasma prorenin, renin and ACE, and for the extraction of genomic 
DNA. Patients using ACE inhibitors (IF7) were excluded from the study be-
cause of interference with the measurement of plasma ACE. Of the remaining 
109 subjects, forty-one had a sporadic form of HCM and fifty had at least one 
other affected first degree family member. The family history of HCM was un-
known in eighteen patients. To avoid potential bias introduced by the presence 
of genetically dependent samples (relatives), we randomly selected one patient 
per family. This resulted in a final cohort of 104 genetically independent pa-
tients, of whom 30 were receiving a beta-adrenergic antagonist, 44 a calcium-
channel blocker and 8 a diuretic. 
The study was approved by the internal review board and patients gave in-
formed consent. 
Echocardiographic methods 
Two-dimensional echocardiography was performed with commercially available 
equipment (Toshiba Sonolayer SSH-140A System, Tokyo, Japan). The heart 
was visualized in a number of cross-sectional planes, using standard transducer 
positions, and images were recorded on videotape for off-line analysis. 
Echocardiographic analysis was performed by two physicians who were blinded 
to the results of the genotyping studies. 
Interventricular septal thickness (IVS) was measured in diastole from the 
parasternal short-axis view at the level of the papillary musclcs. The magnitude 
of LVH was determined by calculating left ventricular mass (LVM, g) accord-
ing to the method described by Devereux et al.(30): LVM ~ 0.8(1.04[(1VS+ 
LVED+LVPW)' - LVED3]) + 0.6 g, where LVED is the left ventricular end-di-
astolic diameter, and LVPW is the end-diastolic thickness of the posterior wall. 
LVM was indexed (LVMI, g/m') to body surface area. 
Systolic anterior motion (SAM) of the anterior leaflet of the mitral valve was 
assessed from the two-dimensional images and graded 0 (absent), 1+ (mild 
[minimal mitral-septal distance> I 0 mm during systole]), 2+ (moderate [mini-
mal mitral-septal distance 0;;10 n1111 during systole)) or 3+ (marked [brief or pro-
longed contact between the mitral valve and septum)) (31). 
Peak left ventricular outflow tract gradient at rest was estimated using the 
modified Bernoulli equation, P~4V2, where P is the pressure gradient and V is 
the velocity determined by Doppler echocardiography. 
Since the echocardiographic measurement of LVMI may not truly reflect the 
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extent of hypertrophy and the involvement (or lack thereof) of the distal (apical) 
half of the septum or laterallVall, the extent of hypertrophy lVas also assessed by 
a semi-quantitative point score method developed by Wigle et al.(32). A maxi-
mum of 10 points are given: I to 4 points for septal hypertrophy based on mag-
nitude of thickness, 2 points for extension of hypertrophy beyond the level of 
the papillary muscles (basal two-thirds of septum), 2 points for extension of hy-
pertrophy to the apex (total septal involvement), and 2 points for extension of 
hypertrophy into the laterallVall. 
Biochemical meaSllremeJlts 
Five mL blood was collected into tubes containing trisodium citrate (tina I con-
centration in blood: 0.026 moIlL). The blood lVas centrifuged at 3000g for 10 
minutes at room temperature, and plasma was stored in I mL aliquots at -70°C. 
Shortly before assaying, the samples lVere rapidly thalVed and kept at room tem-
perature. All assays lVere performed in duplicate. 
Immunoreactive renin lVas quantified in 200 ILL plasma using an immun-
oradiometric assay kit (Nichols Institute, Wychen, The Netherlands), following 
the methods proposed by Derkx et al.(33). Prorenin lVas activated non-pro-
teolytically, by incubation with the renin inhibitor remikiren, and its concentra-
tion lVas calculated by subtracting the results obtained before activation of 
prorenin (i.e., renin) from those obtained after activation (i.e., renin + prorenin). 
The renin and pl'Orenin levels are expressed as mUlL, using the international hu-
man kidney renin standard MRC 68/356 (Medical Research Council, National 
Institute of Biological Standards and Control, London, U.K.) as a reference. The 
normal range in plasma is 8 to 55 mUlL for renin and 88 to 390 mUlL for 
prorenin (33). 
ACE activity lVas measured lVith a commercial kit (ACE Color, Fujirebio, 
Tokyo, Japan); its normal range in plasma is 7 to 20 UIL (34). 
Genetic analysis 
Peripheral leukocytes, obtained after centrifugation of 5 mL blood (see under 
Biochemical Measurements), were used to isolate genomic DNA in H20 using 
the QIAamp Bloodkit (QIAGEN Inc., Santa Clarita, CA). DNA concentrations 
varied from 25-50 ngipL. 
The determination of the ACE gene liD polymorphism lVas based on the 
triple primer method described by Evans et al.(35). This method, IVhich avoids 
mistyping of ID as DD (36), lVas modified into tlVO separate polymerase chain 
reactions (PCR). The first PCR encompassed the entire insertionldeletion re-
gion. Using the sense oligonucleotide primer 5'gctggagaccactcccatcctttct3' and 
the anti-sense primer 5'tagacctccacgagtcccctgcat3', tlVO fragments of 493 base 
pairs (bp) and 781 bp were amplified corresponding to the D- and I allele respec-
tively (Figure I). In the second PCR an insertion-specific sense primer, 
5'tgggattacaggcgtgatacag3', lVas used with the above mentioned anti-sense 
126 
781 bp 
493 bp 
460 bp 
M 
DD 
a b a 
Figure I 
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Agarosc gel electrophoresis of peR products in the region of the ACE insertion (I)/deletion 
(D) polymorphism in three patients with the DD, ID and II genotype, respectively. A triple 
primer method (see 'tvfethods' section) was used to avoid mistyping of ID as Dlio, Lane a, 
.obtained with primers adjacent to the inscI1ion site, shows the prescnce of a 493bp undiDI' a 
781 bp band, representing the D- and the I aHele, respectively. Lane b, obtained with an inscr-
tiollMspccitic primer, shows the presence of a 460bp band, representing the I allele. Lane M 
shows the size marker, which is a mixture of digestion products of pBR328 by Bgi nand 
lIinf I. 
pril11er. This PCR amplified a 460bp n'agl11ent (Figure I). PCR reactions were 
perforl11ed on 2 ilL genomic DNA in a final volul11e of 25 IlL containing 0.4 
nl11ol/L of each primer, 1.5 ml11ol/L MgCI" 75 1111110llL Tris-HCI (pH9.0), 20 
ml11ol/L (NH,),SO" 0.01% (w/v) Tween 20, 0.2 1111110llL of each dNTP, and 0.5 
U Goldstar DNA polymerase (Eurogentec Inc., Seraing, Belgium). The amplifi-
cation profile included an initial denaturation at 96°C for 3 minutes and 35 
cycles of denaturation at 96°C for 30 seconds, annealing at 60°C for 15 seconds, 
and extension at noc for 60 seconds with a final extension time of 10 minutes. 
The PCR products were separated by electrophoresis on 3% agarose gels and vi-
sualized by ethidium bromide staining (Figure I). 
The AT I-R gene A/C"66 polymorphism was determined using a PCR, span-
ning the polymorphic site, and subsequent fluorescent sequence analysis of the 
PCR product (Figure 2). The sense primer in thc PCR was extended at the 5' 
site, with a nucleotide stretch homologous to the sequence analysis primer (-
28M 13Rev) shown in bold, 5'aggaaacagctatgaccatgacatgttcgaaacctgtcca 
taaag3', and the anti-sense primer was 5'cggttcagtccacataatgc3'. These primers 
allowed the amplification of a genomic DNA segment of 139bp which con-
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Fluorescence plots representing the DNA sequence of the PCR product in the region spanning 
the ATI-R A/Cll66 polymorphic site in three patients with the AA, AC and CC genotype, re-
spectively. Each peak represents a different nucleotide [------- : Guanine (G), - . - . - : Cy-
tosine (C), -- : Adenine (A), and - - -: Thymidine (T)J. The nucleotide sequences of 
both alleles are depicted above the plots. The polymorphic site is indicated in bold. 
tained the polymorphic site 88bp downstream the sequencing primer. Reactions 
were performed on I ftL genomic DNA in a final volume of 15 ftL containing 
0.2 nmollL sense primer, 0.4 nmoliL anti-sense primer, 1.5 mmollL MgCI" 75 
mmol/L Tris-HCI (pH9.0), 20 m1l1011L (NH4),S04' 0.01% (w/v) Tween 20, 0.2 
mmol/L of each dNTP, and 0.5 U Goldstar DNA polymerase (Eurogentec Inc., 
Seraing, Belgium). The amplification profile included an initial denaturation at 
96°C for 3 minutes and 35 cycles of denaturation at 96°C for 30 seconds, an-
nealing at 50°C for 15 seconds, and extension at noc for 60 seconds with a fi-
nal extension time of 10 minutes. After completion of the PCR, 6 ftL was used 
to perform sequence analysis reactions using the fluorophore-Iabeled 
'28M 13 Rev DYEnamic ET-primer' and the 'DYEnamic direct cycle sequencing 
kit with 7-deaza dGTP' according to the instructions of Amersham Int. (Little 
Chalfont, U.K.). The sequence reaction products were separated by electro-
phoresis in polyacrylamide gels and analyzed in an ABI PRISM 377 automatic 
DNA sequencer (Perkin-Elmer Corp., Foster City, CAl using the accompanying 
software. 
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Statistical allalysis 
Data are expressed as mean ± SEM 01' as median and range. Statistical analysis 
was performed with the SPSS 7.0 statistical package. Because of non-normal 
distribution, plasma renin and prorenin data were logarithmically transformed 
prior to analysis. The Hardy-Weinberg equilibrium was tested by a X' test. Dif-
ferences between groups (AC+CC vs. AA and ID+DD vs. II, respectively) were 
tested by two-tailed Student's t-test. The probability (p) values for statistical sig-
nificance are reported without correction for multiple comparisons. Univariate 
and multivariate regression analyses were conducted to determine the percent-
age of explained variance in LVMI that is accounted for by the genotypes of the 
candidate modifier genes and other variables. Both polymorph isms were tested 
as codominant 0, I, 01' 2 ordinal variables (presence of 0, I, 01' 2 C 01' 0 alleles). 
In the multivariate regression analysis the two polymorph isms, sex (male~O, fe-
male~I), age, peak left ventricular outflow tract gradient and plasma renin con-
centration were considered independent variables. Plasma prorenin, plasma 
ACE, and SAM were excluded from this analysis because of their respective 
high correlation with plasma renin (r~ 0.680, p< 0.001), ACE genotype (r~ 
0.389, p~ 0.003) and peak left ventricular outflow tract gradient (t~ 0.766, p< 
0.001). 
RESULTS 
The distribution of the ACE 110- and the A T1-R AlCl166 genotypes in 104 ge-
netically independent HCM patients are shown in Table I. The ti'equencies of 
the ACE 1- and 0 alleles (0.50 and 0.50, respectively) and the AT I -R A- and C 
alleles (0.74 and 0.26, respectively) were similar to previously reported numbers 
in normal Caucasian populations (18,25,37,38). Genotype frequencies were in 
agreement with Hardy-Weinberg equilibrium. 
Table 2 lists the characteristics of the HCM patients according to ACE 110 
genotype. No differences with regard to gender, age, BSA, or any of the cardiac 
parameters were found between carriers of the 0 allele and subjects with the II 
genotype. Plasma renin and prorenin (Table 2), as well as the percentage of pa-
tients taking beta-adrenergic antagonists, calcium-channel blockers or diuretics 
(data not shown), were also similar in II and ID+DD patients. In accordance 
with previous studies (39,40) plasma ACE activity was highest in DO subjects 
and intermediate in ID subjects. Regression analysis showed that the ACE geno-
type accounted for 15.1 % of the variability in plasma ACE activity (t~ 0.389, 
p~ 0.003). 
Table 3 lists the characteristics of the HCM patients according to A T1-R AI 
Clt66 genotype. The percentage of patients taking beta-adrenergic antagonists, 
calcium-channel blockers 01' diuretics did not differ between AA and AC+CC 
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If/ble I 
Genotype Frequencies of the ACE· and ATI-R Genes illl-lCM Patients. 
AT1·R Genotype (n) Sum (%) 
AA AC CC 
ACE Genotype II 15 6 3 24 (23%) 
ID 33 21 3 57 (55%) 
DD 9 12 2 23 (22%) 
Sum (%) 57 (55%) 39 (36%) 6 (6%) 104 (100%) 
Table 2 
Characteristics of Heivl Putients According to ACE liD Genotype 
ACE Genotype P 
ID+ DD 
II (n=24) ID (n=57) DD (n=23) vs II 
MenlWomen 14110 36121 1518 NS 
Age, y 49.8±3.3 46.2±2.0 46.0±2.8 NS 
eSA, m2 1.80±0.05 1.65±0.02 1.86±0.04 NS 
IVS,mm 22.0±0.9 22.3±0.7 22.3±1.1 NS 
LVM,g 326.5±22.2 331.1±14.1 315.2±16.4 NS 
lVMI,9/m2 162.5±11.9 1BO.3±B.1 167.0±8.3 NS 
Wigle score, 1-10 6.B±0.4 6.6!0.3 6.5±0.6 NS 
SAM, Ofl +f2+/3+ 411n19 1119111122 5141814 NS 
Gradient, mmHg 55.8±9.4 47.6±5.4 36.H7.9 NS 
Prorenln, mUll 156(86·1339) 173(47·813) 141 (28·299) NS 
Renin, mUll 20.7(7.8·202) 21.0(3.0·65) 20.3(3.0'54) NS 
ACE, U/L 8.7±0.5 9.9±0.4 11.2±0.5 0.036 
Values are mean ± SEM or median(range). Student's t-test was used to compare the mean 
values In the ID+DD vs. the II subjects. NS = non significant. Gradient = peak left ventric-
ular outflow tract gradlenti Wigle score = semi-quantitative point score assessing the ex-
tent of hypertrophy. 
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Table 3 
Characteristics of HCtvl Patients According to ATI-R AlCII66 Genotype. 
AT1-R Genotype P 
AA (n=57) AC (n=39) CC (n=8) (AC+CC vs AA) 
MenlWomen 33124 29/10 315 NS 
Age, y 48.6±2.1 45.7±2.1 47.4±6.9 NS 
BSA. m2 1.84±0.03 1.88±0.03 1.75±0.06 NS 
IVS,mm 21.6±0.7 22.9±0.7 23.4±2.3 NS 
LVM.9 306.2±12.5 350.1±16.2 356.5±49.3 0.D25 
LVMI, glm2 167.9±7.2 186.5±8.1 205.4±30.3 0.048 
Wigle score, 1-10 6.3±0.3 6.9±O.3 7.3±0.8 NS 
SAM. 0/1+/2+/3+ 7/8114123 1215/8/10 1111412 NS 
Gradient, mmHg 53.1±5.5 37.8±6.4 43.6±16.6 NS 
Prorenln, mUll 161(28·741) 147(48·1339) 228(86·813) NS 
Renin, mutL 17.0(3.0·55) 22.7(3.0·202) 24.6(10.2·85) 0.049 
ACE, Ull 10.2±0.4 9.6±0.4 9.9±0.8 NS 
Values are mean ± SEM or median (range). Student's t-test was used to compare the mean 
values in the AC+CC vs. the AA subjects. NS = non significant. Gradient = peak left ventric-
ular outflow tract gradlenti Wigle score= seml·quantltatlve point score assessing the ex-
lent of hypertrophy. 
patients (data not shown). Gender, age, BSA, SAM, and peak left ventricular 
outflow tract gradient were not associated with the A TI-R A/CI166 polymor-
phism. LVM, LVMI and plasma renin were however significantly higher in sub-
jects carrying one 01' two C alleles than in AA homozygotes, and similar pat-
terns were obselved for IVS (p~ 0.162) and Wigle score (p~ 0.108). Regression 
analysis showed that the A T1-R genotype accounted for 4.3% of the variability 
of LVM (1= 0.208, p~ 0.034), 4.5% of the variability of LVMI (1= 0.213, p~ 
0.031) and 4.6% of the variability in plasma renin (r~ 0.214, p~ 0.029). Using a 
two factor ANOV A, no interaction was observed between the ACE D allele and 
the ATI-R C allele with regard to any of the measured parameters. 
Plasma renin, plasma prorenin, and the sum of plasma renin and plasma 
prorenin (plasma total renin) did not correlate with LVM, LVMI or any of the 
other cardiac parameters (data not shown). 
Multivariate regression analysis showed that age, peak left ventricular' out-
flow gradient and the AT I-R A/CI166 polymorphism, but not sex, plasma renin 
The Angiotensin II Type I Receptor A/CII66 Polymorphism 
Table -I 
rvtuitivariatc Regression Analysis of Factors with Potential Effect on L vtvt I 
n SE P 
Sex, male=O, female=1 4.715 11.043 NS 
Age, y ·0.891 0.351 0.013 
ACE Genotype, no. of D alleles ·8.819 7.912 NS 
AT1-R Genotype, no. of C alleles 22.412 8.332 0.010 
Log Renin, mUll -26.842 17.998 NS 
Gradient, mmHg 0.276 0.132 0.040 
SE = standard error; NS = non significant. Gradient = peak left ventricular outflow tract 
gradient. 
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or the ACE liD polymorphism, were significant predictors ofLVMI (Table 4). 
DISCUSSION 
The lll'esent study shows that the A TI-R genotype influences the magnitude of 
LVH in subjects with HCM. LVM and L VMI were significantly higher in pa-
tients carrying the C allele than in AA homozygotes, and a similar pattern was 
observed for IVS and Wigle score, the latter being a semi-quantitative score re-
flecting the extent of cardiac hypertrophy (32). No relationship with SAM or 
peak left ventricular outflow tract gradient was observed. Interestingly, plasma 
renin, but not plasma prorenin, was higher in subjects carrying the C allele than 
in AA homozygotes. 
The A TI-R AICII66 polymorphism is located at the 5' site of the 3' untrans-
lated region of the gene. This polymorphism is probably not functional but 
might be in linkage equilibrium with an unidentified functional variant affecting 
the structure or function of the ATI-R (or adjacent unknown genes). Tiret et 
al.(25) have speculated that the downregulation of the A TI-R gene in response 
to Ang [[ is altered in subjects with the C allele. Such altered down regulation, 
which is most likely tissue-specific (41-44), would not only offer an explanation 
for our findings on cardiac hypertrophy but it might also explain the increased 
renin levels in patients carrying the C allele, since Ang II stimulates cardiac hy-
pertrophy (9,45) and regulates renin release (46,47) via A TI-receptors. In line 
with our findings, Hein et al.( 48) recently showed that overexpression of the 
ATI-R in the mouse leads to an increase in cardiac mass and myocyte hypertro-
phy. 
The C allele has been associated with hypertension (38,49), aortic stiffness 
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(50), thc development of coronary artery stenosis (51), and coronary artery 
vasoconstriction (52), The fj'equency of the C allele in the l-ICM subjects of the 
present study was similar to that reported prcviously in the general population 
(25,50). Thus, the A Tl-R AlCIl66 polymorphism is not associated with HCM as 
such, but rather modulates the phenotypic expression of hypelirophy in subjects 
with HCM. Such modulation might explain why individuals with the same 
HCM mutation show a significant variability in the magnitude of LVI-! (6-8). 
The ACE liD polymorphism has also been repOlied to account for some of the 
variability of LVMl in HCM subjects (20,22). This could not be confirmed in 
the present study, although our data do support the previously described (39,40) 
association between plasma ACE and ACE genotype. It is possible that the in-
fluence of the ACE genotype in I-!CM subjects depends on the specific disease 
gene mutation (23). We did not determine the underlying gene mutations in our 
HCM patients. The presence of different sarcomeric gene mutations in our 
population might however offer an explanation for the lack of association be-
tween ACE genotype and L VH in the present cohort. It might also explain why 
8rugada et al. did not find an association between the A TI -R C allele and car-
diac hypertrophy in their patients (53). In addition, the HCM patients selected 
by 8rugada et al. (53) had a less severe form of HCM (wall thickness d3mm) 
than those selected in the present study (wall thickness> l5mm). This may have 
cnhanced our chance of finding a significant association between hypertrophy 
and the ATl-R C allele (23). 
Theoretically, the high tissue ACE levels found in DD subjects (18) might 
lead to high tissue Ang II levels and thereby enhance the AT I -R C allele-related 
effects on hypertrophy. Such synergy has been described for the risk of MI (25). 
Any interaction between the A Tl-R C allele and the ACE D allele will however 
be obscured by the elevated plasma renin levels found in HCM patients carrying 
the C allele. High plasma renin levels will, via uptake of renin by the heart 
(26,27,54), also lead to high cardiac Ang II levels. Thus, cardiac Ang II levels 
may already be high in AC and CC subjects independently of the ACE gene 
polymorphism, and this could explain the lack of interaction between the two 
gene polymorphisms of the renin-angiotensin system in the present study. 
Recently, plasma renin activity was found to correlate positively with L VM in 
healthy young adults (10). One may therefore argue that the elevated plasma re-
nin levels in subjects carrying the C allele are the underlying reason for the rela-
tionship between the C allele and cardiac hypelirophy. However, plasma renin 
did not correlate with either LVM or LVMl in the present study, and multivari-
ate regression analysis revealed no independent effect of plasma renin after cor-
rection for A Tl-R genotype. Thus it appears that, in HCM subjects, other fac-
tors related to the A Tl-R A/C1l66 polymorphism (e.g., cardiac A TI-R density) 
are more important determinants of cardiac hypertrophy than plasma renin. 
In addition to the A TI -R AlCI !66 polymorphism, age and peak left ventricular 
outflow gradient were also independent predictors of L VMI. 80th associations 
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have been reported before (55-59). LVMI decreases with age, most likely be-
cause progressive wall thinning occurs gradually over time in HCM patients 
(55,56). Mitral leaflet-septal contact determines the magnitude of the pressure 
gradient in the left ventricular outflow tract, and more marked SA M of the mi-
tral valve is associated with an augmentation of LVI-! (55-59). 
In conclusion, the resuits of this study support a modulating role for the A TI-
R A/C II " polymorphism in the development of LVH in patients with HCM, in-
dependently of age, sex, peak left ventricular outflow gradient, plasma renin and 
the ACE lID polymorphism. 
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Summary 
140 Summary 
Hypeltrophic cardiomyopathy is an intriguing disease that puzzled many inves-
tigators due to the heterogeneity in clinical presentation, natural history, aetiol-
ogy and management. 
In this thesis, we have discussed new conceptions concerning prognosis, im-
aging modalities, surgical therapy, coronary flow reserve and modifier genes in 
patients with this disease. 
In Chapter I, a review of the recent literature is presented focusing on the pa-
thology, prevalence, symptoms, clinical outcome, therapeutic interventions and 
alterations in the genetic material responsible for the development of hyper-
trophic cardiomyopathy. 
In Chapter 2, the annual cardiac death is assessed in an unselected outpatient 
population of 113 patients with hypertrophic cardiomyopathy. Mean age at diag-
nosis was 37 ± 16 years (range 5 - 71 years). During a mean follow-up of 7 ± 5 
years, there were II cardiac and 2 noncardiac deaths. The annual cardiac death 
was 1% (95% confidence interval 0.2 - 1.8%). Previous prognosis shldies from 
tertiary referral centres have reported an annual cardiac mortality of 2 - 4%. It 
is believed that investigations performed at these centres were profoundly influ-
enced by referral bias. Patients who are referred to tertiary centres represent, for 
the most part, the segment of patients with severe symptoms 01' those who are at 
risk of sudden death. It is concluded that hypertrophic cardiomyopathy has a 
relatively benign prognosis. 
In Chapter 3, we report the clinical outcome in 9 parturients with hyper-
trophic cardiomyopathy. These women characterize the clinical heterogeinity of 
this disease: Before pregnancy, complaints of dyspnea and/or angina were 
present in 4 patients, septal myectomy becausc of left ventricular outflow tract 
obstruction had been carried out in 5 patients, episodes of ventricular tachycar-
dia were documented in 6 patients and in 6 patients sudden death was reported 
in a first-degree relative. Nine women had 20 pregnancies. During pregnancy, 
cardiac symptoms worsened in only 2 patients, one of whom had to be treated 
with diuretics for relief of healt failure. Five pregnancies ended in spontaneous 
abortion. From 15 births, thirteen children were born by vaginal delivery and 
two by cesarean section because of fetal distress, In the perinatal period, no 
mother nor child died. We conclude that pregnancy is well tolerated in patients 
with hypertrophic cardiomyopathy and caesarean section can be reserved for 
obstretic indications only. 
In Chapter 4, we study the alterations in size and geometry of the left ven-
tricular outflow tract which occur in hypertrophic cardiomyopathy. To this end, 
transthoracic 3-dimensional echocardiography was performed in 17 patients 
with hypertrophic cardiomyopathy and in \0 normal subjects. Both the ratio be-
tween maximal and minimal cross-sectional areas and the ratio between maxi-
mal and minimal diameter of the smallest cross-section were significantly higher 
in patients with hypertrophic cardiomyopathy than in normals (2.6 ± 0.9 vs. 1.4 
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± 0.2, p< 0.000 I; 1.6 ± 0.3 vs. 1.2 ± 0.1, p< 0.00 I, respectively). Patients with 
hypeltrophic cardiomyopathy are characterized by a highly eccentric and asym-
metric shape of the left ventricular outflow tract, and by a smaller minimal 
cross-sectional area compared to normal subjects. 
In Chapter 5, we describe the dcsign features and electrical characteristics of 
a monopolar electrosmgical device called spark erosion for use in septal myec-
tomy in patients with hypertrophic obstructive cardiomyopathy. 
In Chapter 6, we assess the clinical and functional outcome of combined ante-
rior mitral leaflet extension and myectomy in 8 patients with hypertrophic ob-
structive cardiomyopathy. The resuits were compared with 12 patients undergo-
ing myectomy alone. Postoperatively, patients treated by mitral valve extension 
had less mitral insufficiency (p< 0.005), less residual systolic anterior mortion 
(p< 0.0 I), greater improvement in New York Heart Association nmctional class 
(p~ 0.05), and greater reduction in the number of drugs (p< 0.005). We con-
clude that mitral leaflet extension in combination with myectomy is a promising 
new smgical approach that may provide superior resuits to those of myectomy 
alone. 
In Chapter 7, we measme the coronmy flow reserve (CFR) and coronary re-
sistance (CRR) (CRR~ CFR corrected for the enddiastolic pressure) in 10 pa-
tients with hypertrophic cardiomyopathy and in a control group of 8 asymptom-
atic cardiac transplant recipients. Both CFR and CRR were reduced in hyper-
trophic cardiomyopathy (1.8 ± 0.9 vs. 2.6 ± 0.8, p< 0.05; 1.5 ± 0.6 vs. 2.6 ± 0.8, 
p< 0.05, respectively). End-diastolic interventricular septal wall thickness was 
significantly increased, arteriolar lumen divided by wall area (AL) was lower 
and capillary density tended to decrease in patients with hypertrophic cardiomy-
opathy (25.8 ± 2.9 vs. 11.4 ± 3.0 mm, p< 0.05; 21 ± 5% vs. 30 ± 4%, p< 0.05; 
1824 ± 424 vs. 1445 ± 513 per mm', respectively). The decrease in CRR was 
linearly related to a reduction in AL. Fmther analysis revealed that CRR,AL and 
capillary density were all Iincarly related to the degree of hypertrophy. It is con-
cluded that decrements in CRR are related to changes in the mierocireulation 
and that both the decrease in CRR and changes in the coronary microcirculation 
are related to the degree of hypertrophy. 
In Chapter 8, we investigate which other haemodynamie and echocardio-
graphic factors, besides changes in the microcirculation, are responsible for re-
duction in coronary flow reserve in patients with hypertrophic obstructive cardi-
omyopathy. For this study, we calculated CFR in patients with hypertrophic ob-
structive cardiomyopathy (N~10) and in cardiac transplant recipients 
(controlgroup, N~8). As seen before, CFR was reduced in patients with hyper-
trophic cardiomyopathy. An increase in the thickness of the septal myoeardium 
(p~ 0.005), indexed left ventricular mass (p~ 0.005), left ventricular enddiastolic 
pressme (p~ 0.0002) and the left ventricular outflow tract gradient (p~0.03) 
were are related to the reduction in CFR. We conclude that both haemodynamie 
and echocardiographic factors and changes in the mierocirculation may eontrib-
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ute to the occurence of ischaemia in patients with hypel1rophic cardiomyopathy. 
In Chapter 9, we have analysed whether the angiotensin-converting enzyme 
(ACE) insertionldeletion (lID) polymorphism, the angiotensin II type I (A T1-R) 
AIC"66 polymorphism andlor plasma renin activity influenced left ventricular 
hypertrophy in patients with hypertrophic cardiomyopathy. Left ventricular 
mass index (LVMI) and interventricular septal thickness (IVS) were determined 
by two-dimensional echocardiography in 104 genetically independcnt subjects 
with hypertrophic cardiomyopathy. The ACE D allele and the plasma renin ac-
tivity were not associated with more cxtensive left ventricular hypertrophy. 
However, LVMI lVas higher in patients carrying the C allele than in AA ho-
mozygotes (190 ± 8.3 vs. 168 ± 7.2 ginI', p< 0.05). A similar pattern was ob-
served for IVS thickness (23 ± 0.7 vs. 21.6 ± 0.7 mm, p~ 0.162). Statistical 
analysis showed that the ATI-R C"66 allele modulated the phenotypic expres-
sion of hypertrophy in hypertrophic cardiomyopathy independently of plasma 
renin and the ACE liD polymorphism. 
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Hypeltrofische cardiomyopathie werd als ziektebeeld voor het eerst beschreven 
door Brock in 1957. De ziekte wordt veroorzaakt door een mutatie in een van de 
genen welke coderen voor eiwitten van de cardiale sarcomeer. Hypcrtrofische 
cardiomyopathie is een fascinerende aandoening mede door de variatie in 
presentatie, natulll'lijk be loop en behandeling. 
Het doe I van de in dit proefschrift beschreven studies is de evaluatie van het 
natulll'lijk be loop van de ziekte, de evaluatie van nieuwe beeldvol'lnende en 
chirlll'gische technieken en het onderzoek naar pathofysiologische processen die 
de klachten van de patient kunnen verklaren. 
Hoofdstuk I is een overzichtsartikel betreffende hypertrofische cardiomyopathie 
en behandelt de meest recente opvattingen betreffende de pathologie, 
prevalentie, symptomatologie, natulII'lijk be loop, behandeling en veranderingen 
in het genetische materiaal welke vcrantwoordelijk zijn voor de ziekte. 
In hoofdstuk 2, wordt het natulII'lijk beloop van de ziekte beschreven in een 
populatie van 113 patienten met hypertrofische cardiomyopathie. De 
gemiddelde leeftijd bij aanvang van de studie van de patienten was 37 ± 16 jaar 
(spreiding 5 - 71 jam) Na een periodc van gemiddeld 7 (± 5) jaar, waren er 13 
patienten overleden; elf ten gevolge van een cardiale en twee ten gcvolge van 
een niet cardiale oorzaak. De cardiale mortaliteit was I % per jaar (95% 
betrouwbaarheidsinterval 0.2 - 1.8%). Dc cardiale mortaliteit in deze studie was 
beduidend lager dan de mortaliteit van 2 tot 4% per jaar welke in eerdere 
prognose studies we I'd gerapporteeerd. Het verschil in cardia Ie mOltaliteit kan 
worden verklaard door de uiteenlopende samenstelling van de patienten-
populaties. De populatie in onze studie was als voigt samengesteld: (a) 
patienten die primair poliklinisch of klinisch in het "Dijkzigt ziekenhuis" 
werden gediagnostiseerd (b) patienten die werden verwezen door cardiologen 
uit perifere centra tcn behoeve van gespecialiseerde zorg (c) patienten waar 
tijdens kelll'ing of routine cardiologische evaluatie de diagnose hypertrofische 
cardiomyopathie werd gesteld (deze patienten hadden in het algemeen geen 
cardiale klachten) (d) familieleden van patienten; deze personen werden op 
eigen verzoek onderzocht op aanwezigheid van de afwijking. De eerdere 
prognose studies waren voornamelijk afkomstig van zogenaamde tertiare 
klinieken; de patienten populatie werd hier voornamelijk gedomineerd door 
patienten met el'llstige symptomen, patienten met een verhoogd risico op plotse 
dood en patienten die werden verwezen voor chirurgische interventie. Het is 
aannemelijk dat de prognose in deze patienten aanzienlijk wordt beinvloed door 
de zogenaamde "referral bias", De patienten in onze studie waren minder 
geselecteerd en wij concluderen dat patienten met een hypertrofische 
cardiomyopathie een relatief goede prognose hebben. 
In hoofdstuk 3, wordt het beloop van de zwangerschap beschreven bij 9 
patienten met een hypertrofische cardiomyopathie. Vier vrouwen hadden reeds 
voor de zwangerschap cardiale klachten (angina en/of dyspnoe), vijf patienten 
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had den reeds een myeetomie ondergaan vanwege een linker ventrikel 
uitstroombaan obstructie en bij 2 patienten werd er middels Doppler 
echocardiographie een belangrijke gradient (> 35 mm Hg) over linker ventrikel 
uitstroombaan gevonden. De 9 patienten maakten 20 zwangerschappen door. In 
2 patienten namen de cardia Ie klachten toe tijdens de zwangerschap; een van 
deze patienten moest worden behandeld met diuretica wegens tekenen van 
hartfalen. Vijf zwangerschappen eindigden in een spontane abortus. In dertien 
van de 15 zwangerschappen vond er een vaginale bevalling plaats, in 2 gevallen 
werd de zwangerschap beeindigd middels een keizersnede wegens foe tale nood. 
In de perina tale peri ode hebben zich zowel bij de patienten als de neonaten geen 
cardiale complicaties voorgedaan. 
De resultaten van deze studie tonen dat patienten met een hypertrofische 
cardiomyopathie een zwangerschap goed kunnen doorstaan mits adequate 
cardiologische en obstretische begeleiding gewaarborgd is. Een keizersnede is 
aileen aangewezen bij een obstretische indicatie. 
In Hoofdstuk 4, wordcn de veranderingen in vorm van de linker ventrikel 
uitstroombaan bij patienten met een hypertrofische cardiomyopathie beschreven. 
Met transthoracale driedimensionale echocardiografie werd de linker ventrikcl 
uitstroombaan bestudeerd in 17 patienten met een hypertrofische cardio-
myopathie en in 10 patienten zonder cardiale afwijkingen. Zowel de verhouding 
tussen de oppervlakte van de grootste en de kleinste dwarsdoorsnede als de 
verhouding tussen de maximale en minima Ie diameter van de kleinste 
dwarsdoorsnede was duidelijk toegenomen in patienten met een hypertrofische 
cardiomyopathie in vergelijking met de controle patienten (respectievelijk 2.6 ± 
0.9 versus 1.4 ± 0.2, p< 0.0001 en 1.6 ± 0.3 versus 1.2 ± 0.1, p< 0.001). 
Patienten met een hypelirofische cardiomyopathie worden gekenmerkt door een 
asymmetrische vonn van de linker ventrikel uitstroombaan en door een afname 
van de oppel'vlakte van de kleinste dwarsdoorsnede in vergelijking met de 
controle patienten. 
In hoofdstuk 5, worden de eigenschappen van een instrument besproken 
welke gebruikt wordt voor de chirlll'gische behandeling (septale myectomie) van 
patienten met een hypelil'ofische obstructieve cardiomyopathie. Dit instrument, 
ontworpen in het Thol'axcentrllm-Rottel'dam, bewerkstelligt resectie van het 
septale myocard middels vonkerosie. 
Hoofdstuk 6 beschl'ijft de resultaten van een nieuwe chirurgische therapie 
voor patienten met een obstrllctieve hypelirofische cardiomyopathie. Bij deze 
behandeling wordt naast de klassieke myectomie een plastiek van de voorste 
mitralisklep slip uitgevoerd met pericard van de patient. In totaal werden er 8 
patienten volgens de niellwe teclllliek behandeld. De resultaten van 
gecombineerde myectomie en mitralis klepplastiek worden vergeleken met de 
resultaten van de klassieke myectomie welke plaatsvond in 12 patienten. Na 
operatie blijkt er in patienten die met de gecombineerde techniek zijn behandeld 
minder mitralisklep insufficientie te bestaan (p< 0.005), is de kenmerkende 
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beweging van het voortse klepblad ("systolic anterior mortion") meer 
teruggebracht (p< 0.0 I), is er een grotere verbetering in de functionele klasse 
(IFO.05) en is er een grotere afname van de hoeveelheid voorgeschreven 
medicamenten (p< 0.005) in vergelijking met patienten die aileen behandeld zijn 
met myectomie. De combinatie van myectomie en plastiek van het voorste 
mitralisklepblad is een nieuwe, veelbelovende chirurgische benadering voor 
patienten met een obstructieve hypertrofische cardiomyopathie. Een studie met 
grotere patienten aantallen zal de plaats van de nieuwe techniek moeten bepalen. 
Hoofdstuk 7 beschrijft de corona ire bloedstroom reserve ("coronary flow re-
serve" (CFR)) en coronaire weerstand reserve (CRR) (CRR~ CFR gecorrigeerd 
voor de einddiastolische druk) bij 10 patients met een hypertrofische 
cardiomyopathie en bij een controle groep van 8 asymptomatische patienten na 
een harttransplantatie. Zowel de CFR als de CRR waren afgenomen in patienten 
met een hypelirofische cardiomyopathie ( respectievelijk 1.8 ± 0.9 versus 2.6 ± 
0.8, p< 0.05 en 1.5 ± 0.6 versus 2.6 ± 0.8. p< 0.05). De eindiastolische septale 
interventriculaire ventrikel wanddikte was aanzienlijk toegenomen bij patienten 
met een hypelirofische cardiomyopathie (25.8 ± 2.9 versus 11.4 ± 3.0, P < 0.05). 
Tevens we I'd vastgesteld dat het lumen van de arteriolen gecorrigeerd voor de 
oppervlakte van de vaatwand (AL) afgenomen was en dat er een tendens was tot 
afname van de capillaire dichtheid bij patienten met een hypertrofische 
cardiomyopathie (respectievelijk 21 ± 5% versus 30 ± 4%, p< 0.05 en 1824 ± 
424 versus 1445 ± 513 per mm', p=NS). De afname van de CRR was 
rechtevenredig gerelateerd met de reductie van de AL. Bij verdere analyse bleek 
dat zowel de CRR,AL als de capillaire dichtheid rechtevenredig gerelateerd 
waren met de mate van hypertrofie. Op grond van deze resultaten concluderen 
wij dat de afname van de CRR gerelateerd is aan veranderingen in de 
microcirculatie en dat zowel de afname van de CRR als de veranderingen in de 
coronaire microcirculatie samen hangen met de mate van hypertrofie. 
In hoofdstuk 8 wordt onderzocht welke haemodynamische en echocardio-
grafische factoren naast veranderingen in de microcirculatie verantwoordelijk 
zijn voor de afname van de corona ire bloedstroom reserve bij patienten met een 
hypertrofische obstructieve cardiomyopathie. In deze studie we I'd de coronaire 
bloedstroom reserve (CFR) berekend in patienten met een hypertrofische 
obstructieve cardiomyopathie (N= I 0) en in een controle groep van 8 patienten 
na een harttransplantatie. Zoals reeds eerder geconstateerd, was de CFR 
afgenomen in patienten met een hypertrofische cardiomyopathie. Zowel een 
toename van de dikte van de septa Ie interventriculaire ventrikel wanddikte (p~ 
0.005), een toename van de linker ventrikel massa gecorrigeerd voor de 
Iichaamsoppervlakte (p~ 0.005), een toename van de linker ventrikel eind-
diastolische druk (p~ 0.0002) als de mate van de uitstroombaanobstl'llctie 
(p~0.03) waren gerelateerd met de afname van de CFR. Deze haemodynamische 
en echocardiografische bevindingen kunnen naast veranderingen in de corona ire 
microcirculatie verantwoordelijk zijn voor het optreden van ischaemie bij 
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patienten met een hypertrafische cal'diomyopathie. 
In hoofdstuk 9, wordt bestudeel'd of het "angiotensin-converting enzyme" 
(ACE) inseliie/deletie (lID) polymol'fisme, het angiotensine II type I (A T1-R) 
A/C"66 polymol'fisme en/of de plasma renine activiteit de linker kamer 
hypel'trafie beinvloedt bij patienten met hypertrafische cardiomyopathie. 
Hiertoe werd de linker ventrikel massa gecorrigeerd VOOI' de lichaams-
oppel'vlakte (L VMI) en de dikte van het intel'ventriculail'e septa Ie myocal'd 
(lVS) berekend met behulp van twee-dimensionale echocal'diografie in 104 
patienten met een hypelirafische cardiomyopathie. I-let ACE D allele en de 
plasma renine activiteit waren niet gerelateerd met de mate van linker kamer 
hypelirofie. Echtel' zowel de LVMI als de IVS waren toegenomen in patienten 
die het C allele bezaten in vergelijking met de AA homozygoten (rcspectievelijk 
190 ± 8.3 versus 168 ± 7.2 glm', p< 0.05 en 23 ± 0.7 versus 21.6 ± 0.7 mm, p~ 
O. I 62). Na statistische analyse blijkt het A T1-R C"66 allele de fenotypische 
expressie van linker kamer hypertrafie onafhankelijk van het plasma renine of 
het ACE liD polymol'fisme te beinvloeden. 
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Een proefschrift is altijd het resultaat van samenlVerking met anderen. Zonder 
de medelVerking van de cardiologen en lVetenschappelijke medelVcrkcrs in het 
Thoraxcentrum, mijn collega's in het MerlVede ziekenhuis en het Drechtsteden 
ziekenhuis enmijn gezin zou dit proefschrift nooit tot stand gekomen zijn. 
Een aantal mensen die op lVat voor manier dan ook een bijdrage hebben 
geleverd aan de totstandkoming van dit proefschrift lVil ik in het bijzonder 
bedanken: 
Dr. F.J. Ten Cate, beste Folkert, onze samenwerking heeft geresulteerd in 
meerdere publicaties op het gebied van de hyperlrofische cardiomyopathie. Met 
name in de eerste jaren heb je mij begeleid in het opzetten van een data-base, 
het analyseren van patienten gegevens en het schrijven van lVetenschappelijke 
artikelen. Je hebt mij geleerd dat wanneer een artikel afgewezen 1V0rdt, de 
inhoud en de wetenschappelijke lVaarde van het aliikel niet onvoldoende hoeft 
te zijn en dat met lVat aanpassingen de boodschap in een ander tijdschrift wei op 
lVaal'de 1V0rdt geschat. 
Prof. dr J.R.T.C. Roelandt, beste Jos, het is mede jou verdienste dat er in het 
Thoraxcentrum een onderzoeksklimaat heerst. Zelfs voor een perifere 
cardioloog is het daarom mogelijk om, gebruik makend van de faciliteiten die 
het Thoraxcentrum biedt, een proefschrift te schrijven. Door mij aangeboden 
manuscripten werden altijd in korte tijd door jou geanalyseerd, belVerkt en 
voarzien van kritisch commentaar. Mijn dank daarvoor. 
Prof. dr P.W.J.C. Serruys, beste Patrick, gedurende mijn stage op het 
catheterisatie laboratoriulll heb ik kennis gemaakt met joulV bevlogenheid en 
niet aflatende zucht om nieuwe technieken te onderzoeken en te evalueren. lk 
ben in deze periode gepakt door het lVetenschappelijk virus, uiteindelijk heeft 
dit geresulteerd in dit proefschrift. Ik dank je voar de kritische beoordeling van 
een aantal artikelen. 
Dr. L.A. van HerlVerden, beste Lex, je hebt cen belangrijke bijdrage geleverd 
aan dit proefschrift, omdat je een nieuwe chirurgische techniek hebt ontwikkeld 
voor de behandeling van patienten met een hypertrofische obstructieve 
cardiomyopathie. De hoofdstukken 5 en 6 zijn mede in overleg met jou 
geschreven. Mijn dank voor de prettige samenlVerking. 
Prof. dr A.J.J.C. Bogers en Prof. dr W.L. Mosterd dank ik voor hun bereidheid 
om zitting te nemen in de leesconllllissie. 
Dr. R. Krams, beste Rob, het heeft even geduurd voardat men het belang van 
samenwerking tussen de verschillende klinische, experimentele en niet-klinische 
afdelingen inzag. Uiteindelijk heeft ons geloof in de uitkomst van een aantal 
onderzoekprojecten geleid tot een aantalmooie publicaties. 
Chris van der Lee, Arthur Osterop, Jan Danser, Wim Vletter, Alessandro 
Salustri, Ron van Domburg, Eric Boersma, Mike Kliffen, Meindert TaalllS, 
David Waldstein, Jeroen Vas, Peter Ruygrok en Lex Maat dank ik va or hun 
bijdrage aan het proefsclll·ift. 
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Mijn collega's in het Mel'lVede ziekenhuis en Drechtsteden ziekenhuis hebben 
zondel' dat ze zich dat lVaal'schijnlijk I'ealisel'en een belangrijke invloed gehad op 
het ontstaan van dit pl'oefschl'ift. OllZe maatschap 1V0l'dt gekenmel'kt door 
loyaliteit, vriendschap en de wil om zowel op cardiologisch als op bestuurIijk 
gebied innovatief bezig te zijn. Daarnaast proberen we ook tijd vrij te maken 
voar de pl'ettige dingen in het leven. In een sfeel' als deze kun je ook de enel'gie 
opbrengen om wetenschappelijk ondel'zoek te doen. Nico Breuls, Phons Fels, 
Herman Fintelman, Arie Herweyel', Louis Ten Kate, Ies Stoel, Arie de Vries ik 
hoop dat lVe nog jal'en op dezelfde manier ons yak uit kunnen bIijven oefenen. 
De vel'pleeglamdigen op de har1bewaking, de afdeling cal'diologie en de dames 
op de functieafdeling en op de polikliniek van het Merwedeziekenhuis dank ik 
VOOI' de pl'ettige samenlVel'king de afgelopen jal'en. De insteIIing en bel'eidheid 
om el' samen lVat van te maken tekent de mentaliteit op de vel'schillende 
afde!ingen. Regelmatig heb ik met name op de dames van de polik!iniek een 
bel'oep moeten doen om administl'atieve zaken VOOI' mijn pl'oefschl'ift af te 
handelen. Dil was nooit een probleem. Louise Versluis wil ik in het bijzonder 
dank zeggen VOOI' het uittypen van een aantal manuscripten. 
Mijn pal'animfen 'IJebbe Galema en Al1hur van Schaik dank ik VOOI' de "mental 
sUppOI1" de afgelopen maanden. Met Arthur deel ik al jal'en lief en leed, een 
bijzondel'e vl'iendschap waal' I'uimte en begrip is VOOI' elkaal's opvattingen. 
Mijn moedel' dank ik VOOI' de wal'mte en !iefde die ze mij heeft gegeven. Helaas 
heeft ze geen deelgenoot kunnen zijn van aile moo is van de afgelopen jal'en. Ik 
hoop dat el' een plaats is van lVaaruit ze toch een beetje mee kan genieten. 
Mijn vader, Ella, Monique en Frans jl'. dank ik VOOI' hun ondel'steuning. 
Tenslotte, dank ik Karin en onze kindel'en Sandel' en Alme-Claire. Zij zijn het 
levende belVijs dat el' belangrijkel' zaken zijn dan carriere en wetenschappeIijk 
ondel'zoek. 
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